Antagonistic CD73 antibodies

By developing high-affinity anti-CD73 antibody molecules and combining PD-1 antagonists, the problem of insufficient inhibition of CD73 in the prior art was solved, significantly improving the immune response and survival rate of cancer treatment, and achieving more effective cancer treatment.

CN112166124BActive Publication Date: 2024-11-08BOEHRINGER INGELHEIM INT GMBH
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN201980033039.4
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Priority Date
2018-05-19
Filing Date
2019-05-13
Publication Date
2024-11-08
Estimated Expiration
2039-05-13

AI Technical Summary

Technical Problem

The existing cancer treatment methods have limited inhibitory effect on CD73, which makes it difficult to completely prevent immunosuppressive adenosine production, affecting the treatment effect.

Method used

A novel anti-CD73 antibody molecule has high affinity and improved ability to reverse AMP-mediated T cell inhibition, which can effectively inhibit the enzyme activity and adenosine production of CD73, combined with PD-1 antagonists to enhance anti-tumor activity .

Benefits of technology

It significantly improves the proliferation and IFNγ secretion induction ability of T cells, enhances the anti-tumor immune response, improves the objective response and overall survival rate of cancer patients, reduces side effects, and improves the pharmacological properties of the treatment and the convenience of preparation.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN112166124B_ABST
    Figure CN112166124B_ABST
Patent Text Reader

Abstract

The present invention relates to novel antagonistic antibodies to CD73. The present invention also relates to nucleic acids encoding such antibody molecules; methods for preparing such antibody molecules; host cells expressing or capable of expressing such antibody molecules; compositions comprising such antibody molecules; and uses of such antibody molecules or such compositions, in particular for therapeutic purposes in the field of cancer diseases.
Need to check novelty before this filing date? Find Prior Art

Description

Field of the Invention

[0001] The present invention relates to novel CD73-binding polypeptides. The present invention also relates to nucleic acids encoding such polypeptides; methods for preparing such polypeptides; host cells expressing or capable of expressing such polypeptides; compositions comprising such polypeptides; and uses of such polypeptides or such compositions, particularly for therapeutic purposes in the field of cancer diseases. Background of the Invention

[0003] Cancer is a disease characterized by abnormal cell growth that may spread throughout the body. In developed countries, it is the second most common cause of death. The most common types of cancer in men are lung cancer, prostate cancer, colorectal cancer, and stomach cancer, and the most common types in women are breast cancer, colorectal cancer, lung cancer, and cervical cancer. Although the chance of survival depends largely on the type of cancer and the stage identified, the overall 10-year survival rate for lung cancer is approximately 5%.

[0004] In the past, the most common ways to treat cancer were through surgery, radiation therapy, or the use of chemotherapy drugs. However, in recent years, cancer immunotherapy has shown that it can offer great promise as a treatment modality for oncology.

[0005] Cancer immunotherapy is a branch of oncology that activates the immune system to attack cancer, a fundamental departure from current, commonly used treatments that directly remove or treat tumors. This treatment concept is based on the identification of numerous proteins on the surface of T cells that suppress the immune function of these cells. Immunotherapies block these inhibitory molecules to increase immune system activity or stimulate pathways involved in the activation of immune effector cells. Among these proteins, CD73 and PD-1 are particularly noteworthy.

[0006] Cluster of differentiation 73 (CD73), also known as extracellular-5'-nucleotidase (ecto-5'NT, EC 3.1.3.5), is a glycosyl-phosphatidylinositol (GPI)-linked cell surface enzyme found in most tissues but is particularly expressed in endothelial and hematopoietic cell subsets (Resta et al., Immunol Rev 1998; 161: 95-109 and Colgan et al., Purinergic Signal 2006; 2: 351-60).

[0007] CD73 is a cell surface enzyme expressed on cancer cells, stromal cells and tumor-resident immune cells that converts AMP into adenosine and inorganic phosphate. Adenosine is immunosuppressive and can affect the function of several immune cell types. Adenosine has an activating effect on immunosuppressive cells (such as regulatory T cells, MDSCs and M2 macrophages) and an inhibitory effect on effector cells (such as dendritic cells, effector T cells and NK cells). Neutralizing CD73 antibodies can inhibit CD73 function by blocking enzyme activity and / or by reducing CD73 cell surface levels. This will reduce immunosuppressive adenosine and thereby increase T cell activity.

[0008] Dual blockade of CD73 and immune checkpoints, including PD1 and possibly other immune checkpoints, further restores T cell functionality, thereby improving objective responses and prolonging overall survival in cancer patients compared with PD1 monotherapy.

[0009] CD73 has been reported to be expressed on many different cancers, including colon cancer, lung cancer, pancreatic cancer, ovarian cancer, bladder cancer, leukemia, glioma, glioblastoma, melanoma, thyroid cancer, esophageal cancer, prostate cancer, and breast cancer (Jin et al., Cancer Res 2010; 70:2245-55 and Stagg et al., PNAS 2010; 107:1547-52). In addition, CD73 expression in cancer is associated with shorter overall survival in many tumor indications, especially gastrointestinal tumors, breast tumors, and NSCLC tumors (Wang et al., Prognostic value of CD73-adenosinergic pathway in solid tumor: A meta-analysis and systematic review, Oncotarget 2017; Inoue et al., Prognostic impact of CD73 and A2A adenosine receptor expression in non-small-cell lung cancer, Oncotarget 2017). CD73 activity has also been proposed as a prognostic marker in papillary thyroid carcinoma. By generating the immunosuppressive adenosine, CD73 has a wide range of functions on immune cells and creates an immunosuppressive microenvironment within the tumor. Adenosine strongly inhibits T cell responses, such as proliferation, cytotoxicity, and cytokine production. In addition, adenosine alters the differentiation of dendritic cells, thereby impairing T cell responses. Adenosine also acts on NK cells, thereby inhibiting their cytotoxic function. In addition, adenosine has a stimulatory effect on immunosuppressive cell types. Adenosine causes the expansion of immunosuppressive MDSCs and the differentiation of macrophages to the suppressive M2 phenotype. (Antonioli et al., Immunity, inflammation and cancer: a leading role for adenosine. Nature Reviews Cancer 2013; Beavis et al., CD73: A potent suppressor of antitumor immune responses, Trends in Immunology, 2012). In addition to its effects on immune cells, CD73 can also be used to regulate cell-cell and cell-matrix interactions and angiogenesis. Adenosine can also act directly on cancer cells and regulate cell growth and apoptosis and is associated with drug resistance (Hunsucker et al., Pharmacol Ther 2005; 1: 1-30). Therefore, CD73 can directly and indirectly regulate cancer progression, highlighting its potential as a novel therapeutic target.Allard et al. have reported that targeting CD73 enhances the anti-tumor activity of anti-PD-1 and anti-CTLA-4 mAbs (Clin Cancer Res 2013; 19:5626).

[0010] Other agents targeting the same pathway include A2AR antagonists. However, due to the plethora of adenosine receptors, it is expected that A2AR antagonists will not completely prevent adenosine-mediated activity compared to CD73 inhibitors.

[0011] The non-hydrolyzable ADP analog adenosine 5′-(α,β-methylene) diphosphate (APCP) is a commercially available inhibitor of CD73 enzymatic activity. AB421 is a small molecule CD73 inhibitor developed by Arcus Biosciences.

[0012] WO 2016 / 075099 discloses anti-CD73 binding molecules, such as antibodies and antigen-binding fragments thereof (including the MEDI9447 antibody). MEDI9447 reduces CD73 function by inhibiting the enzymatic activity of CD73 to hydrolyze adenosine monophosphate (AMP) and by inducing CD73 internalization.

[0013] WO 2016 / 081748 discloses antibodies that inhibit the enzymatic activity of human CD73 and antibodies (including the BMS 986179 antibody) that internalize CD73 into cells.

[0014] It is an object of the present invention to provide improved pharmacologically active agents that can be used in the treatment of several cancer diseases.

[0015] In particular, the present invention aims to provide such pharmacologically active agents, compositions and / or methods of treatment that offer certain advantages over currently used and / or known agents, compositions and / or methods in the art. These advantages include in vivo efficacy, improved therapeutic and pharmacological properties, fewer side effects and other favorable properties (e.g., improved ease of preparation or reduced product cost), especially compared to candidate drugs known in the art. SUMMARY OF THE INVENTION

[0017] According to a first aspect, anti-CD73 antibody molecules are provided. As further described herein, the anti-CD73 antibody molecules of the present invention have surprising and advantageous properties compared to other anti-CD73 antibodies. For example, they show improved ability to reverse AMP-mediated T cell inhibition (e.g., as demonstrated by higher T cell proliferation levels and stronger IFNγ secretion induction). IFNγ is known to be a key factor in anti-tumor responses mediated by T cells (Tannenbaum, C. and Hamilton, T. Immune-inflammatory mechanisms in IFNγ-mediated anti-tumor activity, Seminars in Cancer Biology, 2000). In addition, compared with the anti-CD73 antibodies of the prior art, the anti-CD73 antibodies described herein exhibit improved CD73 inhibition. The antibodies of the present invention inhibit cell-bound CD73 and non-cell-bound CD73 to the same extent. Compared with the reference anti-CD73 antibody, the anti-CD73 antibodies of the present invention exhibit improved inhibition of adenosine production. In addition, it has a high affinity for human CD73.

[0018] Also provided are nucleic acid molecules encoding anti-CD73 antibody molecules, expression vectors, host cells, and methods for preparing the anti-CD73 antibody molecules of the present invention. Also provided are pharmaceutical compositions comprising the anti-CD73 antibody molecules of the present invention. The anti-CD73 antibody molecules disclosed herein can be used to treat cancerous conditions, including solid tumors and soft tissue tumors.

[0019] More specifically, the anti-CD73 antibody molecule of the present invention comprises:

[0020] (a) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 25 (hcCDR1), SEQ ID NO: 26 (hcCDR2) and SEQ ID NO: 27 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 28 (lcCDR1), SEQ ID NO: 29 (lcCDR2) and SEQ ID NO: 30 (lcCDR3); or

[0021] (b) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 31 (hcCDR1), SEQ ID NO: 32 (hcCDR2) and SEQ ID NO: 33 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 34 (lcCDR1), SEQ ID NO: 35 (lcCDR2) and SEQ ID NO: 36 (lcCDR3); or

[0022] (c) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 37 (hcCDR1), SEQ ID NO: 38 (hcCDR2) and SEQ ID NO: 39 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 40 (lcCDR1), SEQ ID NO: 41 (lcCDR2) and SEQ ID NO: 42 (lcCDR3); or

[0023] (d) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 43 (hcCDR1), SEQ ID NO: 44 (hcCDR2) and SEQ ID NO: 45 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 46 (lcCDR1), SEQ ID NO: 47 (lcCDR2) and SEQ ID NO: 48 (lcCDR3); or

[0024] (e) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 49 (hcCDR1), SEQ ID NO: 50 (hcCDR2) and SEQ ID NO: 51 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 52 (lcCDR1), SEQ ID NO: 53 (lcCDR2) and SEQ ID NO: 54 (lcCDR3); or

[0025] (f) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 55 (hcCDR1), SEQ ID NO: 56 (hcCDR2) and SEQ ID NO: 57 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 58 (lcCDR1), SEQ ID NO: 59 (lcCDR2) and SEQ ID NO: 60 (lcCDR3); or

[0026] (g) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 61 (hcCDR1), SEQ ID NO: 62 (hcCDR2) and SEQ ID NO: 63 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 64 (lcCDR1), SEQ ID NO: 65 (lcCDR2) and SEQ ID NO: 66 (lcCDR3); or

[0027] (h) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 67 (hcCDR1), SEQ ID NO: 68 (hcCDR2) and SEQ ID NO: 69 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 70 (lcCDR1), SEQ ID NO: 71 (lcCDR2) and SEQ ID NO: 72 (lcCDR3).

[0028] According to another aspect of the present invention, a method for treating cancer is also provided. In one embodiment, the anti-CD73 antibody molecule of the present invention can be used in combination with a second therapeutic agent (e.g., a PD-1 antagonist). In some embodiments, the second therapeutic agent (e.g., a PD-1 antagonist) is to be administered simultaneously, in parallel, sequentially, continuously, alternately, or separately with the anti-CD73 antibody molecule. In some embodiments, the PD-1 antagonist is an anti-PD-1 antibody or an anti-PDL-1 antibody. In some embodiments, the PD-1 antagonist is an anti-PD-1 antibody selected from the group consisting of: PDR-001, pembrolizumab, nivolumab, and pidilizumab. In some embodiments, the PD-1 antagonist is an anti-PDL-1 antibody selected from the group consisting of: atezolizumab, avelumab, and durvalumab. In some embodiments, the PD-1 antagonist is an anti-PD-1 antibody selected from the group consisting of PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5.

[0029] Other embodiments of these aspects of the invention include those wherein such antibody molecules of the invention are used in combination with a third therapeutic agent.

[0030] Further aspects, embodiments, uses and methods relating to the antibody molecules of the invention will be apparent from the following detailed description of the invention and the appended claims.

[0031] The present invention provides novel antibody molecules that allow for more effective treatment of several cancer types, including lung cancer (e.g., non-small cell lung cancer NSCLC), various gastrointestinal cancers (e.g., colon cancer, gastric cancer, hepatocellular carcinoma), and kidney cancer (e.g., renal cell carcinoma, e.g., clear cell carcinoma)). BRIEF DESCRIPTION OF THE DRAWINGS

[0033] Figure 1 : Dendritic cell / T cell co-culture. The data (as further described in Example 7) illustrate that AMPs inhibit anti-PD1 responses in a dendritic cell / T cell co-culture assay, and anti-CD73 antibody treatment results in reversal of this AMP-mediated inhibition.

[0034] Figure 2 : Complex formation of anti-CD73 antibodies and CD73. Depicted is the assessment of the oligomeric state of complexes of CD73 and two anti-CD73 antibodies (as described in Example 9). Anti-CD73 antibody molecules according to the invention form antigen-antibody complexes of defined sizes (e.g., 2:2 oligomers) with soluble CD73. These complexes are smaller than those formed by other CD73 antibodies known in the art (e.g., "MEDI9447").

[0035] Figure 3 : Crystal structure of anti-CD73 antibody-CD73 crystals

[0036] (A) depicts the binding of the Fab fragment of the anti-CD73 antibody of the present invention to its conformational epitope on CD73. The residues that contact and / or specifically bind to the Fab fragment of the anti-CD73 antibody of the present invention are depicted in black; H Color it dark gray and change V L Colored in light grey; (B) Magnification of the conformational epitope specifically bound by the antibody of the invention shown in black in (A); the CD73 amino acid residues included in the conformational epitope are labeled using the 3-letter amino acid code; (C) Amino acid residues in the heavy (H) and light (L) chains of the antibody of the invention that generate the paratope of the Fab fragment of the antibody of the invention shown in (A), which contact and / or specifically bind to the conformational epitope depicted in (A); the amino acid residues that contact and / or specifically bind to the conformational epitope on CD73 are labeled using the 3-letter amino acid code with (H) and (L) indicating the heavy and light chain amino acid residues.

[0037] Figure 4 : IFNγ release in human T cell assays

[0038] Stimulated primary human T cells were treated with various αCD73 antibody concentrations followed by the addition of AMP. Induction of proliferation and release of IFNγ was measured. The assay was performed as outlined in Example 6. Detailed Description of the Invention

[0040] definition

[0041] The above and other aspects and embodiments of the invention will become apparent from the further description herein.

[0042] Unless otherwise indicated or defined, all terms used have the common meaning in the art as will be apparent to those skilled in the art. For example, reference may be made to standard manuals (e.g., Sambrook et al., "Molecular Cloning: A Laboratory Manual" (2nd edition), Vols. 1-3, Cold Spring Harbor Laboratory Press (1989); Lewin, "Genes IV", Oxford University Press, New York, (1990); and Roitt et al., "Immunology" (2nd edition), Gower Medical Publishing, London, New York (1989)) and the general background technology cited herein. In addition, unless otherwise indicated, all methods, steps, techniques, and manipulations that can be implemented and implemented in a manner known per se and not explicitly described in detail are as will be apparent to those skilled in the art. For example, reference may also be made to standard manuals, the general background technology mentioned above, and other references cited therein.

[0043] As used herein, the articles "a" and "an" refer to one or more than one (e.g., at least one) of the grammatical term of the article. When used herein, the term "comprising" and its variations (e.g., "comprises" and "comprise") can be replaced by the terms "containing" or "including" or "having" or "has," respectively, and vice versa.

[0044] "Antibody molecules" or "antibodies" (used synonymously herein) are gamma globulins that can be found in the blood or other body fluids of vertebrates and are used by the immune system to identify and neutralize foreign objects (such as bacteria and viruses). They are generally composed of basic structural units (each having two large heavy chains and two small light chains) to form (for example) a monomer with one unit, a dimer with two units, or a pentamer with five units. Antibody molecules can bind to other molecules or structures called antigens through non-covalent interactions. This binding is specific in the sense that antibody molecules only bind to specific structures with high affinity. The unique antigen portion recognized by an antibody molecule is called an epitope or antigenic determinant. The portion of the antibody molecule that binds to the epitope is sometimes called a paratope, which is a molecular determinant within the antibody structure that specifically interacts with the antigen; and the so-called variable domain or variable region (Fv) of the antibody composed of CDRs. The paratope may comprise, in whole or in part, the CDRs of the heavy chain, light chain, or both the heavy and light chains of a given antibody. The variable domain comprises three so-called complementary determining regions (CDRs) separated by framework regions (FRs).

[0045] The terms "complementarity determining region" and "CDR" are known in the art to refer to non-contiguous sequences of amino acids within an antibody variable region that confer antigen specificity and binding affinity. Generally, there are three (3) CDRs in each heavy chain variable region (CDR-H1, CDR-H2, CDR-H3) and three (3) CDRs in each light chain variable region (CDR-L1, CDR-L2, CDR-L3).

[0046] The amino acid sequence boundaries of a given CDR can be determined using any of a number of known schemes, including that described by Kabat et al. (1991), "Sequences of Proteins of Immunological Interest", 5th ed., Public Health Service, National Institutes of Health, Bethesda, Md. ("Kabat" numbering scheme); Al-Lazikani et al. (1997) JMB 273, 927-948 ("Chothia" numbering scheme); MacCallum et al., J. Mol. Biol. 262:732-745 (1996), "Antibody-antigen interactions: Contact analysis and binding site topography", J. Mol. Biol. 262, 732-745. ("contact" numbering scheme); Lefranc MP et al., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Igsuperfamily V-like domains", Dev Comp Immunol, 2003 Jan;27(1):55-77 ("IMGT" or "CCG" numbering scheme); and Honegger A and Plitickthun A, "Yet another numbering scheme for immunoglobulin variable domains: an automatic modeling and analysis tool", J Mol Biol, 2001 Jun. 8;309(3):657-70, (AHo numbering scheme).

[0047] The boundaries of a given CDR may vary according to naming conventions. The amino acid positions assigned to CDRs and FRs can be defined, for example, according to the Kabat numbering system, where the VH framework regions (FRs) and CDRs are positioned as follows: residues 1-30 (FR1), 31-35 (CDR1), 36-49 (FR2), 50-65 (CDR2), 66-94 (FR3), 95-102 (CDR3), and 103-113 (FR4). Similarly, according to the Kabat numbering system, the VL FRs and CDRs are positioned as follows: residues 1-23 (FR1), 24-34 (CDR1), 35-49 (FR2), 50-56 (CDR2), 57-88 (FR3), 89-97 (CDR3), and 98-107 (FR4).

[0048] Alternatively, IMGT or CCG unique numbering has been defined to compare variable domains regardless of antigen receptor, chain type, or species (Lefranc, M.-P., Pommie, C., Ruiz, M., Giudicelli, V., Foulquier, E., Truong, L., Thouvenin-Contet, V., and Lefranc, G., "IMGT unique numbering for immunoglobulin and T cell receptor variable domains and Ig superfamily V-like domains," Dev. Comp. Immunol., 27, 55-77 (2003). In the IMGT unique numbering, conserved amino acids always have the same position, such as cysteine ​​23 (1st-CYS), tryptophan 41 (conserved-TRP), hydrophobic amino acid 89, cysteine ​​104 (2nd-CYS), phenylalanine or tryptophan 118 (J-PHE or J-TRP). The IMGT unique numbering provides standardized delimitations for the framework regions (FR1-IMGT: positions 1 to 26, FR2-IMGT: 39 to 55, FR3-IMGT: 66 to 104, and FR4-IMGT: 118 to 128) and complementarity determining regions (CDR1-IMGT: 27 to 38, CDR2-IMGT: 56 to 65, and CDR3-IMGT: 105 to 117).

[0049] In the context of the present invention, reference to CDRs is based on definitions in CCG / IMGT convention, however, the disclosure is not limited to FRs and CDRs as defined by any one numbering system, but encompasses all numbering systems (including those discussed above).

[0050] Therefore, unless otherwise specified, the terms "CDR" and "complementarity determining region" of a given antibody or region thereof (e.g., variable region) and the individual CDRs (e.g., CDR-H1, CDR-H2) and framework regions (FR) of an antibody or region thereof should be understood to encompass respective regions (e.g., complementary determining regions) as defined by any of the above-mentioned known schemes. In some cases, a scheme for identifying one or more specific CDRs is specified, such as CDRs as defined by Kabat, Chothia, IMGT, AHO, or other methods known in the art. In other cases, the specific amino acid sequence of a given CDR is given.

[0051] In some embodiments, the antibody molecule has a heavy chain constant region selected from the heavy chain constant region of (for example) IgG1, IgG2, IgG3, IgG4, IgM, IgA1, IgA2, IgD and IgE; in particular, the heavy chain constant region is a (for example, human) heavy chain constant region selected from (for example) IgG1, IgG2, IgG3 and IgG4. In another embodiment, the antibody molecule has a light chain constant region selected from (for example) κ or λ (for example, human) light chain constant region. The constant region can be changed (for example, mutated) to modify the properties of the antibody (for example, to increase or decrease one or more of the following: Fc receptor binding, antibody glycosylation, number of cysteine ​​residues, effector cell function and / or complement function). In some embodiments, the antibody has effector function and can fix complement. In other embodiments, the antibody does not recruit effector cells or fix complement. In certain embodiments, the antibody has a reduced or no ability to bind to Fc receptors. For example, it may be an isoform or subtype, fragment or other mutant that does not support binding to an Fc receptor, eg, it has a mutagenized or deleted Fc receptor binding region.

[0052] The antibody constant region changes in some embodiments. Methods for changing the antibody constant region are known in the art. Functional changes, such as antibodies with changed affinity for effector ligands (e.g., FcR on a cell or the C1 component of complement) can be produced by replacing at least one amino acid residue in the constant portion of the antibody with different residues (see, for example, EP 388,151A1, U.S. Patent No. 5,624,821 and U.S. Patent No. 5,648,260, the contents of all such patents are incorporated herein by reference). If applied to murine or other species immunoglobulins, similar changes that will reduce or eliminate these functions can be described. In one embodiment, the antibody comprises L234A and / or L235A mutations (Kabat nomenclature), such mutations corresponding to positions L232A and L233A in the actual numbering of the exemplary antibodies described herein. In one embodiment, the antibody is human IgG1.

[0053] The polypeptides of the present invention may have a modified N-terminal sequence (e.g., deletion of one or more N-terminal amino acids or exchange of, for example, the first N-terminal amino acid (e.g., glutamic acid to alanine)) to optimize the molecule for expression using certain expression systems (e.g., specific vectors or host cells), or expression in inclusion bodies or soluble form, or secretion into the culture medium or periplasmic space, or contained within the cell, or to produce a more homogeneous product. The polypeptides of the present invention may have a modified C-terminal sequence (e.g., additional alanines and / or other amino acid exchanges or deletions at other defined positions in the C-terminal portion or within any framework region, as described, for example, in WO2012 / 175741, WO2011 / 075861, or WO2013 / 024059) to, for example, further enhance the stability of such polypeptides or reduce their immunogenicity.

[0054] The terms "variable region" or "variable domain", used interchangeably herein, may refer to a region of an antibody molecule that essentially consists of four "framework regions" (referred to in the art and hereinafter as "framework region 1" or "FR1," "framework region 2" or "FR2," "framework region 3" or "FR3," and "framework region 4" or "FR4," respectively), interrupted by three "complementarity determining regions" or "CDRs" (referred to in the art and hereinafter as "complementarity determining region 1" or "CDR1," "complementarity determining region 2" or "CDR2," and "complementarity determining region 3" or "CDR3," respectively). Thus, the general structure or sequence of an immunoglobulin variable domain can be indicated as follows: FR1-CDR1-FR2-CDR2-FR3-CDR3-FR4. The immunoglobulin variable domain confers specificity to the antibody for the antigen by carrying the antigen binding site.

[0055] The terms "variable heavy chain (or VH)" and "variable light chain (or VL)" refer to the variable domains of the heavy or light chains of an antibody molecule, respectively. Thus, the CDRs of the heavy chain (HC) are referred to as "HCDRs," and the CDRs of the light chain (LC) are referred to as "LCDRs," respectively.

[0056] The art has further developed antibody molecules and made them versatile tools in medicine and technology. Therefore, in the context of the present invention, the term "antibody molecule" or "antibody" not only includes antibodies that can be found in nature comprising (for example) two light chains and two heavy chains, but also encompasses all molecules that comprise at least one paratope with binding specificity for an antigen and have structural similarity to the variable domains of an antibody molecule.

[0057] Thus, the antibody molecules according to the present invention comprise monoclonal antibodies, human antibodies or humanized antibodies.

[0058] Also encompassed are chimeric antibodies, antibody fragments (particularly Fv, Fab, Fab' or F(ab')2 fragments), single-chain antibodies (particularly single-chain variable fragment (scFv)), small modular immunopharmaceuticals (SMIPs), domain antibodies, nanobodies, and diabodies.

[0059] Monoclonal antibodies (mAbs) are monospecific antibodies with identical amino acid sequences. They can be produced by hybridoma technology from hybrid cell lines (called hybridomas), which represent clones of a fusion of B cells producing specific antibodies and myeloma (B cell cancer) cells (Kohler G, Milstein C. Continuous cultures of fused cells secreting antibodies of predefined specificity. Nature 1975; 256: 495-7.). Alternatively, monoclonal antibodies can be produced by recombinant expression in host cells (Norderhaug L, Olafsen T, Michaelsen TE, Sandlie I. (May 1997). "Versatile vectors for transient and stable expression of recombinant antibody molecules in mammalian cells", J Immunol Methods 204 (1): 77-87. "Recombinant antibodies" are antibodies produced by recombinantly engineered host cells. They are optionally isolated or purified.

[0060] For application in humans, it is generally desirable to reduce the immunogenicity of antibodies originally derived from other species (such as mice). This can be accomplished by constructing chimeric antibodies or by a process known as "humanization". In this context, "chimeric antibodies" are understood to be antibodies comprising sequence portions (such as variable domains) derived from one species (such as mice) and sequence portions (such as constant domains) derived from a different species (such as humans), and the fusion of these two sequence portions. "Humanized antibodies" are antibodies comprising variable domains originally derived from non-human species, in which certain amino acids have been mutated so that the overall sequence of the variable domains more closely resembles a sequence of human variable domains. Methods for chimerizing and humanizing antibodies are well known in the art (Billetta R, Lobuglio AF. "Chimeric antibodies". Int Rev Immunol. 1993; 10(2-3): 165-76; Riechmann L, Clark M, Waldmann H, Winter G (1988). "Reshaping human antibodies for therapy". Nature: 332: 323).

[0061] A "humanized" antibody refers to an antibody comprising amino acid residues from non-human hypervariable regions (HVRs) and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise substantially all of at least one and typically two variable domains, wherein all or substantially all of the HVRs (e.g., complementarity determining regions (CDRs)) correspond to the HVRs of non-human antibodies, and all or substantially all of the framework regions (FRs) correspond to the FRs of human antibodies. A humanized antibody optionally may comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody (e.g., a non-human antibody) refers to an antibody that has been humanized.

[0062] In addition, techniques have been developed for producing antibodies based on sequences derived from the human genome, for example by phage display or using transgenic animals (WO 90 / 05144; D. Marks, HR Hoogenboom, TP Bonnert, J. McCafferty, AD Griffiths and G. Winter (1991) "By-passing immunisation. Human antibodies from V-gene libraries displayed on phage". J. Mol. Biol., 222, 581-597; Knappik et al., J. Mol. Biol. 296: 57-86, 2000; S. Carmen and L. Jermutus, "Concepts in antibody phage display". Briefings in Functional Genomics and Proteomics 20021(2): 189-203; Lonberg N, Huszar D. "Human antibodies from transgenic mice". Int Rev. Immunol. 1995; 13(1): 65-93; Brüggemann M, Taussig MJ. "Production of human antibody repertoires in transgenic mice". Curr Opin Biotechnol. 1997 Aug; 8(4): 455-8.) In the context of the present invention, such antibodies are "human antibodies".

[0063] Also encompassed are molecular fragments retaining antigen-binding properties, such as Fab, Fab' or F(ab')2 fragments. Such fragments can be obtained by fragmentation of antibody molecules (e.g., by proteolytic digestion) or by recombinant expression of such fragments. For example, antibody molecule digestion (WO 94 / 29348) can be accomplished by conventional techniques (e.g., using papain or pepsin). Papain digestion of antibodies typically produces two identical antigen-binding fragments (so-called Fab fragments, each fragment having a single antigen-binding site) and a residual Fc fragment. Pepsin treatment produces F(ab')2. In Fab molecules, the variable domains are each fused to an immunoglobulin constant domain that is preferably human in origin. Therefore, the heavy chain variable domain can be fused to the CH1 domain (so-called Fd fragment), and the light chain variable domain can be fused to the CL domain. Fab molecules can be produced by recombinantly expressing each nucleic acid in a host cell, as described below.

[0064] Many technologies have been developed to place the variable domains of antibody molecules or molecules derived from such variable domains in different molecular backgrounds. Generally speaking, the size of these antibody molecules is smaller than that of natural antibody molecules and may include a single amino acid chain or several amino acid chains. For example, single-chain variable fragment (scFv) is a fusion in which the variable regions of the heavy and light chains of an antibody molecule are linked together through a short linker (usually serine (S) or glycine (G)) (WO 88 / 01649; WO 91 / 17271; Huston et al., International Reviews of Immunology, Vol. 10, 1993, 195-217). "Single domain antibodies" or "nanobodies" have an antigen binding site in a single Ig-like domain (WO 94 / 04678; WO 03 / 050531; Ward et al., Nature. 1989 Oct 12; 341(6242): 544-6; Revets et al., Expert Opin Biol Ther. 5(1): 111-24, 2005). One or more single domain antibodies with binding specificity for the same or different antigens can be linked together. Diabodies are bivalent antibody molecules composed of two amino acid chains containing two variable domains (WO 94 / 13804; Holliger et al., Proc Natl Acad Sci US A. 1993 Jul 15; 90(14): 6444-8). Other examples of antibody-like molecules are immunoglobulin superfamily antibodies (IgSF; Srinivasan and Roeske, Current Protein Pept. Sci. 2005, 6(2):185-96). A different concept leads to so-called small modular immunopharmaceuticals (SMIPs), which comprise an Fv domain connected to a single-chain hinge and an effector domain without the constant domain CH1 (WO 02 / 056910).

[0065] Antibody molecules can be fused (in fusion protein form) or otherwise connected (by covalent or non-covalent bond) to other molecular entities with desired effects on the properties of antibody molecules. For example, it is desirable to improve the pharmacokinetic properties of antibody molecules, the stability in (for example) body fluids (such as blood), especially in the case of single-chain antibodies or single domain antibodies. Thus, many technologies have been developed, especially to extend the half-life of such antibody molecules in circulation, such as pegylation (WO 98 / 25971; WO 98 / 48837; WO 2004081026), antibody molecules are fused or otherwise covalently attached to another antibody molecule (WO 2004041865) with affinity for serum proteins (such as albumin; WO2004003019), or antibody molecules are expressed as fusion proteins (WO 01 / 79258) with all or a portion of serum proteins (such as albumin or transferrin).

[0066] The terms "epitope" and "antigenic determinant" used interchangeably refer to a portion of a macromolecule (e.g., a polypeptide) that is recognized by an antigen binding molecule (e.g., an antibody molecule of the present invention) and, more specifically, by the antigen binding site of the molecule. An epitope defines the minimum binding site of an antibody molecule and thus represents the specific target of the antibody molecule. An epitope can be further defined as a structural epitope or a functional epitope. A "structural epitope" consists of amino acids or other molecules in an area that is in close contact with the antibody, typically as revealed by the structure. A "functional epitope" is defined as those portions of a molecule that contribute energy to binding, wherein binding affinity will decrease when it is altered. Therefore, residues that contact the paratope and residues that contribute to affinity (regardless of whether they are adjacent) are important considerations when defining an epitope. X-ray crystallography is a method for determining the precise site of interaction between an antibody and its antigen. Crystal structure enables accurate determination of key interactions between individual amino acids from side chains and main chain atoms in epitopes and paratopes. Amino acids within 4.5 angstroms of each other are generally considered to be contact residues.

[0067] Antibody molecules that "bind," "bind to," "specifically bind," or "specifically bind to," "have affinity for," and / or "have specificity for," an epitope, antigen, or protein (or at least a portion, fragment, or epitope thereof) are said to be "against" or "directed against" that epitope, antigen, or protein, or to be "binding" molecules with respect to such epitope, antigen, or protein.

[0068] Generally, the term "specificity" refers to the ability of a particular antigen-binding molecule or antigen-binding protein (e.g., immunoglobulin, antibody, immunoglobulin single variable domain) to bind to many different types of antigens or epitopes. The specificity of an antigen-binding protein can be determined based on affinity and / or avidity. Affinity (determined by the equilibrium constant (K) for the dissociation of the antigen from the antigen-binding protein)D K is a measure of the strength of binding between an epitope and the antigen binding site on an antigen binding protein: D The smaller the value, the stronger the binding strength between the epitope and the antigen-binding molecule (or, affinity can also be expressed as affinity constant (K A ), which is 1 / K D As will be clear to those skilled in the art (e.g., based on the other disclosures herein), affinity can be determined in a manner known per se, depending on the specific antigen of interest. Avidity is a measure of the strength of binding between an antigen-binding molecule (e.g., an antibody of the invention) and the relevant antigen. Avidity is related to the affinity between an epitope and its antigen-binding site on the antigen-binding molecule and the number of relevant binding sites present on the antigen-binding molecule.

[0069] Typically, antigen binding proteins (e.g., antibody molecules of the invention) bind to antigens with a dissociation constant (K) of 10E-5 to 10E-14 mol / liter (M) or less, and preferably 10E-7 to 10E-14 mol / liter (M) or less, more preferably 10E-8 to 10E-14 mol / liter, and even more preferably 10E-11 to 10E-13. D ) (as measured, for example, in the Kinexa assay known in the art) and / or with an association constant (K) of at least 10E7 ME-1, preferably at least 10E8 ME-1, more preferably at least 10E9 ME-1, for example at least 10E11 ME-1 A ) for combination. Any K greater than 10E-4M D A value of 0.05 is generally considered to indicate nonspecific binding. Preferably, the antibodies of the invention bind with a K of less than 500 nM, preferably less than 200 nM, more preferably less than 10 nM, for example less than 500 pM. D Binding to the desired antigen. Specific binding of an antigen-binding protein to an antigen or epitope can be determined in any suitable manner known per se, including, for example, assays described herein, such as surface plasmon resonance (SPR), Scatchard analysis, and / or competitive binding assays (e.g., radioimmunoassays (RIA), enzyme immunoassays (EIA), and sandwich competition assays), and various variations thereof known per se in the art.

[0070] The binding affinity of an antibody molecule can be enhanced by a process known as affinity maturation (Marks et al., 1992, Biotechnology 10:779-783; Barbas, et al., 1994, Proc. Nat. Acad. Sci, USA 91:3809-3813; Shier et al., 1995, Gene 169:147-155). Affinity matured antibodies are also encompassed by the present invention.

[0071] For example, affinity maturation of an antibody of the invention may alter one or more amino acids introduced into the framework and / or CDR regions, which may improve binding affinity for the antigen without altering the antibody's specificity for its epitope. Thus, embodiments of the invention include, for example, antibodies that specifically bind to CD73 comprising a heavy chain variable region that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% amino acid sequence identity to SEQ ID NO: 73, SEQ ID NO: 75, SEQ ID NO: 77, SEQ ID NO: 79, SEQ ID NO: 81, SEQ ID NO: 83, SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95 and a heavy chain variable region that has at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% amino acid sequence identity to SEQ ID NO: 74, SEQ ID NO: 76, SEQ ID NO: 78, SEQ ID NO: 80, SEQ ID NO: 82, SEQ ID NO: 84, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: NO: 96 has a light chain variable region with at least 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% amino acid sequence identity. For example, the affinity matured antibodies of the present invention may comprise a light chain variable region comprising 1, 2, 3, 4, 5, 6, 7, 8, 9 or 10 amino acid substitutions as disclosed above (wherein the amino acid substitutions may be conservative amino acid substitutions or non-conservative amino acid substitutions) and / or a heavy chain variable region comprising 1, 2, 3, 4, 5, 6, 7, 8, 9, 10 or 11 amino acid substitutions as disclosed above (wherein the amino acid substitutions may be conservative amino acid substitutions or non-conservative amino acid substitutions).

[0072] For example, the present invention also encompasses mutations in the antibody sequences of the present invention, such mutations may comprise substitutions, deletions (including internal deletions), additions (including additions to generate fusion proteins), or conservative substitutions of amino acid residues within and / or nearby amino acid sequences that do not produce a functional ("silent") change, which results in a functionally equivalent anti-CD73 antibody. Such changes may, for example, comprise conservative amino acid substitutions, which may be made based on similarity in polarity, charge, solubility, hydrophobicity, hydrophilicity, and / or amphipathic properties of the residues involved. For example, non-polar (hydrophobic) amino acids include alanine, leucine, isoleucine, valine, proline, phenylalanine, tryptophan, and methionine; polar neutral amino acids include glycine, serine, threonine, cysteine, tyrosine, asparagine, and glutamine; positively charged (basic) amino acids include arginine, lysine, and histidine; and negatively charged (acidic) amino acids include aspartic acid and glutamic acid. In addition, glycine and proline are residues that can affect chain orientation. Non-conservative substitutions entail exchanging a member of one of these classes for a member of another class.

[0073] In one embodiment, the present invention relates to anti-CD73 antibodies and altered / mutated derivatives thereof with enhanced effector function, including but not limited to derivatives that exhibit altered binding properties (e.g., altered association constant k 缔合 , dissociation constant k, dissociation and / or equilibrium constant or binding affinity K D ) derivatives.

[0074] The compositions and methods disclosed herein encompass polypeptides and nucleic acids having a specified sequence or a sequence substantially identical or similar thereto, e.g., a sequence at least 85%, 90%, 95% identical or higher to a specified sequence. In the context of amino acid sequences, the term "substantially identical" is used herein to refer to a first amino acid that contains a sufficient or minimum number of i) amino acid residues identical to the aligned amino acid residues in the second amino acid sequence, or ii) conservative substitutions of the aligned amino acid residues in the second amino acid sequence, such that the first and second amino acid sequences can have a common structural domain and / or a common functional activity. For example, an amino acid sequence containing a common structural domain that is at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identical to a reference sequence (e.g., a sequence provided herein). In the context of nucleotide sequences, the term "substantially identical" is used herein to refer to a first nucleic acid sequence containing a sufficient or minimum number of nucleotides that are identical to the aligned nucleotides in a second nucleic acid sequence such that the first and second nucleotide sequences encode a polypeptide having a shared functional activity or encode a shared structural polypeptide domain or a shared functional polypeptide activity. For example, a nucleotide sequence having at least about 85%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98% or 99% identity to a reference sequence.

[0075] In the context of two or more nucleic acid or polypeptide sequences, the term "identical" or "percent identity" means that two or more sequences or subsequences are identical or have a specified percentage of identical nucleotides or amino acid residues when compared and aligned for maximum consistency. To determine the percent identity, the sequences are aligned for optimal comparison purposes (for example, gaps can be introduced into a first amino acid or nucleic acid sequence for optimal comparison with a second amino acid or nucleic acid sequence). The amino acid residues or nucleotides at corresponding amino acid positions or nucleotide positions are then compared. When a position in the first sequence is occupied by the same amino acid residue or nucleotide as the corresponding position in the second sequence, then such molecules are identical at that position. The % identity between two sequences is a function of the number of identical positions shared by such sequences (i.e., % identity = number of identical positions / total number of positions (e.g., overlapping positions) × 100). In some embodiments, the two sequences being compared are of the same length after gaps are introduced into the sequences as desired (e.g., excluding additional sequences extending beyond the compared sequences). For example, when comparing variable region sequences, leader sequences and / or constant domain sequences are not considered. In a sequence alignment between two sequences, a "corresponding" CDR refers to the CDR at the same position in both sequences (eg, CDR-H1 in each sequence).

[0076] A mathematical algorithm can be used to determine the percent identity or similarity between two sequences. A preferred, non-limiting example of a mathematical algorithm for comparing two sequences is the algorithm of Karlin and Altschul (1990, Proc. Natl. Acad. Sci. USA 87: 2264-2268), modified according to Karlin and Altschul, 1993, Proc. Natl. Acad. Sci. USA 90: 5873-5877. This algorithm has been incorporated into the NBLAST and XBLAST programs of Altschul et al. 1990, J. Mol. Biol. 215: 403-410. BLAST nucleotide searches can be performed using the NBLAST program (score = 100, word length = 12) to obtain nucleotide sequences homologous to the nucleic acid encoding the protein of interest. BLAST protein searches can be performed using the XBLAST program (score = 50, word length = 3) to obtain amino acid sequences homologous to the protein of interest. To obtain gap alignments for comparison purposes, gap BLAST can be utilized as described in Altschul et al., 1997, Nucleic Acids Res. 25: 3389-3402. Alternatively, PSI-Blast can be used to implement iterative searches to detect long-range relationships between molecules (same document). When utilizing BLAST, gap BLAST, and PSI-Blast programs, the preset parameters of each program (e.g., XBLAST and NBLAST) can be used. Another preferred non-limiting example of a mathematical algorithm for comparing sequences is the algorithm of Myers and Miller (CABIOS, 1989). This algorithm has been incorporated into the ALIGN program (version 2.0), which is a part of the GCG sequence alignment software package. When utilizing the ALIGN program to compare amino acid sequences, a PAM120 weighted residual table, a gap length penalty equal to 12, and a gap penalty equal to 4 can be used. Other algorithms for sequence analysis are known in the art and include ADVANCE and ADAM, as described in Torellis and Robotti, 1994, Comput. Appl. Biosci. 10:3-5; and FASTA, as described in Pearson and Lipman, 1988, Proc. Natl. Acad. Sci. USA 85:2444-8. Within FASTA, ktup is a control option that sets the sensitivity and speed of the search. If ktup=2, similar regions in the two sequences being compared are found by examining pairs of aligned residues; if ktup=1, single aligned amino acids are examined. For protein sequences, ktup can be set to 2 or 1, or to 1 to 6 for DNA sequences. If ktup is not specified, the default value is 2 for proteins and 6 for DNA.Alternatively, protein sequence alignments can be performed using the CLUSTAL W algorithm as described by Higgins et al., 1996, Methods Enzymol. 266:383-402.

[0077] Amino acid residues are indicated according to the standard three-letter or one-letter amino acid code, as generally known and recognized in the art. When comparing two amino acid sequences, the term "amino acid difference" refers to the insertion, deletion, or substitution of the indicated number of amino acid residues at a position in a reference sequence compared to a second sequence. In the case of substitutions, such substitutions are preferably conservative amino acid substitutions, meaning that an amino acid residue is replaced by another amino acid residue of similar chemical structure and that has minimal or substantially no effect on the function, activity, or other biological properties of the polypeptide. Such conservative amino acid substitutions are well known in the art, for example from WO 1998 / 49185, wherein conservative amino acid substitutions are preferably substitutions in which one amino acid from the following groups (i) to (v) is replaced by another amino acid residue from the same group: (i) small aliphatic, non-polar or slightly polar residues: Ala, Ser, Thr, Pro and Gly; (ii) polar, negatively charged residues and their (uncharged) amides: Asp, Asn, Glu and Gin; (iii) polar, positively charged residues: His, Arg and Lys; (iv) large aliphatic, non-polar residues: Met, Leu, Ile, Val and Cys; and (v) aromatic residues: Phe, Tyr and Trp. Particularly preferred conservative amino acid substitutions are as follows: Ala is substituted with Gly or with Ser; Arg is substituted with Lys; Asn is substituted with Gln or with His; Asp is substituted with Glu; Cys is substituted with Ser; Gln is substituted with Asn; Glu is substituted with Asp; Gly is substituted with Ala or with Pro; His is substituted with Asn or with Gln; Ile is substituted with Leu or with Val; Leu is substituted with Ile or with Val; Lys is substituted with Arg, with Gln or with Glu; Met is substituted with Leu, with Tyr or with Ile; Phe is substituted with Met, with Leu or with Tyr; Ser is substituted with Thr; Thr is substituted with Ser; Trp is substituted with Tyr; Tyr is substituted with Trp or with Phe; Val is substituted with Ile or with Leu.

[0078] The terms "polypeptide," "peptide," and "protein" (if single chain) are used interchangeably herein.

[0079] The terms "nucleic acid," "nucleic acid sequence," "nucleotide sequence," or "polynucleotide sequence" and "polynucleotide" are used interchangeably.

[0080] As used herein, the term "isolated" refers to material that has been removed from its original or natural environment (e.g., if it is naturally occurring, the natural environment). For example, a naturally occurring polynucleotide or polypeptide present in a living animal is not isolated, but the same polynucleotide or polypeptide separated from some or all coexisting materials in the natural system by human intervention is isolated. Such a polynucleotide can be part of a vector and / or such a polynucleotide or polypeptide can be part of a composition and still be isolated such that the vector or composition is not part of the environment in which it is found in nature.

[0081] Preferably, the nucleic acid is part of an expression vector, wherein the nucleic acid molecule is operably linked to at least one regulatory sequence, wherein such regulatory sequence may be a promoter, enhancer or terminator sequence, and most preferably a heterologous promoter, enhancer or terminator sequence.

[0082] The terms "PD1" and "PD-1" are used interchangeably herein. The terms "PDL1" and "PDL-1" are also used interchangeably herein. As disclosed below, PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 refer to specific anti-PD-1 antibodies, respectively.

[0083] As used herein, when written in quotation marks (""), "MEDI9447" and "BMS986179" refer to reference antibodies generated according to the information disclosed in WO 2016 / 075099 ("MEDI9447") and WO 2016 / 081748 ("BMS986179," also referred to therein as mAb-CD73.4-Vh-hHC-IgG2-IgGl.1f), respectively. The entire contents of WO 2016 / 075099 and WO 2016 / 081748 are each incorporated herein by reference.

[0084] For the avoidance of doubt, "cluster of differentiation 73" or "CD73" means the human protein encoded by the gene "NT5E - extracellular 5'-nucleotidase [Homo sapiens (human)]", which is provided as follows: NCBI Reference Sequence: NP_002517.1, available at http: / / www.ncbi.nlm.nih.gov / protein / NP_002517.1 (long isoform, which corresponds to UniProt Accession No. P21589); and NCBI Reference Sequence: NP_001191742.1, available at https: / / www.ncbi.nlm.nih.gov / protein / NP_001191742.1 (short isoform); and the respective nucleic acid sequences encoding these proteins. As used herein, "CD73" may refer to monomeric and / or dimeric forms of these proteins. In some embodiments, "CD73" refers to the long isoform of human CD73 as described above. For the crystallographic data as provided herein, the amino acid numbering corresponds to Uniprot Accession No. P21589 (including the signal peptide), wherein the mature protein does not contain the signal peptide corresponding to amino acid residues 1-26 of P21589, however, the numbering scheme in this application refers to the full-length amino acid sequence of P21589. As used herein, murine CD73 refers to Uniprot Accession No. Q61503.

[0085] In living cells and organisms, CD73 typically exists as a dimeric protein anchored to the cell membrane via a glycosylphosphatidylinositol (GPI) membrane linkage (also referred to herein as a "GPI anchor") and has extracellular-5'-nucleotidase activity.

[0086] The terms "soluble CD73" and "sCD73" are used interchangeably herein to refer to CD73 molecules that are not attached to the membrane, for example, via a GPI anchor.

[0087] The term "cell-bound CD73" means a CD73 molecule attached to the cell surface, for example via a GPI anchor.

[0088] The term "non-cell-bound CD73" refers to CD73 present in the extracellular space. It includes soluble CD73 and vesicle-bound CD73 (i.e., CD73 molecules attached to the surface of vesicles in the extracellular space). The term "non-cell-bound CD73" does not include all "cell-bound CD73". The activity of "non-cell-bound CD73" can be determined by measuring CD73 activity in cell culture supernatant, as described in Example 8.

[0089] The terms "IFNγ," "IFNg," "interferon gamma," "interferon-γ," "IFN-γ," "IFNG," "IFNγ (IFNgamma)," "IFN-γ," or the like are used interchangeably herein and refer to cytokines of the interferon family as known in the art (NCBI Gene No.: 3458) that are secreted by cells of the innate and adaptive immune systems, such as T cells.

[0090] Anti-CD73 antibodies of the present invention

[0091] As detailed above, CD73 plays an important role in regulating T cell activity and thereby immune system activity. Antagonist anti-CD73 antibody molecules have been shown in a variety of different cancer settings to reverse adenosine-mediated inhibition of T cell activity, thereby activating the immune system to attack tumors and thereby treating cancer.

[0092] The present invention provides improved anti-CD73 antibodies. From the progenitor murine antibodies of CD73 (referred to as A1, A2, A3 and A4, see Table 9), humanized variants were generated. Preferred anti-CD73 antibody molecules of the present invention are referred to as B1, B2, C1, C2, C3, C4, C5 and C6 (see Table 9), which are humanized monoclonal antibodies. The anti-CD73 antibodies of the present invention may also be referred to, for example, as "antagonistic CD73 antibodies or antagonistic CD73 antibodies," wherein the term "antagonistic" or any grammatical equivalent thereof refers to the inhibition of CD73 function (e.g., solubility and cell surface binding) by the CD73 antibodies of the present invention.

[0093] Using an in vitro T cell activation assay (further described in Example 6), the inventors examined the functional properties of representative anti-CD73 antibodies of the present invention. As can be seen in Example 6 and Tables 5 and 6, the antibodies tested were able to induce T cell proliferation to levels higher than the reference anti-CD73 antibodies in certain donors. In addition, the antibodies tested were able to induce higher IFNγ levels in T cells compared to the reference anti-CD73 antibodies in certain donors. As can be appreciated, this surprising ability of the anti-CD73 antibodies of the present invention to more effectively induce T cell activation than the reference anti-CD73 antibodies of the prior art suggests that they may be more effective in treating cancer and / or improving clinical outcomes.

[0094] The inventors further explored various other functional properties of the anti-CD73 antibody molecules of the present invention. This assessment included determining the ability of the anti-CD73 antibodies to inhibit adenosine formation. This was performed by measuring the inhibition of CD73 on bound cells and the inhibition of CD73 on non-bound cells in cell culture supernatants. Compared to the reference anti-CD73 antibody, the anti-CD73 antibodies of the present invention showed higher activity in inhibiting CD73 on non-bound cells. Therefore, compared to the reference CD73 antibody, these antibodies have the ability to more completely inhibit CD73.

[0095] In contrast to anti-CD73 antibodies known in the art, the anti-CD73 antibodies of the present invention have improved properties, particularly in terms of inhibiting adenosine production and T cell activation. This is different from the known reference anti-CD73 antibody molecules "MEDI9447" and "BMS986179", as can be seen from the accompanying examples. As can be understood, this superiority of the anti-CD73 antibody molecules of the present invention indicates that they may have higher efficacy and / or better clinical results than other anti-CD73 antibodies and thus can be used for more effective cancer therapy.

[0096] Thus, a first aspect of the invention thus provides an anti-CD73 antibody molecule comprising:

[0097] (1) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 1 (hcCDR1), SEQ ID NO: 2 (hcCDR2) and SEQ ID NO: 3 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 4 (lcCDR1), SEQ ID NO: 5 (lcCDR2) and SEQ ID NO: 6 (lcCDR3); or

[0098] (2) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 7 (hcCDR1), SEQ ID NO: 8 (hcCDR2) and SEQ ID NO: 9 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 10 (lcCDR1), SEQ ID NO: 11 (lcCDR2) and SEQ ID NO: 12 (lcCDR3); or

[0099] (3) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 13 (hcCDR1), SEQ ID NO: 14 (hcCDR2) and SEQ ID NO: 15 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 16 (lcCDR1), SEQ ID NO: 17 (lcCDR2) and SEQ ID NO: 18 (lcCDR3); or

[0100] (4) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 19 (hcCDR1), SEQ ID NO: 20 (hcCDR2) and SEQ ID NO: 21 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 22 (lcCDR1), SEQ ID NO: 23 (lcCDR2) and SEQ ID NO: 24 (lcCDR3); or

[0101] (5) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 25 (hcCDR1), SEQ ID NO: 26 (hcCDR2) and SEQ ID NO: 27 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 28 (lcCDR1), SEQ ID NO: 29 (lcCDR2) and SEQ ID NO: 30 (lcCDR3); or

[0102] (6) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 31 (hcCDR1), SEQ ID NO: 32 (hcCDR2) and SEQ ID NO: 33 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 34 (lcCDR1), SEQ ID NO: 35 (lcCDR2) and SEQ ID NO: 36 (lcCDR3); or

[0103] (7) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 37 (hcCDR1), SEQ ID NO: 38 (hcCDR2) and SEQ ID NO: 39 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 40 (lcCDR1), SEQ ID NO: 41 (lcCDR2) and SEQ ID NO: 42 (lcCDR3); or

[0104] (8) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 43 (hcCDR1), SEQ ID NO: 44 (hcCDR2) and SEQ ID NO: 45 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 46 (lcCDR1), SEQ ID NO: 47 (lcCDR2) and SEQ ID NO: 48 (lcCDR3); or

[0105] (9) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 49 (hcCDR1), SEQ ID NO: 50 (hcCDR2) and SEQ ID NO: 51 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 52 (lcCDR1), SEQ ID NO: 53 (lcCDR2) and SEQ ID NO: 54 (lcCDR3); or

[0106] (10) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 55 (hcCDR1), SEQ ID NO: 56 (hcCDR2) and SEQ ID NO: 57 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 58 (lcCDR1), SEQ ID NO: 59 (lcCDR2) and SEQ ID NO: 60 (lcCDR3); or

[0107] (11) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 61 (hcCDR1), SEQ ID NO: 62 (hcCDR2) and SEQ ID NO: 63 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 64 (lcCDR1), SEQ ID NO: 65 (lcCDR2) and SEQ ID NO: 66 (lcCDR3); or

[0108] (12) a heavy chain CDR comprising the amino acid sequence of SEQ ID NO: 67 (hcCDR1), SEQ ID NO: 68 (hcCDR2) and SEQ ID NO: 69 (hcCDR3); and a light chain CDR comprising the amino acid sequence of SEQ ID NO: 70 (lcCDR1), SEQ ID NO: 71 (lcCDR2) and SEQ ID NO: 72 (lcCDR3).

[0109] As outlined above, preferred anti-CD73 antibody molecules of the invention are referred to as B1, B2, C1, C2, C3, C4, C5, and C6. A sequence listing is provided herein (Table 9) which readily allows identification of the individual amino acid sequences of specific anti-CD73 antibody molecules of the invention.

[0110] In addition to the CDR sequences described herein, the antibody molecules of the present invention also include immunoglobulin framework region (FR) sequences. These sequences are preferably not immunogenic in humans and are therefore preferably human or humanized FR sequences. Suitable human or humanized FR sequences are known in the art. Specific preferred FR sequences can be obtained from the embodiments shown herein, which disclose complete antibody molecules and thus CDR sequences and FR sequences.

[0111] Preparation of antibody molecules of the first aspect of the invention is well known in the art, and those skilled in the art will be able to readily prepare antibody molecules having the properties of the first aspect of the invention. Examples of such methods are provided below.

[0112] For the production of antibodies comprising two complete heavy chains and two complete light chains (such as antibodies of IgG1 or IgG4 class), see Norderhaug et al., J Immunol Methods 1997, 204(1):77-87; Kipriyanow and LeGall, Molecular Biotechnology 26:39-60, 2004; Shukla et al., 2007, J. Chromatography B, 848(1):28-39.

[0113] Also known are processes for making scFv antibodies by recombinantly expressing a nucleic acid encoding an scFv construct in a host cell such as E. coli, Pichia pastoris / Komagataella phaffii, or a mammalian cell line (e.g., CHO or NSO) to produce a functional scFv molecule (Rippmann et al., Applied and Environmental Microbiology 1998, 64(12):4862-4869; Yamawaki et al., J. Biosci. Bioeng. 2007, 104(5):403-407; Sonoda et al., Protein Expr. Purif. 2010, 70(2):248-253).

[0114] For the avoidance of doubt, each embodiment listed herein for the first aspect of the present invention is also contemplated for use in its own right.

[0115] A preferred embodiment of the first aspect of the present invention is one wherein the antibody molecule is a humanized antibody molecule.

[0116] In one embodiment, the antibody is a recombinant antibody. In one embodiment, the antibody is isolated. In one embodiment, the antibody is purified.

[0117] Another preferred embodiment of the first aspect of the present invention is one wherein the antibody molecule is a monoclonal antibody, Fab, F(ab')2, Fv or scFv.

[0118] The terms "humanized," "Fab," "F(ab')2," "Fv," and "scFv" are well known in the art and are further discussed herein in the definitions section of the specification.

[0119] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain constant region selected from the group consisting of: IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions. Preferably, the heavy chain constant region is IgG1, more preferably IgG1 with L234A and / or L235A mutations (Kabat numbering; corresponding to positions L232A and L233A in actual numbering).

[0120] In a preferred embodiment, the anti-CD73 antibody molecule has a kappa or lambda light chain constant region.

[0121] In one embodiment, the anti-CD73 antibody molecule has a heavy chain variable domain comprising an amino acid sequence as disclosed above that is at least 85%, 90%, 95% identical to any one of SEQ ID NOs: 73, 75, 77 or 79.

[0122] In one embodiment, the antibody molecule has a heavy chain variable domain comprising the amino acid sequence of any one of SEQ ID NO: 73, 75, 77 or 79.

[0123] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable domain comprising an amino acid sequence that is at least 85%, 90%, 95% identical to any one of SEQ ID NO: 81, 83, 85, 87, 89, 91, 93, or 95. Preferably, the antibody molecule has a heavy chain variable domain comprising the amino acid sequence of any one of SEQ ID NO: 81, 83, 85, 87, 89, 91, 93, or 95. More preferably, the antibody is humanized.

[0124] In one embodiment, the anti-CD73 antibody molecule has a light chain variable domain comprising an amino acid sequence that is at least 85% identical to any one of SEQ ID NOs: 74, 76, 78, or 80.

[0125] In one embodiment, the antibody molecule has a light chain variable domain comprising the amino acid sequence of any one of SEQ ID NO: 74, 76, 78 or 80.

[0126] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable domain comprising an amino acid sequence that is at least 85% identical to any one of SEQ ID NO: 82, 84, 86, 88, 90, 92, 94 or 96. Preferably, the antibody molecule has a light chain variable domain comprising the amino acid sequence of SEQ ID NO: 82, 84, 86, 88, 90, 92, 94 or 96. More preferably, the antibody is humanized.

[0127] Methods of calculating amino acid sequence identity are well known in the art and are further discussed herein in the definitions section of the specification.

[0128] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:81.

[0129] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83.

[0130] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:85.

[0131] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:87.

[0132] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:89.

[0133] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:91.

[0134] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:93.

[0135] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:95.

[0136] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable region comprising the amino acid sequence of SEQ ID NO:82.

[0137] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable region comprising the amino acid sequence of SEQ ID NO:84.

[0138] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable region comprising the amino acid sequence of SEQ ID NO:86.

[0139] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable region comprising the amino acid sequence of SEQ ID NO:88.

[0140] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable region comprising the amino acid sequence of SEQ ID NO:90.

[0141] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable region comprising the amino acid sequence of SEQ ID NO:92.

[0142] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable region comprising the amino acid sequence of SEQ ID NO:94.

[0143] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain variable region comprising the amino acid sequence of SEQ ID NO:96.

[0144] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:105.

[0145] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:107.

[0146] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:109.

[0147] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:111.

[0148] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:113.

[0149] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:115.

[0150] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:117.

[0151] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:119.

[0152] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain comprising the amino acid sequence of SEQ ID NO:106.

[0153] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain comprising the amino acid sequence of SEQ ID NO:108.

[0154] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain comprising the amino acid sequence of SEQ ID NO:110.

[0155] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain comprising the amino acid sequence of SEQ ID NO:112.

[0156] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain comprising the amino acid sequence of SEQ ID NO:114.

[0157] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain comprising the amino acid sequence of SEQ ID NO:116.

[0158] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain comprising the amino acid sequence of SEQ ID NO:118.

[0159] In a preferred embodiment, the anti-CD73 antibody molecule has a light chain comprising the amino acid sequence of SEQ ID NO:120.

[0160] In one embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:73 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:74.

[0161] In one embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:75 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:76.

[0162] In one embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:77 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:78.

[0163] In one embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:79 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:80.

[0164] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:81 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:82.

[0165] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:83 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:84.

[0166] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:85 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:86.

[0167] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:87 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:88.

[0168] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:89 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:90.

[0169] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:91 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:92.

[0170] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:93 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:94.

[0171] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:95 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:96.

[0172] In one embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:97 and a light chain comprising the amino acid sequence of SEQ ID NO:98.

[0173] In one embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:99 and a light chain comprising the amino acid sequence of SEQ ID NO:100.

[0174] In one embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO: 101 and a light chain comprising the amino acid sequence of SEQ ID NO: 102.

[0175] In one embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO: 103 and a light chain comprising the amino acid sequence of SEQ ID NO: 104.

[0176] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO: 105 and a light chain comprising the amino acid sequence of SEQ ID NO: 106.

[0177] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:107 and a light chain comprising the amino acid sequence of SEQ ID NO:108.

[0178] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:109 and a light chain comprising the amino acid sequence of SEQ ID NO:110.

[0179] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:111 and a light chain comprising the amino acid sequence of SEQ ID NO:112.

[0180] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:113 and a light chain comprising the amino acid sequence of SEQ ID NO:114.

[0181] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:115 and a light chain comprising the amino acid sequence of SEQ ID NO:116.

[0182] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO:117 and a light chain comprising the amino acid sequence of SEQ ID NO:118.

[0183] In a preferred embodiment, the anti-CD73 antibody molecule has a heavy chain comprising the amino acid sequence of SEQ ID NO: 119 and a light chain comprising the amino acid sequence of SEQ ID NO: 120.

[0184] For all of the above embodiments, it is to be understood that by using the term "comprising", it is intended to also include embodiments wherein the respective domain or molecule "consists of the indicated amino acid sequence".

[0185] In a preferred embodiment, the anti-CD73 antibody molecule is capable of dissociating with a dissociation constant (K) of less than 10 nM, preferably less than 1 nM, and more preferably less than 100 pM. D ) binds to human CD73.

[0186] In some embodiments, the anti-CD73 antibody molecule is capable of binding to human CD73 (long isoform) and cynomolgus monkey (Macaca fascicularis) CD73 with high affinity. In some embodiments, high affinity refers to K D Less than 10 nM (e.g., 9, 8, 7, 6 nM or lower) as measured by surface plasmon resonance (SPR). In preferred embodiments, high affinity refers to a K D Less than 1 nM, as measured by SPR. In a more preferred embodiment, the anti-CD73 antibody molecule is capable of activating the cytokine receptor with a K of less than 500 pM. D In a most preferred embodiment, the antibody binds to human CD73 with a K of less than 100 pM. D Binds to human CD73. Used for determination of K using SPR D The scheme is provided in the accompanying examples.

[0187] In a preferred embodiment, the anti-CD73 antibody molecule binds to mouse CD73 with a lower affinity than it binds to human CD73 (e.g., 10-fold, 50-fold, 100-fold, or 110-fold lower affinity than human CD73). The sequence of mouse CD73 is available through GenBank Accession No. NP_035981.1 (only 1 identified form). The sequence of cynomolgus macaque CD73 is available through RefSeq Accession No. XP_005552488.1.

[0188] In one embodiment, the anti-CD73 antibody molecule is capable of reducing the activity of human CD73. In some embodiments, the activity of human CD73 refers to the enzymatic function of hydrolyzing AMP into adenosine. Therefore, reducing the activity of human CD73 refers to inhibiting such enzymatic function. In one embodiment, the anti-CD73 antibody inhibits the enzymatic function of human CD73 in vitro, as described in the Examples. In some embodiments, reducing the activity of human CD73 refers to reducing the cell surface level of CD73. In another embodiment, inhibition (by blocking CD73 enzymatic function or by reducing CD73 cell surface levels) is determined in a cell-based assay, for example, using a cancer cell line (e.g., Colo201).

[0189] In some embodiments, the anti-CD73 antibody molecule inhibits the formation of adenosine by at least 70%, preferably greater than 80%, as determined in a cell-based assay described in Example 5. In particularly preferred embodiments, the anti-CD73 antibody molecule inhibits the formation of adenosine in cell culture supernatant by at least 60%, at least 70%, preferably greater than 75%, i.e., it inhibits the activity of non-cell-bound CD73, as described in Example 8. In one embodiment, the anti-CD73 antibody molecule inhibits the formation of adenosine by non-cell-bound CD73 by at least 70%.

[0190] In yet another embodiment, the anti-CD73 antibody inhibits the enzymatic function of human CD73 in vivo.

[0191] Assays for determining inhibition of human CD73 enzymatic activity in vitro or in vivo are known in the art and are further described in detail in the accompanying Examples.

[0192] In some embodiments, the anti-CD73 antibody molecule is capable of activating an IC of less than 5 nM or 4, 3, 2, 1.5, 1, 0.5 nM or less. 90 Inhibits the enzymatic activity of human CD73. In a particularly preferred embodiment, the anti-CD73 antibody molecule has an IC of less than 0.4 nM. 90 Inhibits the enzymatic activity of human CD73. Determine IC 90 In some embodiments, the anti-CD73 antibody is administered with an IC of less than 1 nM. 90 Inhibits human CD73, but only moderately reduces cell surface levels of CD73 (i.e., by less than 30%, less than 25%, or less than 20%).

[0193] In one embodiment, anti-CD73 antibodies are capable of reversing AMP-dependent inhibition of T cell function. In a preferred embodiment, T cell function refers to T cell proliferation, which is known to be inhibited by adenosine generated from adenosine monophosphate (AMP) by CD73. The antibodies of the present invention are capable of reversing the above inhibition by inhibiting the production of adenosine by CD73, preferably to a level substantially the same as the control level (stimulated T cells treated with an isotype control without the addition of AMP). In a preferred embodiment, the antibodies of the present invention are capable of restoring the proliferation of T cells to 40%, 50%, 60%, 70%, 80%, 85%, 90%, 95%, 96%, 97%, 98%, 99% or 100% or even greater than 100% (e.g., 110%, 115%, 120% or 125%) of the control level. An assay for determining AMP-dependent inhibition of T cell function is described in Example 6. In some embodiments, the T cells are CD4+. In other embodiments, the T cells are CD8+.

[0194] In some embodiments, T cell function refers to the release of interferon gamma by T cells. Without being limited to any theory, it is believed that adenosine produced by CD73 inhibits the release of interferon gamma by such T cells. Therefore, the antibodies of the present invention are able to restore the release of interferon gamma by T cells, preferably to a level substantially the same as the control level (stimulated T cells treated with an isotype control without the addition of AMP). In a preferred embodiment, the antibodies of the present invention are able to induce the release of interferon gamma by T cells inhibited by AMP to a maximum of 2× (i.e., twice), 3×, 5×, 10×, 20×, 30×, 40×, 50× or greater than 50× the control level (stimulated T cells treated with an isotype control with the addition of AMP). The assay for determining the release of interferon gamma by T cells is described in Example 6. In some embodiments, the T cells are CD4+. In other embodiments, the T cells are CD8+.

[0195] In a particularly preferred embodiment, T cell function refers to T cell proliferation and interferon gamma release as described above, that is, the anti-CD73 antibody is able to stimulate T cell proliferation and interferon gamma release by T cells.

[0196] In another embodiment, the anti-CD73 antibody molecules form antigen-antibody complexes of defined size (e.g., 2:2 oligomers) with soluble CD73. These complexes are smaller than those formed by other CD73 antibodies known in the art (e.g., see Figure 2The size of the antigen-antibody complex has previously been correlated with Fcγ receptor activation and may thereby play a role in undesirable immunogenicity (Krayukhina et al. Analytical ultracentrifugation with fluorescence detection system reveals differences in complex formation between recombinant human TNF and different biological TNF antagonists invarious environments (2017). mAbs).

[0197] In some embodiments, the present invention provides anti-CD73 antibodies that bind to the same epitope as antibodies A1, A2, A3, A4, B1, B2, C1, C2, C3, C4, C5, or C6 described herein (as mentioned in Table 9). In some embodiments, the anti-CD73 antibodies compete with A1, A2, A3, A4, B1, B2, C1, C2, C3, C4, C5, or C6 (as mentioned in Table 9) for binding to the same epitope. In some embodiments, the anti-CD73 antibodies bind to an epitope that overlaps or substantially overlaps with the epitope of A1, A2, A3, A4, B1, B2, C1, C2, C3, C4, C5, or C6 (as mentioned in Table 9). Preferably, the anti-CD73 antibodies are monoclonal antibodies.

[0198] In one embodiment, an anti-CD73 antibody of the invention as disclosed above comprises a light chain variable region paratope that binds to at least two, three, four, five, six, seven, eight, nine, ten or all of the following amino acids on CD73 (Uniprot No. P21589): F137, P138, I139, A151, S152, S155, G156, L157, Y158, L159, P160, Y161, K162, E203 and K206, wherein binding of the light chain variable region to said amino acid residues on CD73 contributes to inhibition of CD73 function by the anti-CD73 antibody of the invention.

[0199] According to a preferred embodiment, the anti-CD73 antibodies of the present invention as disclosed above comprise, for example, light chain variable region paratopes that bind to at least two, three, four, five, six, seven, eight, nine, ten, or all of the amino acid residues disclosed above (e.g., F137, P138, I139, A151, S152, S155, G156, L157, Y158, L159, P160, Y161, K162, E203, and K206), which are amino acid residues on CD73 comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, E203, and K206. : 157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 (amino acid numbering corresponds to Uniprot accession number P21589 (including the signal peptide), wherein the mature protein does not contain a signal peptide comprising amino acid residues 1-26, however, the numbering scheme in this application refers to the full-length amino acid sequence of P21589) and is part of a conformational epitope specifically bound by an anti-CD73 antibody of the invention, wherein the variable light chain of the anti-CD73 antibody of the invention comprises an amino acid sequence according to SEQ ID NO: 78, SEQ ID NO: 86, SEQ ID NO: 88, SEQ ID NO: 90, SEQ ID NO: 92, SEQ ID NO: 94, SEQ ID NO: 96. The term "conformational epitope" according to the present invention (bound by the anti-CD73 antibodies of the present invention as disclosed herein) refers to a non-linear epitope, wherein the epitope recognized and bound by the antibodies of the present invention is formed by the secondary and / or tertiary structure of a polypeptide or protein and is unique to the folded three-dimensional conformation of the polypeptide or protein. Typically, a conformational epitope consists of amino acids that are discontinuous in a linear sequence but are clustered together in the folded structure of the protein. However, a conformational epitope may also consist of a linear sequence of amino acids that adopts a conformation that is unique to the folded three-dimensional conformation of the polypeptide and that is not present in the denatured state of the polypeptide or protein.

[0200] According to one embodiment, an anti-CD73 antibody of the invention as disclosed above comprises a heavy chain variable region paratope that binds to at least two, three, four, five, six, seven, eight, nine, ten or all of the following amino acid residues L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, T209, L210 and N211, which are amino acid residues on CD73 comprising amino acid residues F137, P138, I139, A1 51, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 (amino acid numbering corresponds to Uniprot accession number P21589), wherein the binding of the heavy chain variable region to the said amino acid residues on CD73 contributes to the inhibition of CD73 function by the anti-CD73 antibodies of the present invention.

[0201] According to one embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain variable region paratope comprising one of the amino acid sequences according to SEQ ID NO: 85, SEQ ID NO: 87, SEQ ID NO: 89, SEQ ID NO: 91, SEQ ID NO: 93, SEQ ID NO: 95 and binding to at least two, three, four, five, six, seven, eight, nine, ten or all of amino acid residues L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, T209, L210 and N211 on CD73, wherein these amino acid residues are obtained by the anti-CD73 antibody of the present invention. Specifically binds to a portion of the conformational epitope formed by amino acids F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, and N211 of human CD73 (Uniprot Accession No. P21589).

[0202] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a light chain comprising an amino acid sequence of one of SEQ ID NO: 102, SEQ ID NO: 110, SEQ ID NO: 112, SEQ ID NO: 114, SEQ ID NO: 116, SEQ ID NO: 118, SEQ ID NO: 120 and is bound, for example, to at least two, three, four, five, six, seven, eight, nine, ten or all of the amino acid residues disclosed above (e.g., F137, P138, I139, A151, S152, S155, G156, L157, T158, L159, P160, Y161, K162, E203 and K206), which amino acid residues constitute a CD73 light chain. 73 by amino acids F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 (amino acid numbering corresponds to Uniprot accession number P21589) and is part of it. As disclosed above, the binding of the light chain of the present invention to the conformational epitope on CD73 comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, and N211 contributes to the specific binding of the anti-CD73 antibodies of the present invention to CD73, thereby inhibiting its function.

[0203] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain comprising an amino acid sequence according to one of SEQ ID NO: 101, SEQ ID NO: 111, SEQ ID NO: 113, SEQ ID NO: 115, SEQ ID NO: 117, SEQ ID NO: 119 and binding to at least two, three, four, five, six, seven, eight, nine, ten or all of amino acids L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, T209, L210 and N211 on CD73, which amino acids constitute a heavy chain comprising ... The conformational epitope formed by and is part of amino acids F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 (Uniprot Accession No. P21589). As disclosed above, the binding of the heavy chain of the present invention to the conformational epitope formed by amino acids F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, and N211 on CD73 contributes to the specific binding of the anti-CD73 antibodies of the present invention to CD73, thereby inhibiting CD73 function.

[0204] According to one embodiment, binding of an anti-CD73 of the invention as disclosed above to a conformational epitope formed by amino acids F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 of human CD73 (Uniprot Accession No. P21589) induces IFNγ release in T cells (see, e.g., Figure 4For example, the anti-CD73 antibodies of the present invention as disclosed above (comprising heavy chain CDRs 1-3 comprising the amino acid sequences according to SEQ ID NO: 55 (HCDR1), 56 (HCDR2) and SEQ ID NO: 57 (HCDR3) and light chain CDRs 1-3 comprising the amino acid sequences according to SEQ ID NO: 58 (LCDR1), SEQ ID NO.: 59 (LCDR2) and SEQ ID NO: 60 (LCDR3), or comprising a V comprising the amino acid sequence according to SEQ ID NO: 91) H and V comprising the amino acid sequence according to SEQ ID NO 92 L , or (for example) comprising a heavy chain comprising the amino acid sequence according to SEQ ID NO: 115 and a light chain comprising the amino acid sequence according to SEQ ID No: 116) induces IFNγ release in T cells (see, for example Figure 4 ), for example, the in vitro IFNγ release induced by the antibodies of the invention is at least 5-, 6-, 7-, 8-, 9-, 10-, 11-fold greater than that of the isotype control + AMP, wherein the IFNγ level can be determined, for example, as disclosed in Example 6. Thus, the antibodies of the invention are capable of restoring IFNγ release from T cells to a level substantially the same as the control level (stimulated T cells treated with an isotype control without added AMP) (e.g., 75%, 80%, 85%, 90%, 95% of the control level).

[0205] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain according to SEQ ID NO: 101 and a light chain according to SEQ ID NO: 102, and inhibits CD73 function by binding to at least two, three, four, five, six, seven, eight, nine, ten or all amino acid residues of a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 on CD73.

[0206] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain according to SEQ ID NO: 109 and a light chain according to SEQ ID NO: 110, and inhibits CD73 function by binding to at least two, three, four, five, six, seven, eight, nine, ten or all amino acid residues of a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 on CD73.

[0207] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain according to SEQ ID NO: 111 and a light chain according to SEQ ID NO: 112, and inhibits CD73 function by binding to at least two, three, four, five, six, seven, eight, nine, ten or all amino acid residues of a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 on CD73.

[0208] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain according to SEQ ID NO: 113 and a light chain according to SEQ ID NO: 114, and inhibits CD73 function by binding to at least two, three, four, five, six, seven, eight, nine, ten or all amino acid residues of a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 on CD73.

[0209] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain according to SEQ ID NO: 115 and a light chain according to SEQ ID NO: 116, and inhibits CD73 function by binding to at least two, three, four, five, six, seven, eight, nine, ten or all amino acid residues of a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 on CD73.

[0210] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain according to SEQ ID NO: 117 and a light chain according to SEQ ID NO: 118, and inhibits CD73 function by binding to at least two, three, four, five, six, seven, eight, nine, ten or all amino acid residues of a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 on CD73.

[0211] According to a preferred embodiment, the anti-CD73 antibody of the present invention as disclosed above comprises a heavy chain according to SEQ ID NO: 119 and a light chain according to SEQ ID NO: 120, and inhibits CD73 function by binding to at least two, three, four, five, six, seven, eight, nine, ten or all amino acid residues of a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 on CD73.

[0212] According to a preferred embodiment, the present invention provides an anti-CD73 antibody that binds to a conformational epitope formed by amino acids F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 of human CD73 and cross-competes for binding to a conformational epitope of the anti-CD73 antibody of the invention disclosed above (e.g., competes for binding with an anti-CD73 antibody comprising a heavy chain according to SEQ ID NO: 115 and a light chain according to SEQ ID NO: 116). Cross-competition for antibody binding can be assessed, for example, by suitable methods known in the art, such as those described in Anal Biochem. 2009 Mar 15; 386(2): 172-80.

[0213] According to a preferred embodiment, amino acid residues T28, T31, Y32, W33, Y52, L55, D57, L99, L100, D101, and Y102 of the heavy chain variable region of the anti-CD73 antibody of the present invention are in contact with and / or specifically comprise amino acid residues R30, S31, Y32, W49, Y50, T51, S52, R53, S65, G66, S67, and E92 of the light chain variable region of the anti-CD73 antibody of the present invention. The invention further comprises an anti-CD73 antibody comprising an amino acid sequence according to SEQ ID NO: 115 and an amino acid sequence according to SEQ ID NO: 116, wherein the anti-CD73 antibody of the invention binds heterotropically to a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, N211 on CD73, wherein the anti-CD73 antibody of the invention comprises an amino acid sequence according to SEQ ID NO: 115 and an amino acid sequence according to SEQ ID NO: 116, and wherein the anti-CD73 antibody of the invention has an IC of less than 5 nM, 4 nM, 3 nM, 2 nM, 1.5 nM, 1 nM, 0.5 nM or less. 90 , preferably with an IC of less than 0.5 nM 90 Inhibit CD73 enzymatic activity. For example, the antibodies of the invention as disclosed above may inhibit adenosine formation by at least 60%, at least 70%, preferably greater than 75%. As described in Example 8, the inhibition of adenosine formation in vitro by the antibodies of the invention as disclosed above may be evaluated, for example, in cell culture supernatants. The inhibition may be assessed, for example, in blood samples or in samples obtained from the tumor microenvironment by L,Pehrsson S, G, H, Nylander S (2018) Accurate measurement of endogenous adenosine in human blood. PLoS ONE 13(10): e0205707. https: / / doi.org / 10.1371 / journal.pone.0205707 was used to evaluate the inhibition of adenosine formation in vivo by the antibodies of the present invention.

[0214] For example, in a preferred embodiment, the anti-CD73 antibodies of the present invention as disclosed above inhibit the enzymatic activity of CD73 by inhibiting CD73 from adopting "open" and "closed" conformations, which are required for the enzymatic activity of CD73 to hydrolyze AMP, by binding to a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, and N211.

[0215] According to a preferred embodiment, the anti-CD73 antibodies of the present invention as disclosed above inhibit CD73 enzymatic activity by binding to a conformational epitope comprising amino acid residues F137, P138, I139, A151, S152, G156, L157, Y158, L159, P160, Y161, K162, V163, P165, G167, D168, E169, V170, E203, K206, T209, L210, and N211 on CD73, thereby reducing the cell surface level of CD73 (see Example 4).

[0216] Preferably, the anti-CD73 antibodies are humanized. Such antibodies can be generated using methods known in the art, for example, by using epitope sequences for immunization or recombinantly expressed and purified CD73 protein.

[0217] The epitope of an antibody can be determined using methods known in the art, for example, by hydrogen-deuterium exchange mass spectrometry (HDX-MS), NMR, site-directed mutagenesis (e.g., alanine scanning), or X-ray crystallography of the antibody-antigen complex.

[0218] Hydrogen / deuterium exchange mass spectrometry (HDX-MS) determines protein conformation and conformational dynamics in solution by monitoring the rate and extent of deuterium exchange of amide hydrogen atoms from the protein backbone. The extent of exchange by HDX depends on protein solvent accessibility and hydrogen bonding, and the mass increase of the protein on HDX can be precisely measured by MS. When this technique is paired with enzymatic digestion, structural features can be resolved at the peptide level, enabling the distinction of surface-exposed peptides from internally folded peptides. In epitope mapping experiments, deuterium labeling and subsequent quenching experiments are performed in parallel on antigens and antigen / mAb complexes, followed by online pepsin digestion, peptide separation, and MS analysis.

[0219] Competition for binding to an epitope can be determined using any method known in the art. For example, a standard ELISA assay or a competitive ELISA assay can be used, in which recombinant human CD73 protein is immobilized on a plate, various concentrations of an unlabeled first antibody are added, the plate is washed, a labeled second antibody is added, washed, and the amount of bound label is measured. If increasing concentrations of an unlabeled (first) antibody (also referred to as a "blocking antibody") inhibit the binding of the labeled (second) antibody, the first antibody is considered to inhibit the binding of the second antibody to the target on the plate, or to compete for the binding of the second antibody. Additionally or alternatively, surface plasmon resonance (SPR) analysis can be used to evaluate the ability of such antibodies to compete. The ability of a test antibody to inhibit the binding of an anti-CD73 antibody described herein (e.g., antibody A1, A2, A3, A4, B1, B2, C1, C2, C3, C4, C5, or C6, Table 9) to CD73 confirms that the test antibody can compete with the antibody for binding to CD73.

[0220] The above-mentioned anti-CD73 antibodies (i.e., according to the first aspect of the present invention) are also collectively referred to herein as "antibodies of the present invention," "CD73 antibodies of the present invention," "anti-CD73 antibodies of the present invention," "antibodies described herein," or the like.

[0221] Another aspect of the invention provides an isolated nucleic acid molecule encoding the heavy chain variable region and / or light chain variable region of the anti-CD73 antibody molecule of any one of the first aspect of the invention.

[0222] The nucleic acid molecules of the present invention include, but are not limited to, DNA molecules encoding the anti-CD73 antibody amino acid sequences provided herein. Similarly, the present invention also relates to nucleic acid molecules that hybridize to DNA molecules encoding the polypeptide sequences shown in the sequence listing under high stringency binding and washing conditions (as defined in WO 2007 / 042309). Preferred molecules (from an mRNA perspective) are molecules that have at least 75% or 80% (preferably at least 85%, more preferably at least 90%, and most preferably at least 95%) homology or sequence identity with one of the DNA molecules described herein. For example, given that the antibodies are expressed in eukaryotic cells, the DNA sequences shown in the sequence listing have been designed to match the codon usage in eukaryotic cells. If it is desired to express the antibodies in E. coli, these sequences can be altered to match the E. coli codon usage. Variants of the DNA molecules of the present invention can be constructed in several different ways, as described, for example, in WO 2007 / 042309.

[0223] In another aspect, the present invention provides an expression vector containing a nucleic acid molecule comprising a nucleotide sequence encoding the heavy chain variable region and / or light chain variable region of the anti-CD73 antibody molecule of any one of the first aspect of the invention.

[0224] Preferably, the nucleic acid molecule comprises a nucleotide sequence encoding the heavy chain variable region of any one of SEQ ID NOs: 81, 83, 85, 87, 89, 91, 93 and 95. Preferably, the nucleic acid molecule comprises a nucleotide sequence encoding the light chain variable region of any one of SEQ ID NOs: 82, 84, 86, 88, 90, 92, 94 or 96.

[0225] Preferably, the expression vector further comprises a nucleic acid molecule, preferably a DNA molecule, encoding the constant domain of the heavy chain and / or the constant domain of the light chain, such constant domains being linked to a nucleic acid molecule, preferably a DNA molecule, encoding the variable domain of the heavy chain and / or the variable domain of the light chain, respectively.

[0226] In a particularly preferred embodiment, two expression vectors can be used, one expression vector for expressing the heavy chain and another expression vector for expressing the light chain, and then both expression vectors can be transfected into host cells for recombinant protein expression.

[0227] Preferably, the expression vector is a vector comprising the nucleic acid molecule operably linked to at least one regulatory sequence, wherein such regulatory sequence may be a promoter, enhancer or terminator sequence and most preferably a heterologous promoter, enhancer or terminator sequence.

[0228] The nucleic acids of the invention can be prepared or obtained in a manner known per se (eg by automated DNA synthesis and / or recombinant DNA techniques) based on the information on the amino acid sequences of the antibodies of the invention given herein.

[0229] In another aspect, the present invention relates to a host cell having an expression vector as described above, for example, an expression vector encoding the heavy chain of an anti-CD73 antibody molecule of the invention and an expression vector encoding the light chain of an anti-CD73 antibody molecule of the invention. In some embodiments, the host cell comprises a vector encoding both the light chain and the heavy chain of an anti-CD73 antibody molecule of the invention, particularly when the antibody is a single-chain antibody, such as an scFv.

[0230] According to a particularly preferred embodiment, the host cell is a eukaryotic cell, such as a mammalian cell, in particular a human cell (in vitro). In another embodiment, such a host cell is a bacterial cell. Other useful cells are yeast cells or other fungal cells.

[0231] Mammalian cells that can be used as expression hosts are well known in the art and include, among others, Chinese hamster ovary (CHO, CHO-DG44) cells, NSO, SP2 / 0 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human cancer cells (e.g., Hep G2), A549 cells, 3T3 cells, or derivatives / progeny of any such cell lines. Other mammalian cells, including but not limited to human, mouse, rat, monkey, and rodent cell lines, or other eukaryotic cells, including but not limited to yeast, insect, and plant cells, or prokaryotic cells (e.g., bacteria), can be used. The antibodies of the present invention are produced by culturing the host cells for a period of time sufficient to allow expression of the antibody in the host cells. However, amphibian cells, insect cells, plant cells, and any other cells known in the art for expressing heterologous proteins can also be used.

[0232] In another aspect, the present invention provides a method for preparing an anti-CD73 antibody molecule of the invention, comprising the steps of:

[0233] - culturing a host cell as described above under conditions that allow the formation of the anti-CD73 antibody molecule of the invention; and

[0234] - recovering said antibody molecule.

[0235] In one embodiment, the preparation method further comprises the step of further purifying the antibody, as further described below.

[0236] In one embodiment, the method of preparation further comprises the step of further modifying the antibody, as further described herein.

[0237] In one embodiment, the method of preparation further comprises the step of formulating the antibody molecule into a pharmaceutical composition, as further described herein.

[0238] Any method known in the art for producing antibodies can be used, eg, as described herein.

[0239] In another aspect, the present invention provides an anti-CD73 antibody as described above for use in medicine. Specific medical uses of the antibodies of the present invention are described in further detail below.

[0240] In another aspect, a pharmaceutical composition is provided, comprising an anti-CD73 antibody of the present invention and a pharmaceutically acceptable carrier. Suitable carriers are known in the art and are further described below. This composition may also comprise another therapeutic agent, such as, but not limited to, a PD-1 antagonist, as described in more detail below.

[0241] Pharmaceutical compositions comprising anti-CD73 antibodies and other therapeutic agents (e.g., PD-1 antagonists); kits, methods, and uses

[0242] PD-1 plays an important role in regulating T cell activity and thus the immune system activity.

[0243] Antagonist anti-PD-1 antibody molecules have been shown in a variety of different cancer settings to increase T cell activity, thereby activating the immune system to attack tumors and thereby treating cancer.

[0244] It is well known that monoclonal antibodies that block the PD-1 receptor are associated with durable clinical responses against multiple cancer types and have great potential as novel cancer therapeutics. It has also been shown that targeting CD73 enhances the anti-tumor activity of anti-PD-1 antibodies.

[0245] Based on this background, the inventors attempted to explore the combination of the anti-CD73 antibody of the present invention and the PD-1 antibody.

[0246] Using a dendritic cell / T cell co-culture assay (further summarized in Example 7), the inventors examined the functional properties of representative anti-CD73 antibody molecules of the invention in combination with anti-PD-1 molecules. Figure 1 As seen in Figure 3, the effects of anti-PD1 antibodies are inhibited by AMP, which clearly shows that the PD1 response is dependent on AMP. The combination of the anti-CD73 antibody molecules of the present invention and a PD-1 antagonist (e.g., an anti-PD-1 antibody) can restore AMP-dependent inhibition and restore IFNγ levels.

[0247] Therefore, another aspect of the present invention provides a pharmaceutical composition comprising an anti-CD73 antibody of the present invention, a PD-1 antagonist, and a pharmaceutically acceptable carrier. Suitable carriers are known in the art and are further described below.

[0248] Suitable PD-1 antagonists are described below.

[0249] In some embodiments, the PD-1 antagonist is an anti-PD-1 antibody. In some embodiments, the PD-1 antagonist is an anti-PD-1 antibody. In some embodiments, the anti-PD-1 antibody is selected from the group consisting of PDR-001, pembrolizumab, nivolumab, and pilizumab. Preferably, the anti-PD-1 antibody molecule is selected from PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 as described herein.

[0250] In some embodiments, the anti-PDL-1 antibody is selected from atezolizumab, avelumab, or durvalumab.

[0251] In addition to the anti-CD73 antibodies of the present invention, another anti-CD73 antibody may be used, such as MEDI9447, BMS986179, CPX-006, CPX-0016, or an antibody as described in WO08007648, WO2016075099, WO2016081748, WO2016055609, WO2016131950, WO17064043, WO2017100670, WO17152085, or WO2018013611.

[0252] Another aspect of the present invention provides a kit comprising an anti-CD73 antibody molecule of the present invention and a PD-1 antagonist. The kit may further comprise instructions for use.

[0253] Suitable PD-1 antagonists are described below.

[0254] In some embodiments, the PD-1 antagonist is an anti-PD-1 antibody. In some embodiments, the PD-1 antagonist is an anti-PD-1 antibody. In some embodiments, the anti-PD-1 antibody is selected from the group consisting of PDR-001, pembrolizumab, nivolumab, and pilizumab. Preferably, the anti-PD-1 antibody molecule is selected from PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 as described herein.

[0255] In some embodiments, the anti-PDL-1 antibody is selected from atezolizumab, avelumab, or durvalumab.

[0256] In addition to the anti-CD73 antibodies of the present invention, another anti-CD73 antibody may be used, such as MEDI9447, BMS986179, CPX-006, CPX-0016, or an antibody as described in WO08007648, WO2016075099, WO2016081748, WO2016055609, WO2016131950, WO17064043, WO2017100670, WO17152085, or WO2018013611.

[0257] It will be clear to those skilled in the art based on the above that also disclosed herein are pharmaceutical compositions for treating diseases (as specified in more detail below) using the above-mentioned antibody molecules of the invention (e.g., the anti-CD73 antibodies and PD-1 antagonists of the invention) and methods of treating diseases (as specified in more detail below) using such pharmaceutical compositions or antibody molecules of the invention.

[0258] For the avoidance of doubt, all embodiments relating to pharmaceutical compositions, kits, methods of treatment, medical uses, methods of administration, and dosages as described herein encompass any anti-CD73 antibody described herein (alone or in combination with other therapeutic agents, such as PD-1 antagonists). Any PD-1 antagonist as described herein (including inhibitors of PD-1 and PDL-1) may be used, such as pembrolizumab, nivolumab, pilizumab, atezolizumab, avelumab, durvalumab, PD1-1, PD1-2, PD1-3, PD1-4, or PD1-5 as described herein.

[0259] When the anti-CD73 antibody molecules of the present invention and the anti-PD-1 antibody molecules of the present invention are to be administered simultaneously via the same route of administration, they may be administered as different pharmaceutical formulations or compositions or as part of a combined pharmaceutical formulation or composition. Similarly, when the anti-CD73 antibody molecules of the present invention and the anti-PD-1 antibody molecules of the present invention are to be used as part of a combined treatment regimen, each antibody may be administered in the same amount and according to the same regimen as when one antibody is used on its own, and the combined use may or may not produce a synergistic effect. However, when the antibodies are used in combination to produce a synergistic effect, it is also possible to reduce the amount of one or both antibodies while still achieving the desired therapeutic effect. This can, for example, be used to avoid, limit or reduce any undesirable side effects associated with the use of one or both antibodies when used in conventional amounts while still obtaining the desired pharmacological or therapeutic effect.

[0260] In addition to the anti-CD73 antibody and PD-1 antagonist, the above-described compositions and kits may further comprise another therapeutic agent as described in more detail below.

[0261] Pharmaceutical composition, administration method, dosage

[0262] The present invention further relates to pharmaceutical compositions for treating diseases (as specified in more detail below), wherein such compositions comprise at least one anti-CD73 antibody as provided herein. The present invention further encompasses methods of treating diseases (as specified in more detail below) using at least one anti-CD73 antibody or pharmaceutical composition as previously stated, and further encompasses the preparation of medicaments for treating such diseases by using such anti-CD73 antibody molecules or pharmaceutical compositions of the present invention.

[0263] Such compositions encompass any of the anti-CD73 antibodies described herein, alone or in combination with other therapeutic agents, e.g., a PD-1 antagonist, such as pembrolizumab, nivolumab, pilizumab, atezolizumab, avelumab, durvalumab, PD1-1, PD1-2, PD1-3, PD1-4, or PD1-5.

[0264] Depending on the specific pharmaceutical formulation or composition to be used, anti-CD73 antibodies and / or compositions comprising the same can be administered to a patient in need thereof in any suitable manner. Thus, anti-CD73 antibodies and / or compositions comprising the same can be administered, for example, in an effective amount or dosage using the following means: intravenous (iv), subcutaneous (sc), intramuscular (im), intraperitoneal (ip), transdermal, oral, sublingual (e.g., in the form of a sublingual tablet, spray, or drops that are placed under the tongue and absorbed into the capillary network under the tongue via the mucosa), intranasal (e.g., in the form of a nasal spray and / or aerosol), topically, by means of a suppository, by inhalation, or any other suitable means.

[0265] Anti-CD73 antibodies and / or compositions comprising the same are administered according to a treatment regimen suitable for treating and / or alleviating the disease, disorder or condition to be treated or alleviated. Clinicians are generally able to determine an appropriate treatment regimen based on factors such as the disease, disorder or condition to be treated or alleviated, the severity of the disease, the severity of its symptoms, the specific antibody molecule of the invention to be used, the specific route of administration and pharmaceutical formulation or composition to be used, the patient's age, sex, weight, diet, general condition, and similar factors familiar to clinicians. Typically, a treatment regimen will comprise administering one or more antibody molecules of the invention or one or more compositions comprising the same in a therapeutically effective amount or dosage.

[0266] Typically, for the treatment and / or alleviation of the diseases, disorders and conditions mentioned herein and depending on the specific disease, disorder or condition to be treated, the efficacy of the specific antibody molecule of the invention to be used, the specific route of administration and the specific pharmaceutical formulation or composition used, the antibody molecule of the invention is typically administered continuously (e.g., by infusion) or more preferably as a single dose (e.g., twice weekly, weekly or monthly doses; see below) in an amount between 0.05 mg / kg body weight and dose and 50.0 mg / kg body weight and dose, preferably between 5.0 mg / kg / dose and 20.0 mg / kg / dose and more preferably between 10 mg / kg / dose and 15 mg / kg / dose, but may vary significantly depending on, among other things, the parameters mentioned above. Thus, in some cases, it may be sufficient to use less than the minimum dose given above, while in other cases the upper limit may have to be exceeded. When administered in large quantities, it may be appropriate to divide it into many smaller doses administered at different times of the day.

[0267] Depending on the specific antibody molecule of the present invention and its specific pharmacokinetic and other properties, it can be administered daily, every second, third, fourth, fifth or sixth day, weekly, monthly and in a similar manner. The administration regimen may include long-term weekly treatment. "Long-term" means lasting at least two weeks and preferably lasting for several months or years.

[0268] Depending on the specific disease involved, the efficacy of the antibody molecules of the invention and compositions comprising the same can be tested using any suitable in vitro assay, cell-based assay, in vivo assay and / or animal model known per se, or any combination thereof. Suitable assays and animal models will be clear to those skilled in the art and, for example, include those used in the Examples below.

[0269] Formulations

[0270] For pharmaceutical applications, the antibody molecules of the present invention can be formulated as pharmaceutical preparations comprising: (i) at least one anti-CD73 antibody of the present invention, and (ii) at least one pharmaceutically acceptable carrier, diluent, excipient, adjuvant and / or stabilizer, and (iii) optionally one or more other pharmacologically active polypeptides and / or compounds (e.g., PD-1 antagonists). "Pharmaceutically acceptable" means that the respective material does not exhibit any biological or otherwise undesirable effect when administered to an individual and does not interact in a harmful manner with any other component (e.g., pharmaceutically active ingredient) of the pharmaceutical composition containing it. Specific examples can be found in standard manuals, such as Remington's Pharmaceutical Sciences, 18th edition, Mack Publishing Company, USA (1990). For example, the antibodies of the present invention can be formulated and administered in any manner known per se for conventional antibodies and antibody fragments and other pharmaceutically active proteins. Thus, according to another embodiment, the present invention relates to a pharmaceutical composition or formulation containing at least one CD73 antibody of the present invention and at least one pharmaceutically acceptable carrier, diluent, excipient, adjuvant and / or stabilizer and optionally one or more other pharmacologically active substances as further described herein (e.g., PD-1 antagonists).

[0271] Pharmaceutical preparations for parenteral administration (e.g., intravenous, intramuscular, subcutaneous injection or intravenous infusion) may, for example, be sterile solutions, suspensions, dispersions, emulsions or powders comprising the active ingredient and suitable for infusion or injection (optionally after another dissolution or dilution step). Suitable carriers or diluents for such preparations include, but are not limited to, sterile water and pharmaceutically acceptable aqueous buffers and solutions, such as physiological phosphate-buffered saline, Ringer's solution, dextrose solution and Hank's solution; water-oil; glycerol; ethanol; glycols, such as propylene glycol; and mineral, animal and vegetable oils, such as peanut oil, soybean oil; and suitable mixtures thereof.

[0272] The solution of the antibody molecule of the present invention may also contain a preservative to prevent the growth of microorganisms, which preservative is (for example) an antibacterial and antifungal agent, such as p-hydroxybenzoates, paraben, chlorobutanol, phenol, sorbic acid, thimerosal, ethylenediaminetetraacetic acid (its alkali metal salts) and the like. In many cases, it is preferred to include an isotonic agent, such as a sugar, a buffer or sodium chloride. Optionally, an emulsifier and / or a dispersant can be used. Suitable fluidity can be maintained, for example, by forming liposomes, by maintaining the desired particle size (in the case of a dispersion) or by using a surfactant. Other agents that delay absorption, such as aluminum monostearate and gelatin, can also be added. The solution can be filled into injection vials, ampoules, infusion bottles, etc.

[0273] In all cases, the final dosage form must be sterile, flowable, and stable under the conditions of manufacture and storage. Sterile injectable solutions are prepared by incorporating the required amount of the active compound in an appropriate solvent with, optionally, the other ingredients enumerated above, followed by filtered sterilization. In the case of sterile powders for the preparation of sterile injectable solutions, the preferred methods of preparation are vacuum drying and freeze drying techniques, which yield a powder of the active ingredient plus any additional desired ingredients present in a previously sterile-filtered solution.

[0274] Typically, aqueous solutions or suspensions are preferred. Typically, suitable formulations for therapeutic proteins (e.g., antibodies of the present invention) are buffered protein solutions, for example, comprising a solution comprising a protein at a concentration (e.g., 0.001 mg / ml to 400 mg / ml, preferably 0.005 mg / ml to 200 mg / ml, more preferably 0.01 mg / ml to 200 mg / ml, more preferably 1.0-100 mg / ml, e.g., 1.0 mg / ml, 50 mg / ml, or 100 mg / ml) and an aqueous buffer such as:

[0275] - phosphate buffered saline, pH 7.4,

[0276] -Other phosphate buffers, pH 6.2 to 8.2,

[0277] - Acetate buffer, pH 3.2 to 7.5, preferably pH 4.8 to 5.5

[0278] - Histidine buffer, pH 5.0 to 7.0,

[0279] - succinate buffer, pH 3.2 to 6.6, and

[0280] - Citrate buffer, pH 2.1 to 6.2,

[0281] and optionally, salts (eg NaCl) and / or sugars (eg sucrose and trehalose) and / or other polyols (eg mannitol and glycerol) and / or surfactants for rendering the solution isotonic.

[0282] A preferred buffered protein solution is a solution comprising about 50 mg / ml of an antibody of the invention (alone or in combination with a PD-1 antagonist, dissolved in 25 mM acetate buffer (pH 5.5)), optionally containing 0.67 mM methionine and adjusting isotonicity by adding 240 mM trehalose. Other surfactants (e.g., 0.04% Tween-20, Tween-80, or polysorbate 80) may also be included in such solutions. Formulations for subcutaneous application may include significantly higher concentrations of the antibody of the invention, for example, up to 100 mg / ml or even higher than 100 mg / ml. However, it will be clear to those skilled in the art that the ingredients and amounts given above represent only one preferred choice. Alternative forms and variations thereof will be immediately clear to those skilled in the art, or can be easily conceived starting from the above disclosure.

[0283] According to another aspect of the invention, the antibody molecules of the invention may be used in combination with a device useful for administering the antibody, such as a syringe, injection pen, mini-pump or other device.

[0284] Therapeutic uses / treatment methods

[0285] Another aspect of the present invention provides a method for treating cancer, comprising administering a therapeutically effective amount of an anti-CD73 antibody molecule of the present invention to a patient in need thereof. In a preferred embodiment, the method further comprises administering a PD-1 antagonist (e.g., an anti-PD-1 antibody or an anti-PDL-1 antibody) to such a patient. Preferably, the anti-PD-1 antibody is selected from the group consisting of: pembrolizumab, nivolumab, pilizumab, PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 as described herein. Preferably, the anti-PDL-1 antibody is selected from the group consisting of: atezolizumab, avelumab, and durvalumab.

[0286] In some embodiments, the cancer is renal cancer, gastrointestinal cancer, or lung cancer. In some embodiments, the gastrointestinal cancer is colon cancer, gastric cancer, or hepatocellular carcinoma. In some embodiments, the renal cancer is renal cancer, preferably clear cell carcinoma. In a preferred embodiment of the present invention, the cancer is lung cancer, preferably non-small cell lung cancer (NSCLC). In some embodiments, the colon cancer is CRC.

[0287] In some embodiments, the anti-CD73 antibody molecules of the present invention are optionally administered in combination with a PD-1 antagonist as described above and one or more other therapeutic agents and / or procedures, such agents and procedures are described in further detail below. Non-limiting examples are therapeutic agents or procedures selected from the group consisting of chemotherapy, targeted anti-cancer therapy, oncolytic drugs, cytotoxic agents, immune-based therapies, cytokines, surgical procedures, radiation procedures, vaccines, or cellular immunotherapy.

[0288] In some embodiments, the additional therapeutic agent is an A2AR antagonist, a CD39 antagonist, a LAG-3 antagonist, a CTLA-4 antagonist, an EGFR antagonist, or a HER2 antagonist.

[0289] Another aspect of the present invention provides an anti-CD73 antibody molecule of the present invention for use in a method for treating cancer. In a preferred embodiment, this aspect further includes the additional use of a PD-1 antagonist (e.g., an anti-PD-1 antibody or an anti-PDL-1 antibody). Preferably, the anti-PD-1 antibody is selected from the group consisting of: pembrolizumab, nivolumab, pilizumab, PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 as described herein. Preferably, the anti-PDL-1 antibody is selected from the group consisting of: atezolizumab, avelumab, and durvalumab.

[0290] In some embodiments, the cancer is renal cancer, gastrointestinal cancer, or lung cancer. In some embodiments, the gastrointestinal cancer is colon cancer, gastric cancer, or hepatocellular carcinoma. In some embodiments, the renal cancer is renal cancer, preferably clear cell carcinoma. In a preferred embodiment of the present invention, the cancer is lung cancer, preferably non-small cell lung cancer (NSCLC). In some embodiments, the colon cancer is CRC.

[0291] In some embodiments, the anti-CD73 antibody molecules of the present invention are optionally administered in combination with a PD-1 antagonist as described above and one or more other therapeutic agents and / or procedures, such agents and procedures are further described in detail below. Non-limiting examples are therapeutic agents or procedures selected from the group consisting of chemotherapy, targeted anti-cancer therapy, oncolytic drugs, cytotoxic agents, immune-based therapies, cytokines, surgical procedures, radiation procedures, vaccines, or cellular immunotherapy.

[0292] As is known in the art, "targeted anticancer therapy" refers to the systemic administration of drugs with a specific mechanism of action that acts specifically on a well-defined target or biological pathway that, when activated or inactivated, can regress or destroy the malignant process while minimizing side effects on healthy tissues (Li et al., Target Oncol. 2012; 7(1): 69-85). "Immuno-based therapy" or "immunotherapy" is the treatment of a disease by inducing, enhancing, or suppressing an immune response. In the context of cancer, immuno-based therapy generally refers to a therapy that induces and / or enhances an immune response, for example, using an immunotherapeutic agent as described below.

[0293] In some embodiments, the additional therapeutic agent is an A2AR antagonist, a CD39 antagonist, a LAG-3 antagonist, a CTLA-4 antagonist, an EGFR antagonist, or a HER2 antagonist.

[0294] PD-1 antagonists within the meaning of the present invention and all its embodiments are compounds that inhibit the interaction of PD-1 with its receptor. PD-1 antagonists are well known in the art, for example, as reviewed by Li et al., Int. J. Mol. Sci. 2016, 17, 1151 (incorporated herein by reference). PD-1 antagonists may be inhibitors of PD-1 or inhibitors of PDL-1, such as anti-PD-1 antibodies or anti-PDL-1 antibodies. In some embodiments, the PD-1 antagonist is an anti-PD-1 antibody. In some embodiments, the PD-1 antagonist is an anti-PDL-1 antibody. Any PD-1 antagonist, in particular an antibody (e.g., an antagonist disclosed by Li et al.), and other antibodies disclosed below can be used according to the present invention. Preferably, the PD-1 antagonist of the present invention and all its embodiments is selected from the group consisting of the following antibodies:

[0295] -Pembrolizumab (anti-PD-1 antibody);

[0296] -Nivolumab (anti-PD-1 antibody);

[0297] -Pilivizumab (anti-PD-1 antibody);

[0298] -PDR-001 (anti-PD-1 antibody);

[0299] - Atezolizumab (anti-PD-1 antibody);

[0300] - Avelumab (anti-PD-1 antibody);

[0301] -Durvalumab (anti-PD-1 antibody)

[0302] - PD1-1, PD1-2, PD1-3, PD1-4 and PD1-5 (anti-PD1 antibodies) as described herein.

[0303] Pembrolizumab (formerly also known as lambrolizumab; trade name Keytruda; also known as MK-3475; disclosed, for example, in Hamid, O. et al. (2013) New England Journal of Medicine 369(2):134-44) is a humanized IgG4 monoclonal antibody that binds to PD-1; it contains a mutation at C228P designed to prevent Fc-mediated cytotoxicity. Pembrolizumab is disclosed, for example, in US 8,354,509 and WO2009 / 114335. It is approved by the FDA for the treatment of patients with unresectable or metastatic melanoma and patients with metastatic NSCLC.

[0304] Nivolumab (CAS Reg. No. 946414-94-4; BMS-936558 or MDX1106b) is a fully human IgG4 monoclonal antibody that specifically blocks PD-1 and has no detectable antibody-dependent cellular cytotoxicity (ADCC). Nivolumab is disclosed, for example, in US 8,008,449 and WO 2006 / 121168. It has been approved by the FDA for the treatment of patients with unresectable or metastatic melanoma, metastatic NSCLC, and advanced renal cell carcinoma.

[0305] Pilivizumab (CT-011; Cure Tech) is a humanized IgG1k monoclonal antibody that binds to PD- 1. Pilivizumab is disclosed, for example, in WO 2009 / 101611.

[0306] PDR-001 or PDR001 is a high-affinity, ligand-blocking, humanized anti-PD-1 IgG4 antibody that blocks the binding of PDL-1 and PD-L2 to PD-1. PDR-001 is disclosed in WO2015 / 112900 and WO2017 / 019896.

[0307] According to this and any other aspect of the invention, antibodies PD1-1 to PD1-5 are antibody molecules as disclosed in EP16170174.3 and are further defined by the sequences shown in Table 9 below.

[0308] Thus, PD1-1 has a heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 122;

[0309] PD1-2 has a heavy chain comprising the amino acid sequence of SEQ ID NO: 123 and a light chain comprising the amino acid sequence of SEQ ID NO: 124;

[0310] PD1-3 has a heavy chain comprising the amino acid sequence of SEQ ID NO: 125 and a light chain comprising the amino acid sequence of SEQ ID NO: 126;

[0311] PD1-4 has a heavy chain comprising the amino acid sequence of SEQ ID NO: 127 and a light chain comprising the amino acid sequence of SEQ ID NO: 128; and

[0312] PD1-5 has a heavy chain comprising the amino acid sequence of SEQ ID NO: 129 and a light chain comprising the amino acid sequence of SEQ ID NO: 130.

[0313] Another aspect of the present invention is the use of the anti-CD73 antibody molecules of the present invention for the preparation of a pharmaceutical composition for the treatment of cancer. In a preferred embodiment, this aspect further comprises the additional use of a PD-1 antagonist (e.g., an anti-PD-1 antibody or an anti-PDL-1 antibody). Preferably, the anti-PD-1 antibody is selected from the group consisting of: pembrolizumab, nivolumab, pilizumab, PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 as described herein. Preferably, the anti-PDL-1 antibody is selected from the group consisting of: atezolizumab, avelumab, and durvalumab.

[0314] In one embodiment, the anti-CD73 antibody molecule is to be administered simultaneously, concurrently, sequentially, continuously, alternatingly or separately with the PD-1 antagonist.

[0315] The medical use aspects of the present invention may comprise any specific anti-CD73 antibody molecule of the present invention and / or a PD-1 antagonist as described herein.

[0316] Due to their biological properties, the antibodies of the invention are suitable for the treatment of diseases characterized by excessive or abnormal cell proliferation (eg cancer).

[0317] As used herein, the term "cancer" is intended to include all types of cancerous growths or oncogenic processes, metastatic tissues, or malignantly transformed cells, tissues, or organs, regardless of the histopathological type or stage of invasion. Examples of cancerous conditions include, but are not limited to, solid tumors, hematological cancers, soft tissue tumors, and metastatic lesions.

[0318] Exemplary cancers whose growth can be inhibited using the antibody molecules disclosed herein include cancers that are typically responsive to immunotherapy.

[0319] For example, and without limitation, the following cancers, tumors, and other proliferative diseases can be treated using antibodies according to the present invention:

[0320] Examples of solid tumors include malignancies such as sarcomas and carcinomas (including adenocarcinomas and squamous cell carcinomas) of various organ systems, such as sarcomas and carcinomas of the liver, lymph nodes, genitourinary tract (e.g., kidney, urothelial cells), and pharynx. Adenocarcinomas include malignancies such as most colon cancers, renal cell carcinomas, liver cancers, non-small cell lung cancers, and small intestinal cancers. Squamous cell carcinomas include, for example, malignancies in the lungs, esophagus, skin, HNSCC, oral cavity, anus, and cervix.

[0321] Other indications that can be treated include renal cancer (e.g., kidney cancer, such as clear cell carcinoma), gastrointestinal cancer, gastric cancer, CRC, colon cancer, anal region cancer, pancreatic cancer, ovarian cancer, melanoma (e.g., metastatic malignant melanoma, such as cutaneous or intraocular malignant melanoma), breast cancer, HNSCC, HCC, lung cancer, small cell lung cancer, non-small cell lung cancer (NSCLC), squamous non-small cell lung cancer (NSCLC), non-NSCLC, glioma, endometrial cancer, prostate cancer (e.g., hormone-refractory prostate adenocarcinoma or castration-resistant prostate cancer (CRPC)), thyroid cancer, neuroblastoma, tumors, glioblastoma (glioblastoma multiforme), cervical cancer, gastric cancer, bladder cancer, hepatoma, germ cell tumors, pediatric sarcomas, sinonasal natural killer lymphomas, bone cancer, uterine cancer, testicular cancer, fallopian tube cancer, endometrial cancer, cervical cancer, vaginal cancer, vulvar cancer, esophageal cancer, small intestine cancer, endocrine system cancer, parathyroid cancer, adrenal cancer, soft tissue sarcoma, urethral cancer, penile cancer, childhood solid tumors, ureteral cancer, renal pelvis cancer, central nervous system (CNS) tumors, primary CNS lymphomas, spinal axis tumors, brainstem gliomas, pituitary adenomas, Kaposi's sarcoma sarcoma), epidermoid cancers, T-cell lymphomas, environmentally induced cancers (including cancers induced by asbestos), virus-related cancers (e.g., human papillomavirus (HPV)-associated tumors); and hematological malignancies derived from the two major blood cell lineages, the myeloid lineage (which produces granulocytes, erythrocytes, platelets, macrophages, and mast cells) or the lymphoid lineage (which produces B cells, T cells, NK cells, and plasma cells), such as all types of leukemias, lymphomas, and myelomas, such as acute, chronic, lymphocytic, and / or myeloid leukemias, such as acute leukemia (ALL), acute myeloid leukemia (AML), and myeloid leukemia. acute lymphoblastic leukemia (AML), acute lymphoblastic leukemia, chronic lymphocytic leukemia (CLL), chronic lymphoid leukemia, and chronic myeloid leukemia (CML), undifferentiated AML (MO), myeloblastic leukemia (M1), myeloblastic leukemia (M2; with cell maturation), promyelocytic leukemia (M3 or M3 variant [M3V]), myelomonocytic leukemia (M4 or M4 variant [M4E] with eosinophilia), monocytic leukemia (M5), erythroleukemia (M6), megakaryoblastic leukemia (M7), isolated granulocytic sarcoma, and chloroma;Lymphomas, e.g., Hodgkin's lymphoma (HL), non-Hodgkin's lymphoma (NHL), B-cell lymphoma, precursor lymphoma, lymphoplasmacytoid lymphoma, lymphocytic lymphoma, acute myeloid lymphoma, monocytoid B-cell lymphoma, mucosa-associated lymphoid tissue (MALT) lymphoma, anaplastic (e.g., K1+) large cell lymphoma, adult T-cell lymphoma / leukemia, mantle cell lymphoma, angioimmunoblastic T-cell lymphoma, angiocentric lymphoma, intestinal T-cell lymphoma, primary mediastinal B-cell lymphoma, T-lymphoblastic lymphoma, peripheral T-cell lymphoma, lymphoma, precursor T-lymphoblastic lymphoma, post-transplant lymphoproliferative disorder, true histiocytic lymphoma, primary central nervous system lymphoma, primary effusion lymphoma, lymphoblastic lymphoma (LBL), diffuse large B-cell lymphoma, Burkitt's lymphoma, follicular lymphoma, diffuse histiocytic lymphoma (DHL), immunoblastic large cell lymphoma, precursor B-lymphoblastic lymphoma, cutaneous T-cell lymphoma (CTLC) (also known as mycosis fungoides or Sezary syndrome), anaplastic large cell lymphoma, and leukemia with Waldenstrom's macroglobulinemia. myelocytic lymphoma (LPL) of the myeloid lineage; myelomas, such as IgG myeloma, light chain myeloma, nonsecretory myeloma, smoldering myeloma (also known as indolent myeloma), solitary plasmacytoma and multiple myeloma, hairy cell lymphoma; hematopoietic tumors of the myeloid lineage, tumors of mesenchymal origin (including fibrosarcoma and rhabdomyosarcoma); seminoma, teratoma, central and peripheral nervous system tumors, including astrocytoma, schwannoma; tumors of mesenchymal origin, including fibrosarcoma, rhabdomyosarcoma and osteosarcoma; and other tumors, including xeroderma pigmentosum, keratoacanthoma, seminoma, follicular thyroid carcinoma and teratoma; hematopoietic tumors of the lymphoid lineage, such as T-cell and B-cell tumors, including but not limited to T-cell disorders, such as T-pro-lymphocytic leukemia (TPLL), including small cell and cerebriform cell types; large granular lymphocytic leukemia (LGL), preferably of the T-cell type; a / d T-NHL hepato-splenic lymphoma; peripheral / post-thymic T-cell lymphoma (polymorphic and immunoblastic subtypes); angiocentric (nasal) T-cell lymphoma; colorectal cancer; and any combination of these cancers. The methods described herein can also be used to treat metastatic cancers, cancers that are resistant or refractory to previous treatment (e.g., cancers that are refractory to previous immunotherapy with, for example, antibodies that block CTLA-4 or PD-1 or PDL-1), and recurrent cancers.

[0322] In some embodiments, the cancer is renal cancer, gastrointestinal cancer, or lung cancer. In some embodiments, the gastrointestinal cancer is colon cancer, gastric cancer, or hepatocellular carcinoma. In some embodiments, the renal cancer is renal cancer, preferably clear cell carcinoma. In a preferred embodiment of the present invention, the cancer is lung cancer, preferably non-small cell lung cancer (NSCLC). In some embodiments, the colon cancer is CRC.

[0323] All cancers, tumors, neoplasms mentioned above as being characterized by a specific location / origin in the body are meant to include both the primary tumor and metastatic tumors derived therefrom.

[0324] It is possible that if a patient has a cancer characterized by high CD73 expression (on the cancer cells themselves or on stromal cells or immune cells within the tumor); and / or if the cancer is infiltrated by immune cells (e.g., tumor infiltrating lymphocytes), the patient is more likely to respond to treatment with the antibody molecules of the invention (as described herein). Although it is expected that some CD73 expression may be required, treatment with the antibody molecules of the invention is not necessarily limited to cancers with high CD73 expression. Thus, in embodiments of the invention, the patient to be treated has a cancer characterized by high CD73 expression, and / or the cancer is infiltrated by immune cells. In some embodiments, the patient has a cancer characterized by high PDL-1 and / or CD73 expression on cancer cells, stromal cells, or immune cells within the tumor, and is treated using an anti-CD73 antibody and a PD-1 antagonist as described herein.

[0325] Such expression can be determined, for example, on cancer cells, tumor infiltrating lymphocytes (e.g., CD8+ T cells or CD4+ T cells), tumor vasculature, tumor stroma by methods known in the art, such as flow cytometry or immunohistochemistry.

[0326] In a preferred embodiment, patients to be treated are selected based on increased CD73 expression.

[0327] In addition, it is possible that if a patient suffers from a cancer characterized by a high mutation load, the patient is more likely to respond to treatment using an antibody molecule of the invention (as described herein). Examples of how a high mutation load can be evaluated include determining whether a cancer is characterized by microsatellite instability or poor DNA mismatch repair efficiency. It is believed that such cancers are more immunogenic and are thus more likely to respond to treatment using an immunomodulatory treatment regimen (e.g., an antibody molecule of the invention). Therefore, in one embodiment of the invention, the patient to be treated suffers from a cancer characterized by a high mutation load.

[0328] The antibody molecules of the present invention may be used in treatment regimens in the first-line, second-line or any other line of treatment setting.

[0329] In one embodiment, the patient to be treated has previously been treated with another therapeutic agent. In some embodiments, such therapeutic agent can be a PD-1 antagonist as described herein, such as pembrolizumab, nivolumab, pilizumab, atezolizumab, avelumab, durvalumab, or PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 as described herein.

[0330] In one embodiment, the patient to be treated is a patient who is a poor responder to treatment with the therapeutic agent. For example, the patient may have a cancer that is known to be unresponsive, minimally responsive, or inadequately responsive to treatment with the therapeutic agent. In one embodiment, a patient who is a poor responder to treatment with the therapeutic agent is an individual whose cancer tissue or cancer-adjacent tissue is characterized by insufficient or low levels of inflammation (e.g., compared to a reference). In one embodiment, a patient who is a poor responder to treatment with the therapeutic agent is an individual who has received treatment with the therapeutic agent and whose cancer has progressed. In one embodiment, an individual who is a poor responder or has a poorly responsive cancer is an individual who has a poor disease prognosis for treatment with the therapeutic agent. Individuals who are poorly responsive to treatment with the therapeutic agent can be identified based on one or more predictors, for example, by a high or higher risk of cancer progression (e.g., compared to individuals with a good disease prognosis). In one embodiment, the predictor comprises the presence of an elevated number of CD73-expressing T cells and / or elevated levels of CD73-expressing cells or adenosine levels in the tumor microenvironment (in the tumor or tumor-adjacent tissue). In one embodiment, the predictor comprises the presence or absence of a mutation in one or more genes. In one embodiment, the mutation defines a new epitope recognized by a T cell. In one embodiment, the predictor comprises the expression level of one or more genes or proteins in tumor cells (e.g., PDL-1, reduced or increased PDL-1 levels on tumor cells). In one embodiment, the predictor comprises the expression level of one or more genes or proteins (e.g., PD-1) in effector T cells in the circulation or tumor environment. In one embodiment, the predictor comprises a high mutation load as described above.

[0331] In some embodiments, the therapeutic agent is a PD-1 antagonist as described herein, such as pembrolizumab, nivolumab, pilizumab, atezolizumab, avelumab, durvalumab, or PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 as described herein.

[0332] The antibody molecules of the present invention can be used for the prevention, short-term or long-term treatment of the diseases mentioned above, which are optionally combined with radiotherapy, chemotherapy and / or surgery. Therefore, in another embodiment, the patient to be treated has previously been treated with radiotherapy or chemotherapy (as further described below). In one embodiment, the patient to be treated is a person who has a poor response to radiotherapy or chemotherapy, as described above.

[0333] Of course, the above also includes the use of the antibody molecules of the present invention in various methods for treating the above-mentioned diseases by administering a therapeutically effective dose to a patient in need thereof; and the use of these antibody molecules for preparing medicaments for treating such diseases; and pharmaceutical compositions comprising such antibody molecules of the present invention; and the preparation and / or manufacture of medicaments comprising such antibodies of the present invention; and the like.

[0334] Combination with other active substances or treatments

[0335] The anti-CD73 antibody molecules of the invention or the combination of an anti-CD73 antibody of the invention and a PD-1 antagonist can be used alone or in combination with one or more other therapeutic agents or procedures, particularly selected from chemotherapeutic agents (such as DNA damaging agents) or therapeutically active compounds that inhibit angiogenesis, signal transduction pathways or mitotic checkpoints in cancer cells.

[0336] In some embodiments, the anti-CD73 antibody used in such combinations may be any of the antibodies described above in the first aspect of the invention. Preferred anti-CD73 antibodies are B1, B2, C1, C2, C3, C4, C5 and C6 (Table 9).

[0337] In some embodiments, it is also contemplated that other anti-CD73 antibodies known in the art may be used in place of or in addition to the antibodies of the first aspect. In addition to the anti-CD73 antibodies of the first aspect of the invention, another anti-CD73 antibody may be used, such as MEDI9447, BMS986179, CPX-006, CPX-0016, or antibodies as described in WO2008007648, WO2016075099, WO2016081748, WO2016055609, WO2016131950, WO17064043, WO2017100670, WO17152085, or WO2018013611.

[0338] The additional therapeutic agent can be administered simultaneously with the antibody molecule (optionally as components of the same pharmaceutical formulation), or before or after it.

[0339] In certain embodiments, the additional therapeutic agent may be, but is not limited to, one or more inhibitors selected from the group consisting of inhibitors of EGFR, VEGFR, HER2-neu, Her3, AuroraA, AuroraB, PLK and PI3 kinase, FGFR, PDGFR, Raf, Ras, KSP, IAP (SMAC mimetic), Bcl-2, Mcl-1, HDAC (tissue protein deacetylase), GSK3β, PDK1, PTK2, IGF-R, or IR.

[0340] Other examples of additional therapeutic agents are inhibitors of CDK, Akt, src / bcr abl, cKit, cMet / HGF, c-Myc, Flt3, HSP90, hedgehog antagonists, inhibitors of JAK / STAT, Mek, mTor, NFκB, proteasome, Rho or ubiquitination pathway inhibitors or another inhibitor of the Notch signaling pathway or c-FLIP (cellular FLICE-inhibitory protein) modulators.

[0341] Examples of Aurora inhibitors are, but are not limited to, PHA-739358, AZD-1152, AT 9283, CYC-116, R-763, VX-680, VX-667, MLN-8045, PF-3814735.

[0342] An example of a PLK inhibitor is GSK-461364.

[0343] Examples of raf inhibitors are BAY-73-4506 (also a VEGFR inhibitor), PLX 4032, RAF-265 (also a VEGFR inhibitor), sorafenib (also a VEGFR inhibitor) and XL 281.

[0344] Examples of KSP inhibitors are ispinesib, ARRY-520, AZD-4877, CK-1122697, GSK246053A, GSK-923295, MK-0731 and SB-743921.

[0345] Examples of SMAC mimetics (IAP antagonists) are, but are not limited to, LCL-161, Debio 1143, and ASTX-660.

[0346] Examples of src and / or bcr-abl inhibitors are dasatinib, AZD-0530, bosutinib, XL 228 (also an IGF-1R inhibitor), nilotinib (also a PDGFR and cKit inhibitor), imatinib (also a cKit inhibitor), and NS-187.

[0347] An example of a PDK1 inhibitor is BX-517.

[0348] An example of a Rho inhibitor is BA-210.

[0349] Examples of PI3 kinase inhibitors are PX-866, BEZ-235 (also an mTor inhibitor), XL 418 (also an Akt inhibitor), XL-147 and XL 765 (also an mTor inhibitor).

[0350] Examples of cMet or HGF inhibitors are XL-184 (also an inhibitor of VEGFR, cKit, Flt3), PF-2341066, MK-2461, XL-880 (also an inhibitor of VEGFR), MGCD-265 (also an inhibitor of VEGFR, Ron, Tie2), SU-11274, PHA-665752, AMG-102 and AV-299.

[0351] An example of a c-Myc inhibitor is CX-3543.

[0352] Examples of Flt3 inhibitors are AC-220 (also an inhibitor of cKit and PDGFR), KW 2449, lestaurtinib (also an inhibitor of VEGFR, PDGFR, PKC), TG-101348 (also a JAK2 inhibitor), XL-999 (also an inhibitor of cKit, FGFR, PDGFR and VEGFR), sunitinib (also an inhibitor of PDGFR, VEGFR and cKit) and tandutinib (also an inhibitor of PDGFR and cKit).

[0353] Examples of HSP90 inhibitors are tanespimycin, alvespimycin, IPI-504 and CNF 2024.

[0354] Examples of JAK / STAT inhibitors are CYT-997 (also interacts with tubulin), TG 101348 (also a Flt3 inhibitor), and XL-019.

[0355] Examples of Mek inhibitors are ARRY-142886, PD-325901, AZD-8330 and XL 518.

[0356] Examples of mTor inhibitors are temsirolimus, AP-23573 (which also acts as a VEGF inhibitor), everolimus (another VEGF inhibitor), XL-765 (also a PI3 kinase inhibitor), and BEZ-235 (also a PI3 kinase inhibitor).

[0357] Examples of Akt inhibitors are perifosine, GSK-690693, RX-0201 and triciribine.

[0358] Examples of cKit inhibitors are AB-1010, OSI-930 (also a VEGFR inhibitor), AC-220 (also an inhibitor of Flt3 and PDGFR), tandutinib (also an inhibitor of Flt3 and PDGFR), axitinib (also an inhibitor of VEGFR and PDGFR), XL-999 (also an inhibitor of Flt3, PDGFR, VEGFR, FGFR), sunitinib (also an inhibitor of Flt3, PDGFR, VEGFR) and XL-820 (also a VEGFR- and PDGFR inhibitor), imatinib (also a bcr-abl inhibitor), nilotinib (also an inhibitor of bcr-abl and PDGFR).

[0359] Examples of hedgehog antagonists are IPI-609 and CUR-61414.

[0360] Examples of CDK inhibitors are seliciclib, AT-7519, P-276, ZK-CDK (also inhibits VEGFR2 and PDGFR), PD-332991, R-547, SNS-032, PHA-690509 and AG 024322.

[0361] Examples of proteasome inhibitors are bortezomib, carfilzomib and NPI-0052 (also an NFκB inhibitor).

[0362] An example of an NFκB pathway inhibitor is NPI-0052.

[0363] An example of an ubiquitination pathway agent is HBX-41108.

[0364] In a preferred embodiment, the additional therapeutic agent is an anti-angiogenic agent.

[0365] Examples of anti-angiogenic agents are inhibitors of FGFR, PDGFR and VEGFR or their respective ligands (e.g., VEGF inhibitors such as pegaptanib, or the anti-VEGF antibody bevacizumab), and thalidomides, such agents being selected from, but not limited to, nintedanib, bevacizumab, motesanib, CDP-791, SU-14813, telatinib, KRN-951, ZK-CDK (also a CDK inhibitor), ABT-869, BMS-690514, RAF-265, IMC-KDR, IMC-18F1, IMiDs (immunomodulatory drugs), the thalidomide derivative CC-4047, lenalidomide, ENMD 0995, IMC-D11, Ki 23057, brivanib, cediranib, XL-999 (also an inhibitor of cKit and Flt3), 1B3, CP 868596, IMC 3G3, R-1530 (also an inhibitor of Flt3), sunitinib (also an inhibitor of cKit and Flt3), axitinib (also an inhibitor of cKit), lestaurtinib (also an inhibitor of Flt3 and PKC), vatalanib, tandutinib (also an inhibitor of Flt3 and cKit), pazopanib, GW 786034, PF-337210, IMC-1121B, AVE-0005, AG-13736, E-7080, CHIR 258, sorafenib tosylate (also a Raf inhibitor), RAF-265 (also a Raf inhibitor), vandetanib, CP-547632, OSI-930, AEE-788 (also an inhibitor of EGFR and Her2), BAY-57-9352 (also a Raf inhibitor), BAY-73-4506 (also a Raf inhibitor), XL 880 (also a cMet inhibitor), XL-647 (also an inhibitor of EGFR and EphB4), XL 820 (also a cKit inhibitor) and nilotinib (also an inhibitor of cKit and brc-abl).

[0366] Additional therapeutic agents may also be selected from EGFR inhibitors, which may be small molecule EGFR inhibitors or anti-EGFR antibodies. Examples of anti-EGFR antibodies include, but are not limited to, cetuximab, panitumumab, and matuzumab; examples of small molecule EGFR inhibitors include, but are not limited to, gefitinib, afatinib, osimertinib, and olmutinib. Another example of an EGFR modulator is the EGF fusion toxin.

[0367] EGFR and Her2 inhibitors that can be used in combination with the antibody molecules of the invention are lapatinib, gefitinib, erlotinib, afatinib, cetuximab, trastuzumab, nimotuzumab, zalutumumab, vandetanib (also a VEGFR inhibitor), pertuzumab, XL-647, HKI-272, BMS-599626, ARRY-334543, AV 412, mAB-806, BMS-690514, JNJ-26483327, AEE-788 (also a VEGFR inhibitor), ARRY-333786, IMC-11F8, Zemab.

[0368] Other agents that may be advantageously combined in therapy with the antibody molecules of the invention are tositumumab and ibritumomab tiuxetan (two radiolabeled anti-CD20 antibodies), alemtuzumab (anti-CD52 antibody), denosumab (osteoclast differentiation factor ligand inhibitor), galiximab (CD80 antagonist), ofatumumab (CD20 inhibitor), zanolimumab (CD4 antagonist), SGN40 (CD40 ligand receptor modulator), rituximab (CD20 inhibitor), epratuzumab (CD22 antibody), or mapatumumab (TRAIL-1 receptor agonist).

[0369] Other chemotherapeutic drugs that can be used in combination with the antibody molecules of the invention are selected from, but are not limited to, hormones, hormone analogs, and anti-hormones (e.g., tamoxifen, toremifene, raloxifene, fulvestrant, megestrol acetate, flutamide, nilutamide, bicalutamide, cyproterone acetate, finasteride, buserelin acetate, acetate), fludrocortisone, fluoxymesterone, medroxyprogesterone, octreotide, arzoxifene, pasireotide, vapreotide), aromatase inhibitors (e.g., anastrozole, letrozole, liarozole, exemestane, atamestane, formestane), LHRH agonists and antagonists (e.g., goserelin acetate), acetate), leuprolide, abarelix, cetrorelix, deslorelin, histrelin, triptorelin), antimetabolites (e.g., antifolates such as methotrexate, pemetrexed, pyrimidine analogs (e.g., 5-fluorouracil, capecitabine, decitabine, nelarabine, and gemcitabine), purine and adenosine analogs (e.g., mercaptopurine, thioguanine, cladribine, and pentostatin, cytarabine, fludarabine);Antitumor antibiotics (e.g., anthracyclines such as doxorubicin, daunorubicin, epirubicin, and idarubicin, mitomycin-C, bleomycin, dactinomycin, plicamycin, mitoxantrone, pixantrone, streptozocin); platinum derivatives (e.g., cisplatin); , oxaliplatin, carboplatin, lobaplatin, satraplatin); alkylating agents (e.g., estramustine, meclorethamine, melphalan, chlorambucil, busulphan, dacarbazine, cyclophosphamide, ifosfamide, hydroxyurea, urea), temozolomide, nitrosoureas (e.g., carmustine and lomustine), thiotepa); antimitotic agents (e.g., vinca alkaloids, such as vinblastine, vindesine, vinorelbine, vinflunine, and vincristine; and taxanes, such as paclitaxel, docetaxel, and their derivatives preparations, larotaxel; simotaxel; and epothilones, such as ixabepilone, patupilone, ZK-EPO; topoisomerase inhibitors (e.g., epipodophyllotoxins, such as etoposide and etopophos, teniposide, amsacrine, topotecan, irinotecan);and various chemotherapeutic agents, such as amifostine, anagrelide, interferon alpha, procarbazine, mitotane, porfimer, bexarotene, and celecoxib. ;

[0370] Particularly preferred are ATP-generating chemotherapeutic agents such as doxorubicin, where a positive effect of combining doxorubicin with CD73 blockade has been demonstrated (Loi, Proc Natl Acad Sci US A. 2013; 110(27): 11091-6).

[0371] In certain embodiments, the additional therapeutic agent may be another immunotherapeutic agent, such as a modulator of TIM-1, TIM3, TIM-4, PDL-1 (e.g., atezolizumab, avelumab, or durvalumab), PD-L2, LAG3, CTLA-4, Galectin-9, Galectin-1, CD69, CD113, GPR56, CD48, GARP, CAECAM-1, BTLA, TIGIT, CD160, LAIR1, 2B4, CEACAM, CD39, TGFβ, IL-10, Fas ligand, ICOS, IDO, Toll-like receptors, B7 family (B7-1, B7-2, B7-H1 (PDL-1), B7-DC (PD-L2), B7-H2 (ICOS-L), B7-H3, B7-H4, B7-H5 (VISTA), and B7-H6).

[0372] In some embodiments, the additional immunotherapeutic agent is a TNF family member that binds to a molecule of a cognate TNF receptor family member: CD40 and CD40L, OX-40, OX-40L, CD70, CD27L, CD30, CD30L, 4-1BBL, CD137, GITR, TRAIL / Apo2-L, TRAILR1 / DR4, TRAILR2 / DR5, TRAILR3, TRAILR4, OPG, RANK, RANKL, TWEAKR / Fn14, TWEAK, BAFFR, EDAR, XEDAR, TACI, APRIL, BCMA, LIGHT, DcR3, HVEM, VEGI / TLlA, TRAMP / DR3 , EDAR, EDAl, XEDAR, EDA2, TNFRl, lymphotoxin α / TNFβ, TNFR2, TNFα, LTβR, lymphotoxin α1β2, FAS, FASL, RELT, DR6, TROY, NGFR.

[0373] In some embodiments, the additional immunotherapeutic agent is selected from (i) antagonists of cytokines that inhibit T cell activation (e.g., IL-6, IL-10, TGF-B, VEGF; "immunosuppressive cytokines") and / or (ii) agonists of cytokines that stimulate T cell activation and / or cytokines used to stimulate an immune response (e.g., for the treatment of proliferative diseases, such as cancer) (e.g., IL2).

[0374] In some embodiments, the additional immunotherapeutic agent is an agonist of a protein that stimulates T cell activation (eg, CD28, GITRL, OX40L, CD27, and CD28H).

[0375] The anti-CD73 antibodies described herein can also be used to design bispecific antibodies that target effector cells expressing Fcα or Fcγ receptors to tumor cells (see, e.g., U.S. Patent Nos. 5,922,845 and 5,837,243, which are incorporated herein by reference). Bispecific antibodies can be used to target two separate antigens. For example, anti-Fc receptor / anti-tumor antigen (e.g., Her-2 / neu) bispecific antibodies have been used to target macrophages to tumor sites. This targeting can more effectively activate tumor-specific responses. Alternatively, antigens can be delivered directly to DCs by using bispecific antibodies that bind to tumor antigens and dendritic cell-specific cell surface markers.

[0376] In other embodiments, the immunotherapeutic agent may be a cancer vaccine.

[0377] Other molecules that can be combined with CD73 antibodies include antagonists of inhibitory receptors on NK cells or agonists of activating receptors on NK cells (e.g., KIR antagonists such as lirilumab).

[0378] In some embodiments, the additional therapeutic agent may be an agent that inhibits or depletes macrophages or monocytes, including but not limited to CSF-1R antagonists.

[0379] In other embodiments, the additional therapeutic agent may be an agent that depletes or blocks Treg cells, such as an agent that specifically binds to CD25.

[0380] In some embodiments, the additional therapeutic agent may be an inhibitor of the A2A or A2B receptor. Examples are, but are not limited to, ATL-444, Istradefylline (KW-6002), MSX-3, Preladenant (SCH-420,814), SCH-58261, SCH-412348, SCH-442416, ST-1535, Caffeine, VER-6623, VER-6947, VER-7835, Vipadenant (BIIB-014), PD116,948, ZM 241385, KW 6002, CGS 15943, ST1535, SYN-115, PSB1115, PSB 603, MRS 1754, CPI-444, PBF-509, AZD-4635, or ZM-241385.

[0381] In preferred embodiments, the additional therapeutic agent is an A2AR antagonist, a CD39 antagonist, a LAG-3 antagonist, a CTLA-4 antagonist, an EGFR antagonist, or a HER2 antagonist.

[0382] When two or more substances or ingredients are to be used as part of a combined treatment regimen, they may be administered via the same route of administration or via different routes of administration at essentially the same time (i.e., simultaneously, concurrently) or at different times (e.g., sequentially, sequentially, alternatingly, continuously or in any other manner according to an alternating regimen).

[0383] When a substance or component is to be administered simultaneously via the same route of administration, it can be administered as a different pharmaceutical formulation or composition or as part of a combination pharmaceutical formulation or composition. Similarly, when two or more active substances or components are to be used as part of a combination therapy regimen, each substance or component can be administered in the same amount and according to the same regimen as when using the compound or component itself, and such combined use may or may not produce a synergistic effect. However, when the combined use of two or more active substances or components produces a synergistic effect, it is also possible to reduce the amount of one, multiple or all substances or components to be administered, while still achieving the desired therapeutic effect. This can, for example, be used to avoid, limit or reduce any undesirable side effects associated with the use of one or more substances or components when used in a conventional amount and still obtain the desired pharmacological or therapeutic effect.

[0384] Of course, the above includes formulations and methods for preparing the antibodies of the present invention for use in combination with the above-mentioned combination partners. Also included are formulations and methods for preparing the above-mentioned combination partners for use in combination with the antibodies of the present invention.

[0385] The antibody molecules of the invention can be used alone or in combination with other therapeutic options (eg, surgery and / or radiation therapy).

[0386] Kits and methods of manufacture and purification

[0387] The present invention also encompasses kits comprising at least an anti-CD73 antibody as described herein and one or more additional components selected from the group consisting of other drugs for the treatment of diseases and disorders as described above.

[0388] In one embodiment, the kit comprises a composition containing an effective amount of an anti-CD73 antibody molecule of the invention in unit dosage form. In another embodiment, the kit comprises a composition containing an effective amount of an anti-CD73 antibody molecule of the invention in unit dosage form; and a composition containing an effective amount of a PD-1 antagonist (e.g., an anti-PD-1 antibody, most preferably PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5 as described herein) in unit dosage form.

[0389] In some embodiments, the kit comprises a sterile container containing such a composition; such a container can be a box, ampoule, bottle, vial, tube, bag, pouch, blister pack, or other suitable container form known in the art. Such a container can be made of plastic, glass, laminated paper, metal foil, or other materials suitable for holding pharmaceutical agents.

[0390] If desired, the anti-CD73 antibody molecule (alone or in combination with another therapeutic agent, such as a PD-1 antagonist) is provided with instructions for administering one or more antibodies to an individual suffering from cancer. The instructions will typically include information about using the composition to treat or prevent cancer. In other embodiments, the instructions include at least one of the following: a description of the therapeutic agent; dosage regimens and administration for treating or preventing cancer or its symptoms; precautions; warnings; indications; contraindications; overdose information; adverse reactions; animal pharmacology; clinical studies; and / or references. The instructions may be printed directly on the container (if present) or applied to the container with a label, or in the form of a separate sheet of paper, brochure, card, or binder supplied in or with the container.

[0391] In some embodiments, the kit comprises an anti-CD73 antibody molecule as described herein together with a PD-1 antagonist (as further described herein) and optionally another therapeutic agent as described above.

[0392] The present invention further provides methods of making the antibody molecules of the present invention, such methods generally comprising the steps of:

[0393] - culturing a host cell comprising an expression vector containing a nucleic acid encoding an antibody molecule of the invention under conditions that allow the formation of the antibody of the invention; and

[0394] - recovering the antibody molecule expressed by the host cell from the culture; and

[0395] - optionally further purifying and / or modifying and / or formulating the antibody molecule of the invention.

[0396] The nucleic acid of the present invention can be, for example, a DNA molecule comprising a coding sequence and regulatory sequences and optional natural or artificial introns, or can be a cDNA molecule. It can have its original codons or can have optimized codon usage that is particularly suitable for expression in the intended host cell or host organism. According to one embodiment of the present invention, the nucleic acid of the present invention is in a substantially isolated form as defined above.

[0397] The nucleic acids of the invention are typically incorporated into an expression vector (ie, a vector that can express a polypeptide when transfected into an appropriate host cell or other expression system).

[0398] To produce the antibodies of the present invention, one skilled in the art can choose from a variety of expression systems well known in the art (eg, those reviewed by Kipriyanow and Le Gall, 2004).

[0399] Expression vectors include plasmids, retroviruses, clays, EBV-derived episomes, etc. Expression vectors and expression control sequences are selected to be compatible with host cells. The antibody light chain gene and the antibody heavy chain gene can be inserted into separate vectors. In certain embodiments, two DNA sequences are inserted into the same expression vector.

[0400] Convenient vectors are those encoding fully functional human CH (heavy chain constant region) or CL (light chain constant region) immunoglobulin sequences, with appropriate restriction sites engineered to facilitate insertion and expression of any VH (heavy chain variable region) or VL (light chain variable region) sequence, as described above. For the antibody heavy chain, it can be, but is not limited to, any IgG isotype (IgG1, IgG2, IgG3, IgG4) or other immunoglobulins (including allelic variants).

[0401] The recombinant expression vector may also encode a signal peptide that facilitates secretion of the antibody chain from the host cell. The DNA encoding the antibody chain can be cloned into the vector so that the signal peptide is linked in-frame to the amino terminus of the mature antibody chain DNA. The signal peptide can be an immunoglobulin signal peptide or a heterologous peptide from a non-immunoglobulin protein. Alternatively, the DNA sequence encoding the antibody chain may already contain a signal peptide sequence.

[0402] In addition to the antibody chain DNA sequence, the recombinant expression vector typically carries regulatory sequences, optionally heterologous regulatory sequences, including promoters, enhancers, termination and polyadenylation signals, and other expression control elements that control the expression of the antibody chain in the host cell. Examples of promoter sequences (exemplified for expression in mammalian cells) are promoters and / or enhancers derived from CMV (e.g., the CMV simian nephrovirus 40 (SV40) promoter / enhancer), adenovirus (e.g., the adenovirus major late promoter (AdMLP)), polyoma virus, and strong mammalian promoters (e.g., the natural immunoglobulin and actin promoters). Examples of polyadenylation signals are BGH poly A, SV40 late or early poly A; alternatively, the 3′ UTR of an immunoglobulin gene can be used.

[0403] The recombinant expression vector may also carry sequences that regulate vector replication in the host cell (e.g., an origin of replication) and selectable marker genes. Nucleic acid molecules encoding the heavy chain or antigen-binding portion thereof and / or light chain or antigen-binding portion thereof of an antibody of the present invention and vectors comprising such DNA molecules may be introduced into a host cell (e.g., a bacterial cell or a higher eukaryotic cell (e.g., a mammalian cell)) according to transfection methods well known in the art (including liposome-mediated transfection, polycation-mediated transfection, protoplast fusion, microinjection, calcium phosphate precipitation, electroporation, or transfer by viral vectors).

[0404] Preferably, the DNA molecules encoding the heavy and light chains are present on two expression vectors that are co-transfected into a host cell, preferably a mammalian cell.

[0405] Mammalian cell lines that can be used as expression hosts are well known in the art and include, among others, Chinese hamster ovary (CHO) cells, NSO, SP2 / 0 cells, HeLa cells, baby hamster kidney (BHK) cells, monkey kidney cells (COS), human cancer cells (e.g., Hep G2 and A549 cells), 3T3 cells, or derivatives / progeny of any of these cell lines. Other mammalian cells (including but not limited to human, mouse, rat, monkey, and rodent cell lines) or other eukaryotic cells (including but not limited to yeast, insect, and plant cells) or prokaryotic cells (e.g., bacteria) can be used.

[0406] Antibody molecules of the present invention are produced by culturing host cells for a period of time sufficient to allow expression of antibody molecules in host cells. Antibody molecules are preferably recovered from culture medium in the form of secreted polypeptides or they can be recovered from host cell lysates (if, for example, expressed without secretion signals). Standard protein purification methods for recombinant proteins and host cell proteins need to be used to purify antibody molecules in order to obtain substantially homogeneous preparations of antibodies. For example, the purification method of the state-of-the-art for obtaining antibody molecules of the present invention comprises (as a first step) removing cells and / or particulate cell debris from culture medium or lysate. The antibody is then purified from pollutants, soluble proteins, polypeptides, and nucleic acid, for example, by fraction separation, ethanol precipitation, reversed-phase HPLC, Sephadex chromatography, silica, or cation exchange resins on immunoaffinity or ion exchange columns. As the final step in the process of obtaining antibody molecule preparations, purified antibody molecules (for example, freeze-dried) can be dried, as described below for therapeutic applications.

[0407] The present invention is further illustrated by the following examples, which are not necessarily limited to such embodiments of the invention. The examples or portions thereof (including compounds, dosages and routes of administration, and therapeutic combinations) each form part of the present invention either by themselves or in combination with the above detailed description. Example

[0408] Example 1: Generation and optimization of antibodies against CD73

[0409] CD73 knockout mice were immunized with the complete extracellular domain of human CD73 (UniProt Accession No. P21589) with a C-terminal 6xHis tag and the complete extracellular domain of mouse CD73 (UniProt Accession No. Q61503; with a C-terminal human Fc tag (SEQ ID NO: 131). Samples were identified and recovered using a single B cell antibody generation platform. They were screened for binding to human, cynomolgus monkey, mouse, and rat CD73 and tested for CD73 inhibition in functional assays, as described in Examples 2 to 6. Antibody molecules with the best set of properties according to these assays were used as the basis for additional optimized variants.

[0410] The CDR sequences from these anti-CD73 mouse antibodies were optimized using a phage screening method to human frameworks from closely matched germlines for the heavy and light chains (as described by Singh et al., MAbs. 2015 Jul-Aug; 7(4):778-791). The binding activity of the variants was assessed by ELISA. Variants with high affinity for human CD73 and a high ratio of human residues and low predicted immunogenicity (low Epivax score) were selected.

[0411] Example 2: Target Binding and Cell Selectivity

[0412] For affinity format, experiment is implemented on Bio-Rad ProteOn XPR36 instrument. Via protein A / G capture antibody and make non-covalent dimer antigen flow through capture surface top. The running buffer and all diluents of this experiment are prepared in PBS-T-EDTA. GLM sensor chip is normalized and preconditioned according to the recommendation of manufacturer. Use an equal amount mixture of EDC / s-NHS to activate sensor chip 300s in horizontal direction with a flow rate of 30 μ L / min and use recombinant protein A / G (50 μ g / ml, in 10mM acetate (pH 4.5)) to fix 300s in horizontal direction with a flow rate of 30 μ L / min, thereby producing about 5000RU protein A / G on the surface. Use 1M ethanolamine-HCl with a flow rate of 30 μ L / min in horizontal direction by sensor chip passivation 300s. The sensor chip was regenerated twice horizontally and twice vertically using 0.85% phosphoric acid (18 s) at a flow rate of 100 μL / min.

[0413] Approximately 300 RU of antibody was captured vertically on the Protein A / G surface at a flow rate of 30 μL / min for 60 s. The capture surface was stabilized by injecting PBS-T-EDTA horizontally for 60 s at a flow rate of 100 μL / min. The analyte (human CD73-His) was injected horizontally over the captured antibody at a flow rate of 30 μL / min for 600 s and dissociated for 1200 s. The concentrations of human CD73-His were 0 nM, 3.125 nM, 6.25 nM, 12.5 nM, 25 nM, and 50 nM. The surface was regenerated by injecting 0.85% phosphoric acid horizontally for 18 s once and vertically once at a flow rate of 100 μL / min.

[0414] The midpoint (interaction with the sensor surface) and blank (PBS-T-EDTA or 0 nM analyte) were subtracted from the raw data. The sensorgrams were globally fitted to a 1:1 Langmuir binding using Bio-Rad ProteOn Manager software to provide association rate constants (ka), dissociation rate constants (kd), and equilibrium dissociation constant (KD) values.

[0415] Table 1: Binding affinity of anti-CD73 antibodies to CD73 obtained by SPR

[0416]

[0417]

[0418] Cell selectivity was determined in a FACS-based assay using cell lines that endogenously express CD73 as well as CD73-negative cell lines. Binding was readily detected in CD73-positive cells, whereas no detectable binding was observed in CD73-negative cells at concentrations up to 1000 nM.

[0419] Binding of anti-CD73 to mouse CD73 was also determined by SPR and compared to binding to human CD73 (P21589, “long isoform”).

[0420] The antibodies tested bound to human CD73 with higher affinity than to mouse CD73 (binding to human CD73 was higher than to mouse CD73: C1: 96-fold; C2: 138-fold; C3: 117-fold; C4: 120-fold; C5: 163-fold, C6: 58-fold).

[0421] Example 3: Inhibition of CD73 enzyme function

[0422] CD73 enzyme function was measured using a luciferase-based assay. The CD73 substrate AMP is a product of the luciferase reaction and exhibits inhibitory activity against luciferase. The plate was closed and recombinant human CD73 protein was subsequently added. CD73 antibodies of varying concentrations were then added. The plate was mixed and incubated at 37°C for 10 min. Substrate AMP was added, the plate was mixed and incubated at 37°C for 30 min. CellTiterGlo reagent (CellTiterGlo Luminescent Cell Viability Assay Kit, Promega, catalog number G7571) was dissolved in reagent buffer and added to each well. The plate was mixed and incubated in the dark at room temperature for 10 min. The luminescent signal was measured using an EnVision2104 Multilabel reader.

[0423] As shown in Table 2, the CD73 antibodies described herein exhibit low nanomolar IC values ​​for inhibition of CD73 enzymatic function. 90 The data shown are from two independent experiments.

[0424] Table 2: Inhibition of CD73 enzymatic function by anti-CD73 antibodies.

[0425] Antibody <![CDATA[IC 90 [nM] Mean + / - SD B2 1.04+ / -0.12 C1 0.49+ / -0.09 C2 0.49+ / -0.08 C3 0.32+ / -0.01 C4 0.24+ / -0.08 C5 0.29+ / -0.05 C6 0.24+ / -0.03

[0426] Example 4: Reduction of CD73 protein surface levels.

[0427] Reduction in CD73 protein surface levels was determined by flow cytometry. Colo201 cell lines were incubated with CD73 antibodies for 1 h and 24 h, and the levels of CD73-binding antibodies on the cell surface were measured using a secondary antibody.

[0428] Colo201 cells were isolated by adding TripLE solution (Gibco, No. 12604-013) and seeded into 96-well plates. After 24 hours, CD73 antibodies were added. Samples were analyzed by flow cytometry using labeled secondary antibodies after 1 hour and 24 hours. Sample analysis was performed using FlowJo X software version 10.0.7r2. The mean fluorescence intensity (FI) of the gated population was normalized to its corresponding mean FI at time point 0 (incubated with CD73 antibodies for 1 hour). The data were then normalized, where the fluorescence value of cells incubated with a CD73 antibody that does not induce a decrease in CD73 surface levels (as disclosed in US20090203538 as "067-213 antibody") was set to 100% (maximum CD73 level).

[0429] The CD73 antibodies described herein exhibited moderate activity in inducing a decrease in CD73 surface levels. The data shown are from at least two independent experiments.

[0430] Table 3: Reduction of CD73 surface levels by anti-CD73 antibodies.

[0431]

[0432]

[0433] Example 5: Inhibition of adenosine formation in cell lines

[0434] A cell-based assay was used to determine the reduction in adenosine levels achieved by CD73 inhibition. AMP was added to Colo-201 cells so that AMP was converted to adenosine by CD73 expressed on the cells. The conversion of AMP was inhibited by the anti-CD73 antibodies of the present invention as provided herein. Colo-201 cells were cultured at 37°C for 24 hours in the presence of CD73 antibodies. A blocking solution containing red 9-(2-hydroxy-3-nonyl)adenine was then added to block adenosine deaminase, a blocking solution containing 5-iodotuberculin was added to block adenosine kinase, a blocking solution containing β-glycerophosphate was added to block alkaline phosphatase, and a blocking solution containing dipyridamole was added to block ENT1-4 (Ramakers 2008). After incubation for 20 minutes, 300 μM AMP was added for 30 minutes and the reaction was terminated by adding 15 mM HCl solution. In a 96-well plate format, 50 μl aliquots of cell supernatant from each mAb concentration incubation were added to a 50 μl plate containing 0.5 mM isotope-labeled 13C5-adenosine was used as an internal standard in 500 μl of acetonitrile + 50 μl of blocking solution. Calibration standards were prepared by serial dilution in 12 steps. 50 μl of cell incubation medium (as blank matrix) plus 50 μl of each standard or QC solution were added to a 50 μl flask containing 0.5 mM isotope-labeled 13 Calibration and quality control samples were prepared in 500 μl of acetonitrile with C5-adenosine as an internal standard. After centrifugation, 50 μl of the supernatant was transferred to another 96-well plate, evaporated to dryness under N2, and redissolved in 25% methanol + 0.01% formic acid. Adenosine concentration was determined by HPLC-MS / MS using ESI+ ionization at unit mass resolution. Samples were injected into an HPLC / MS system with a CTC PAL HTS-xt autosampler (injection volume of 5 μL). Quantitative analysis was performed at room temperature using an Agilent HP1200 HPLC system equipped with a Phenomenex Synergy Hydro-RP C18 reversed-phase HPLC column (particle size of 2.5 μm, column dimensions of 2×50 mm). An HPLC gradient using 5 mmol / L ammonium acetate (pH 4.0) as solvent A and acetonitrile containing 0.1% formic acid as solvent B was applied, with a flow rate of 700 μl / min and a cycle time of 5 min / sample. Solvent B was increased from 2% to 15% from 0 min to 3.0 min, increased to 95% B from 3.0 min to 3.1 min, kept constant at 95% B from 3.1 min to 4.0 min, then returned to 2% B from 4.0 min to 4.1 min and re-equilibrated from 4.1 min to 5.0 min. The HPLC system was coupled to an ABSCIEX API 5000 triple quadrupole mass spectrometer operating in MRM mode. Declustering potential (DP) and collision energy (CE) settings were automatically optimized using ABSCIEX Discovery Quant™ 2.1 software. Adenosine was used with a DP of 268.2 to 136.1 (DP: 62, CE: 27) and 13 Quantification was performed by the MRM transition of C5-adenosine from 273.3 to 136.2 (DP: 64, CE: 27) (retention time: 70 ms). The source temperature of the Turbo ion spray source was set at 650°C. The chromatogram was integrated and analyzed using Peak areas were determined using 1.5.1 (ABSCIEX). The absolute amount of adenosine formed was calculated from the measured adenosine concentration and the incubation volume. The data were fitted by iterative calculation using a symmetrical sigmoidal curve analysis program (Graph Pad PRISM) with a variable Hill slope. The adenosine level obtained for cells treated with the isoform without AMP was set to 100% inhibition; the adenosine level obtained for cells treated with the isoform with AMP added was set to 0% inhibition.

[0435] The CD73 antibodies described herein reduced adenosine levels in Colo201 cells by >75% compared to cells treated with the isoform + / - AMP addition.

[0436] The anti-CD73 antibodies described herein exhibited superior activity in reducing adenosine levels in Colo201 cells compared to the reference anti-CD73 antibodies "MEDI9447" and "BMS986179" (as defined above), as shown in Table 4.

[0437] Table 4: Inhibition of adenosine formation in Colo201 cells.

[0438]

[0439]

[0440] Example 6: Induction of T cell proliferation and IFNγ release.

[0441] Primary human T cell assays were used to explore the effects of CD73 inhibition on T cells. Human peripheral blood mononuclear cells (PBMCs) from STEMCELL Technologies were thawed and enriched for T cells by negative selection (T cell enrichment kit, EasySep negative selection; Stem Technologies No. 19051). The donor was an internally labeled donor AF. T cells were labeled using Cell Trace Violet (CellTrace™ Violet Proliferation Kit, Molecular Probes, No. C34557) according to the manufacturer's protocol. The assay was performed overnight at 4°C in 96-well round-bottom plates pre-coated with anti-CD3 (Ultra-LEAF™ purified anti-CD3 antibody, clone HIT3a, Biolegend, No. 300332). T cells labeled with CTV were plated and incubated with anti-CD28 (Ultra-LEAFTM purified anti-CD28 antibody, clone CD28.2; Biolegend, No. 302934) and anti-huCD73 or anti-TNP HuIgG1KO controls at different concentrations. After incubation for 22 hours at 37°C and 5% CO2, AMP (adenosine 5'-monophosphate disodium salt; Sigma Aldrich, catalog number 01930) was added at a final concentration of 200 μM. The cells were incubated for another 5 days at 37°C and 5% CO2. The supernatant was obtained and IFNγ secretion was analyzed by Meso Scale Diagnostics V-PLEX human IFN-y kit according to the manufacturer's instructions. The values ​​were normalized to cells treated with the stimulated isotype to which AMP was added. Cell proliferation was determined by analyzing the CTV markers on CD4+ and CD8+ cells using a BD FACS Canto II flow cytometer and BD FACSDiva software (version 8.0.1). The proliferation of cells treated with the same type of stimulation without the addition of AMP was set to 100%, and the proliferation of cells treated with the same type of stimulation with the addition of AMP was set to 0%.

[0442] The CD73 antibodies described herein restore T cell proliferation and cytokine release.

[0443] Compared to "MEDI9447" and "BMS986179", the antibodies described herein exhibited superior activity in inducing T cell proliferation and IFNγ release in primary human T cells from certain donors (Tables 5 and 6). Thus, the generated CD73 antibodies were able to restore T cell function in certain donors that was inhibited by AMP to a higher degree than the two competitor molecules.

[0444] Table 5: CD8 T cell proliferation, presented as [%] of control (+ / - isotype-treated cells, where cells treated with the stimulated isotype without added AMP were set at 100% and cells treated with the stimulated isotype with added AMP were set at 0%); nd: not determined

[0445] CD73 mAb Donor A Donor B Donor C Donor D Donor E Donor F B2 55.6 62.2 95.8 98.5 99.1 -8.9 C1 103.5 86.7 106.9 99.5 100.9 84.2 C2 103.0 68.5 nd nd nd nd C3 103.2 80.2 116.5 99.3 101.0 91.3 C4 103.5 70.3 110.9 98.5 100.2 92.6 C5 103.2 80.3 100.6 99.3 100.4 86.0 C6 102.4 65.4 88.3 99.6 100.4 91.1 "MEDI 9447" 43.9 46.7 115.1 98.0 85.5 -34.1 "BMS 986179" 40.7 61.7 99.6 98.7 95.4 22.5

[0446] Table 6: IFNγ release [fold change from control]. Controls were stimulated isotype treated cells with addition of AMP.

[0447] CD73 mAb Donor A Donor B Donor C Donor D Donor E Donor F B2 12.6 8.1 34.1 17.7 11.1 3.1 C1 20.9 12.0 51.3 20.9 12.8 6.7 C2 20.3 7.8 nd nd nd nd C3 19.9 7.7 31.9 19.0 14.2 6.7 C4 20.2 8.7 35.2 13.7 14.1 7.1 C5 24.5 11.3 59.3 22.9 12.4 5.8 C6 24.3 12.9 55.5 25.8 14.0 10.3 "MEDI 9447" 7.7 5.3 16.2 20.7 5.0 1.1 "BMS 986179" 10.9 5.2 36.4 13.3 7.2 2.9

[0448] Tables 5 and 6 above demonstrate that the tested anti-CD73 antibodies exhibit superior activity in inducing T cell proliferation and IFNγ release in certain donors compared to MEDI9447 and BMS986179. The data are from a head-to-head comparison at a CD73 antibody concentration of 1 nM; four biological replicates were used for each donor.

[0449] Example 7: Dendritic cell / T cell co-culture

[0450] In addition, a dendritic cell / T cell co-culture system is established. Human peripheral blood mononuclear cells (PBMCs) are separated from heparinized blood of healthy donors by Ficoll-Hypaque density gradient centrifugation and stored frozen at -150°C. PBMCs are thawed and enriched for monocytes by negative selection (magnetic beads). Monocytes are cultured together with 3ng / ml human IL-4 and 50ng / ml human GM-CSF at 37°C and 5% CO2 in culture medium to differentiate into dendritic cells (DCs). On the 5th day, 10ng / ml TNFα is added to reach maturity and the cells are cultured overnight. PBMCs from different donors are thawed, T cells are separated by immunomagnetic negative selection and cultured overnight in culture medium with 5ng / ml human IL-2. 200,000 cells / well of T cells were co-cultured with 50,000 cells / well of allogeneic mature DCs in 96-well plates in the presence of various concentrations of the anti-PD-1 antibody pembrolizumab (as further described herein and, for example, in WO2009 / 114335 and WO2015 / 088847) and various anti-CD73 antibodies of the present invention. Human IgG4Pro and human IgG1KO isotype controls were used as negative controls. After 22 hours at 37°C and 5% CO2, adenosine 5'-monophosphate disodium salt (AMP) was added. The co-cultures were incubated at 37°C for 5 days, after which the supernatants were obtained and analyzed for IFNγ secretion by the Meso Scale Diagnostics V-PLEX human IFN-γ kit according to the manufacturer's instructions.

[0451] The effects of inhibiting PD1, CD73, or both can be explored in this system. Addition of AMP was found to inhibit the anti-PD1 response, and anti-CD73 treatment using the antibodies provided herein reversed this AMP-mediated inhibition (see Figure 1 ). Data shown are from a head-to-head comparison at a CD73 antibody concentration of 1 μg / ml; 5 biological replicates were used for each donor and antibody.

[0452] Example 8: Inhibition of CD73 in Bound and Non-Bound Cells

[0453] Colo-201 cells were incubated with CD73 antibodies at 37°C for 24 hours, and then blocking solution (see "Inhibition of adenosine formation in cell lines") was added for 20 minutes. The cells were pelleted by centrifugation and the supernatant was transferred to a new low-binding plate. The cells were washed and 300 μM AMP was added to the cells and the supernatant. After an incubation time of 30 minutes, the reaction was terminated by adding 15 mM HCl solution. The supernatant was obtained and mixed with an acetonitrile / blocking solution mixture to terminate possible enzymatic reactions. The samples were analyzed for adenosine levels by liquid chromatography-mass spectrometry. This made it possible to explore the inhibition of CD73 bound to cells and the inhibition of CD73 in the cell culture supernatant (CD73 not bound to cells). The adenosine level obtained for the isotype treatment without the addition of AMP was set to 100% inhibition; the adenosine level obtained for the isotype treatment with the addition of AMP was set to 0% inhibition. As shown in Tables 7 and 8, the CD73 antibodies according to the present invention (particularly C1, C2, C3, C4, C5, and C6) inhibited cell-bound CD73 and CD73 present in the cell culture supernatant (non-cell-bound CD73) by 70-80%. "MEDI9447" showed a lower inhibitory activity of approximately 20% against cell-bound CD73. Both "MEDI9447" and "BMS 986179" exhibited lower activity in inhibiting CD73 present in the cell culture supernatant. Thus, the CD73 antibodies according to the present invention inhibited CD73 more completely than the two competitor molecules.

[0454] Table 7: Inhibition of CD73 binding to cells

[0455] Antibody Maximum adenosine inhibition % B2 70+ / -3 C1 79+ / -3 C2 78 C3 81+ / -4 C4 82+ / -3 C5 82+ / -6 C6 81+ / -3 "MEDI 9447" 62+ / -4 "BMS 986179" 84+ / -5

[0456] Table 7 shows that the antibodies of the present invention are superior to the prior art comparative antibody "MEDI 9447" in inhibiting CD73 binding to cells. The data shown are from at least two independent experiments, except for antibody C2 (n=1).

[0457] Table 8: Inhibition of CD73 in non-bound cells

[0458]

[0459]

[0460] Table 8 shows that the antibodies of the present invention are superior to the prior art comparative antibodies "MEDI 9447" and / or "BMS 986179" in inhibiting CD73 in cell culture supernatants. The data shown are from at least two independent experiments, excluding antibody C2 (n=1).

[0461] Example 9: Complex formation between anti-CD73 antibodies and CD73

[0462] The oligomeric state of the complex of CD73 and two anti-CD73 antibodies was investigated by sedimentation velocity analytical ultracentrifugation ("SV-AUC") experiments using samples of CD73 and two different antibodies, both as single components and as a mixture with a 1:1 CD73:antibody molar ratio. The mixture was examined at a concentration of 2.4 μM for optimal signal-to-noise ratio at 280 nm. Individual aliquots of CD73 protein and antibodies of the invention were also examined at a concentration of 2.4 μM to facilitate g(s) comparison. CD73 protein and antibodies of the invention were dialyzed into PBS buffer prior to mixing and centrifugation.

[0463] SV-AUC experiments were analyzed qualitatively by making g(s) distribution curves (by transforming the raw data) and more quantitatively by various curve fitting algorithms. For less dispersed irreversible systems or for all interactions above K greater than or equal to 2 orders of magnitude, D For a reversible system of values, the c(s) distribution function is a robust curve fitting method that returns accurate estimates of the percentage and molecular weight of each species. The individual components (CD73 and related anti-CD73 antibodies (anti-CD73 antibody C4 of the present invention; "MEDI9447")) were of sufficient purity to fit the curves by the c(s) algorithm and return the expected molecular weights. The mixture of CD73 protein and anti-CD73 antibodies produced a broad distribution that was not suitable for deconvolution by the c(s) algorithm, so g(s) (an apparent sedimentation distribution plot) was generated to qualitatively compare the distributions of species formed by CD73 and anti-CD73 antibodies.

[0464] Material

[0465] CD73 HuCD73_plus His tag, dimer molecular weight (Daltons): 118,032, partial specific volume: 0.73744, A280 / mg / ml / cm 0.954, storage buffer: 1×PBS, 0.2M sucrose, 0.01% CHAPS, 5% glycerol, 1mM TCEP, pH-7.2.

[0466] Anti-CD73 antibody C04, calculated molecular weight 148,232 Da, includes 3000 Da of glycosylation. Anti-CD73 antibody "MEDI9447", calculated molecular weight 150,669 Da, includes an estimated 3000 Da of glycosylation.

[0467] method

[0468] Data for the SV-AUC experiment were collected using a Beckman XL-I analytical ultracentrifuge (Beckman Coulter, Brea, California). On each experimental day, samples stored at the appropriate storage temperature were thawed as needed and gently mixed at room temperature by pipetting and diluted to a concentration that produced an absorbance signal within the linear range of the signal detector. The sample was loaded into the sample partition of a charcoal-filled epon cell with a sapphire or quartz window. 400 μL of diluted sample was loaded into the sample partition. 406 μL of matching buffer was used in the reference partition of the cell. The experiment was performed using an analytical 4-hole titanium An-60 Ti rotor (Beckman Coulter). The calibration balance was placed in hole 4. An initial scan was performed at 3000 RPM to verify cell integrity and perform radial instrument calibration. Similarly, a wavelength scan was performed at 3000 RPM on each cell to verify absorbance. The sample was allowed to reach temperature equilibrium at 20°C and maintained for at least 2 hours before centrifugation at high speed (40,000 RPM). Data scans for each cell (reporting concentration as a function of radial position) were collected by absorbance scanning at 280 nm with a radial step size of 0.003 cm, continuous scanning, and 1 flash per channel.

[0469] Data analysis of SV-AUC using the c(s) algorithm.

[0470] Scans were selected from the first scan to approximately the tenth scan after sample pelleting. Excess scans after sample pelleting contain no information and overweight the baseline contribution. Buffer properties and partial specific volume estimates calculated from protein sequence were input as parameters for curve fitting. The data, which generated a continuous c(s) distribution, were analyzed using the software package SEDFIT version 15.01b (Schuck Biophys J. 2000 Mar;78(3):1606-19).

[0471] The apparent sedimentation coefficient distribution function, g(s) curve, and full boundary curve fitting were performed using the program SEDANAL (www.sedanal.org; Biophysical Chemistry 108 (2004) 231-243). All c(r) data files were inspected and metadata (e.g., meniscus position, fit range, cell base, and optical correction) were written to channel data files (*.abr files for SEDANAL) as needed. The g(s) plot is the apparent sedimentation distribution function plot and represents the transformation of the raw data on the x-axis (or velocity axis) of the apparent sedimentation coefficient and the y-axis of the g(s) function (derivative form of the c(r) data). This is a model-free transformation and the peak position represents the boundary velocity, while the boundary width represents the diffusion of a single species or the diffusion and growth separation of multiple species (if multiple species are present). A small number of c(r) pairs were used to generate each g(s) plot. The exact shape of the g(s) plot depends on the time span and the time elapsed since the start of the loop over the data used to generate the plot. On the x-axis, even the g(s) of a single ideal species will be narrower and higher and proportional to the elapsed time of the scan since the start of sedimentation. Overlays of time-span matching groups of g(s) plots can be used to confirm or refute reversible self-association of the same sample over a dilution series.

[0472] SEDANAL also performs direct curve fitting on raw data transformed by the dc / dt (change in concentration divided by change in time) operation. Using a user-specified model, SEDANAL performs a nonlinear least-squares curve fit on the dc / dt curves of a subset of data channels to obtain the best model-fitting parameters for the data. SV-AUC is one of the few biophysics methods that can rank the goodness-of-fit of multiple models to help analysts select the best model for the data.

[0473] result

[0474] Samples for CD73 were run and curves were fitted by SEDANAL and SEDFIT.

[0475] SEDANAL curve fitting of HuCD73his 20170303 S value 6.341 Weight 121000 Sedfit curve fitting of HuCD73his 20170303 S value 6.389 Weight 126000

[0476] Run the CO4 sample and fit the curve using SEDANAL and SEDFIT

[0477]

[0478]

[0479] Run sample "MEDI9447" and fit the curve via SEDANAL and SEDFIT

[0480] SEDANAL curve fitting of "MEDI9447" S value 6.347 Weight 141000 SEDFIT curve fitting of "MEDI9447" S value 6.321 Weight 147000

[0481] Fitting the mixture by c(s) and SEDANAL curves did not return reliable results and it was concluded that there were too many species to deconvolute. For qualitative comparison, an overlay of g(s) was prepared (see Figure 2 ).

[0482] Correlation between Svedberg and molecular weight:

[0483] (Svedberg) Mw Dalton 2 30,000 4 85,000 6 156,000 8 241,000 10 337,000 12 442,000 14 558,000 16 681,000 18 813,000 20 952,000 24 1,250,000 28 1,580,000 32 1,930,000

[0484] Example 10: Crystallography

[0485] CD73 protein:

[0486] The CD73 protein construct was based on Knapp, K. et al. (2012) Structure 20:2161-2173 ( 10.1016 / j.str.2012.10.001 ) and contains mutations to support protein production and crystallization behavior. The mutations are ASN53ASP, LYS145SER, LYS147SER, ASN311ASP, ASN333ASP, ASN403ASP, and LYS478SER. It also contains SER, PRO, ASP, and PRO at the N-terminus after enterokinase cleavage. Expression, refolding, and purification were performed as described in Knapp, K. et al. (2012) Structure 20:2161-2173.

[0487] FAB:

[0488] The Fab fragment of the anti-CD73 antibody of the present invention is obtained by enterokinase cleavage.

[0489] Crystal structure determination

[0490] The proteins were complexed (Fab fragment and CD73), purified by gel filtration and concentrated to 21 mg / ml in 10 mM Tris, 150 mM NaCl (pH = 8). Crystals were obtained at 20°C by mixing 0.2 μl of a solution containing 12% PEG8000, 0.1 M MOPS (pH 7.6) and 0.1 M magnesium acetate with 0.2 μL of protein solution. After 3 days, plate-shaped crystals grew. The crystals were transferred to a storage solution supplemented with 25% PEG400 and snap-frozen in liquid nitrogen. Diffraction data were collected at the Swiss Light Source and the structure was solved by molecular replacement. Model building and improvement can produce Figure 3 Crystal structure of the CD73:anti-CD73 Fab complex depicted in .

[0491] Example 11: Pharmaceutical Formulation for iv Administration

[0492] Any of the above-mentioned antibody molecules of the present invention can be selected to produce a pharmaceutical formulation for intravenous administration having the following composition:

[0493] Drug substance: 50 mg / ml

[0494] Histidine buffer: 10 mM, pH 6.0

[0495] Sucrose: 220 mM

[0496] Polysorbate 20: 0.02%

[0497] The above composition is formulated as a solution of the above composition in water for injection (WFI), sterilized and stored in 10 ml vials at 2° C. to 8° C. The above composition can optionally be provided as a lyophilized formulation to be reconstituted in WFI before use.

[0498] Example 12: Pharmaceutical Use in Humans

[0499] The solution outlined above in Example 9 is administered to a patient in need thereof (eg, a human with cancer) by intravenous infusion (dosage range of 0.05 mg to 50.0 mg per kilogram of body weight and dosage) every two to four weeks.

[0500] According to the Examples, a number of different anti-CD73 antibodies of the present invention were prepared. In the table below, the sequences of such antibodies are provided. A1, A2, A3, and A4 are murine antibodies, respectively. B1, B2, C1, C2, C3, C4, C5, and C6 are humanized antibodies, respectively. The CDR sequences are provided according to the IMGT definition as described herein.

[0501] Additionally, the sequences of the anti-PD1 antibodies of the present invention (referred to as PD1-1, PD1-2, PD1-3, PD1-4, and PD1-5, respectively) are provided.

[0502] Table 9: Amino acid sequences and SEQ ID NOs of CDRs, VH, VL, light chains and heavy chains of anti-CD73 and anti-PD1 antibodies of the present invention.

[0503]

[0504]

[0505]

[0506]

[0507]

[0508]

[0509]

[0510]

[0511] Sequence Listing <110> Boehringer Ingelheim International GmbH <120> Antagonistic CD73 antibodies <130> 12-0426-WO1 <160> 131 <170> BiSSAP 1.2 <210> 1 <211> 10 <212> PRT <213> Artificial sequence <220> <223> A1 - HCDR1 <400> 1 Gly Phe Thr Phe Ser His Tyr Tyr Met Ser 1 5 10 <210> 2 <211> 17 <212> PRT <213> Artificial sequence <220> <223> A1 - HCDR2 <400> 2 Thr Ile Asn Gly Gly Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val Lys 1 5 10 15 Asp <210> 3 <211> 12 <212> PRT <213> Artificial sequence <220> <223> A1 - HCDR3 <400> 3 Gly Gly Pro Tyr Ser Asn Tyr Val Trp Phe Ala Tyr 1 5 10 <210> 4 <211> 15 <212> PRT <213> Artificial sequence <220> <223> A1 - LCDR1 <400> 4 Arg Ala Ser Gln Ser Val Thr Thr Ser Ser Tyr Thr Tyr Met His 1 5 10 15 <210> 5 <211> 7 <212> PRT <213> Artificial sequence <220> <223> A1 - LCDR2 <400> 5 Tyr Ala Ser Asn Leu Glu Ser 1 5 <210> 6 <211> 9 <212> PRT <213> Artificial sequence <220> <223> A1 - LCDR3 <400> 6 Gln His Ser Trp Glu Asn Pro Tyr Thr 1 5 <210> 7 <211> 10 <212> PRT <213> Artificial sequence <220> <223> A2-HCDR1 <400> 7 Gly Phe Thr Phe Ser Ser Ser Tyr Ile Ser 1 5 10 <210> 8 <211> 17 <212> PRT <213> Artificial sequence <220> <223> A2 - HCDR2 <400> 8 Trp Ile Tyr Ala Gly Thr Gly Asn Thr Asn Tyr Asn Gln Lys Phe Thr 1 5 10 15 Asp <210> 9 <211> 9 <212> PRT <213> Artificial sequence <220> <223> A2 - HCDR3 <400> 9 His Val Asn Trp Asp Tyr Phe Asp Tyr 1 5 <210> 10 <211> 11 <212> PRT <213> Artificial sequence <220> <223> A2 - LCDR1 <400> 10 Lys Ala Ser Gln Asp Val Gly Thr Ala Val Val 1 5 10 <210> 11 <211> 7 <212> PRT <213> Artificial sequence <220> <223> A2 - LCDR2 <400> 11 Trp Ala Ser Ser Arg His Thr 1 5 <210> 12 <211> 9 <212> PRT <213> Artificial sequence <220> <223> A2 - LCDR3 <400> 12 Gln Gln Tyr Arg Ser Tyr Pro Trp Thr 1 5 <210> 13 <211> 10 <212> PRT <213> Artificial sequence <220> <223> A3 - HCDR1 <400> 13 Gly Tyr Thr Phe Thr Thr Tyr Trp Met His 1 5 10 <210> 14 <211> 17 <212> PRT <213> Artificial sequence <220> <223> A3 - HCDR2 <400> 14 Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 15 <211> 8 <212> PRT <213> Artificial sequence <220> <223> A3 - HCDR3 <400> 15 Leu Leu Asp Tyr Ala Met Asp Tyr 1 5 <210> 16 <211> 11 <212> PRT <213> Artificial sequence <220> <223> A3 - LCDR1 <400> 16 Arg Ala Ser Gln Asp Ile Arg Asn Tyr Leu Asn 1 5 10 <210> 17 <211> 7 <212> PRT <213> Artificial sequence <220> <223> A3 - LCDR2 <400> 17 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 18 <211> 9 <212> PRT <213> Artificial sequence <220> <223> A3 - LCDR3 <400> 18 Gln Gln Gly Asn Thr Leu Pro Trp Thr 1 5 <210> 19 <211> 10 <212> PRT <213> Artificial sequence <220> <223> A4 - HCDR1 <400> 19 Gly Leu Thr Phe Ser Ser Tyr Val Met Ser 1 5 10 <210> 20 <211> 17 <212> PRT <213> Artificial sequence <220> <223> A4 - HCDR2 <400> 20 Thr Ile Ser Ser Gly Gly Val Ser Thr Tyr Tyr Pro Asp Thr Val Lys 1 5 10 15 Gly <210> twenty one <211> 11 <212> PRT <213> Artificial sequence <220> <223> A4 - HCDR3 <400> twenty one Arg Glu Thr Ala Arg Ala Thr Gly Phe Ala Tyr 1 5 10 <210> twenty two <211> 11 <212> PRT <213> Artificial sequence <220> <223> A4 - LCDR1 <400> twenty two Lys Ala Ser Gln Ser Val Ser Asn Asp Val Thr 1 5 10 <210> twenty three <211> 7 <212> PRT <213> Artificial sequence <220> <223> A4 - LCDR2 <400> twenty three Tyr Ala Ser Asn Arg Tyr Thr 1 5 <210> twenty four <211> 9 <212> PRT <213> Artificial sequence <220> <223> A4 - LCDR3 <400> twenty four Gln Gln Asp Tyr Ser Ser Pro Trp Thr 1 5 <210> 25 <211> 10 <212> PRT <213> Artificial sequence <220> <223> B1 - HCDR1 <400> 25 Gly Leu Thr Phe Ser Ser Tyr Val Met Ser 1 5 10 <210> 26 <211> 17 <212> PRT <213> Artificial sequence <220> <223> B1 - HCDR2 <400> 26 Thr Ile Ser Ser Gly Gly Val Ser Thr Tyr Tyr Pro Asp Thr Val Lys 1 5 10 15 Gly <210> 27 <211> 11 <212> PRT <213> Artificial sequence <220> <223> B1 - HCDR3 <400> 27 Arg Glu Thr Ala Arg Ala Thr Gly Phe Ala Tyr 1 5 10 <210> 28 <211> 11 <212> PRT <213> Artificial sequence <220> <223> B1 - LCDR1 <400> 28 Lys Ala Ser Gln Ser Val Ser Asn Asp Val Thr 1 5 10 <210> 29 <211> 7 <212> PRT <213> Artificial sequence <220> <223> B1 - LCDR2 <400> 29 Tyr Ala Ser Asn Arg Tyr Thr 1 5 <210> 30 <211> 9 <212> PRT <213> Artificial sequence <220> <223> B1 - LCDR3 <400> 30 Gln Gln Asp Tyr Ser Ser Pro Trp Thr 1 5 <210> 31 <211> 10 <212> PRT <213> Artificial sequence <220> <223> B2 - HCDR1 <400> 31 Gly Leu Thr Phe Ser Ser Tyr Val Met Ser 1 5 10 <210> 32 <211> 17 <212> PRT <213> Artificial sequence <220> <223> B2 - HCDR2 <400> 32 Thr Ile Ser Ser Gly Gly Val Ser Thr Tyr Tyr Pro Asp Thr Val Lys 1 5 10 15 Gly <210> 33 <211> 11 <212> PRT <213> Artificial sequence <220> <223> B2 - HCDR3 <400> 33 Arg Glu Thr Ala Arg Ala Thr Gly Phe Ala Tyr 1 5 10 <210> 34 <211> 11 <212> PRT <213> Artificial sequence <220> <223> B2 - LCDR1 <400> 34 Lys Ala Ser Gln Ser Val Ser Asp Asp Val Thr 1 5 10 <210> 35 <211> 7 <212> PRT <213> Artificial sequence <220> <223> B2 - LCDR2 <400> 35 Tyr Ala Ser Asn Arg Tyr Thr 1 5 <210> 36 <211> 9 <212> PRT <213> Artificial sequence <220> <223> B2 - LCDR3 <400> 36 Gln Gln Asp Tyr Ser Ser Pro Trp Thr 1 5 <210> 37 <211> 10 <212> PRT <213> Artificial sequence <220> <223> C1 - HCDR1 <400> 37 Gly Tyr Thr Phe Thr Thr Tyr Trp Met His 1 5 10 <210> 38 <211> 17 <212> PRT <213> Artificial sequence <220> <223> C1 - HCDR2 <400> 38 Ala Ile Tyr Pro Gly Phe Ser Asp Thr Thr Tyr Tyr Ser Gln Lys Phe Lys 1 5 10 15 Gly <210> 39 <211> 8 <212> PRT <213> Artificial sequence <220> <223> C1 - HCDR3 <400> 39 Leu Leu Asp Tyr Ala Met Asp Tyr 1 5 <210> 40 <211> 11 <212> PRT <213> Artificial sequence <220> <223> C1 - LCDR1 <400> 40 Arg Ala Ser Gln Asp Ile Arg Ser Tyr Leu Asn 1 5 10 <210> 41 <211> 7 <212> PRT <213> Artificial sequence <220> <223> C1 - LCDR2 <400> 41 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 42 <211> 9 <212> PRT <213> Artificial sequence <220> <223> C1 - LCDR3 <400> 42 Gln Gln Gly Glu Thr Leu Pro Trp Thr 1 5 <210> 43 <211> 10 <212> PRT <213> Artificial sequence <220> <223> C2-HCDR1 <400> 43 Gly Tyr Thr Phe Thr Thr Tyr Trp Met His 1 5 10 <210> 44 <211> 17 <212> PRT <213> Artificial sequence <220> <223> C2 - HCDR2 <400> 44 Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Tyr Ser Gln Lys Phe Lys 1 5 10 15 Gly <210> 45 <211> 8 <212> PRT <213> Artificial sequence <220> <223> C2-HCDR3 <400> 45 Leu Leu Asp Tyr Ala Met Asp Tyr 1 5 <210> 46 <211> 11 <212> PRT <213> Artificial sequence <220> <223> C2 - LCDR1 <400> 46 Arg Ala Ser Gln Asp Ile Arg Ser Tyr Leu Asn 1 5 10 <210> 47 <211> 7 <212> PRT <213> Artificial sequence <220> <223> C2 - LCDR2 <400> 47 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 48 <211> 9 <212> PRT <213> Artificial sequence <220> <223> C2 - LCDR3 <400> 48 Gln Gln Gly Glu Thr Leu Pro Trp Thr 1 5 <210> 49 <211> 10 <212> PRT <213> Artificial sequence <220> <223> C3-HCDR1 <400> 49 Gly Tyr Thr Phe Thr Thr Tyr Trp Met His 1 5 10 <210> 50 <211> 17 <212> PRT <213> Artificial sequence <220> <223> C3 - HCDR2 <400> 50 Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Tyr Ser Gln Lys Phe Lys 1 5 10 15 Gly <210> 51 <211> 8 <212> PRT <213> Artificial sequence <220> <223> C3 - HCDR3 <400> 51 Leu Leu Asp Tyr Ala Met Asp Tyr 1 5 <210> 52 <211> 11 <212> PRT <213> Artificial sequence <220> <223> C3 - LCDR1 <400> 52 Arg Ala Ser Gln Asp Ile Arg Ser Tyr Leu Asn 1 5 10 <210> 53 <211> 7 <212> PRT <213> Artificial sequence <220> <223> C3 - LCDR2 <400> 53 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 54 <211> 9 <212> PRT <213> Artificial sequence <220> <223> C3 - LCDR3 <400> 54 Gln Gln Gly Glu Thr Leu Pro Trp Thr 1 5 <210> 55 <211> 10 <212> PRT <213> Artificial sequence <220> <223> C4-HCDR1 <400> 55 Gly Tyr Thr Phe Thr Thr Tyr Trp Met His 1 5 10 <210> 56 <211> 17 <212> PRT <213> Artificial sequence <220> <223> C4-HCDR2 <400> 56 Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 57 <211> 8 <212> PRT <213> Artificial sequence <220> <223> C4-HCDR3 <400> 57 Leu Leu Asp Tyr Ala Met Asp Tyr 1 5 <210> 58 <211> 11 <212> PRT <213> Artificial sequence <220> <223> C4-LCDR1 <400> 58 Arg Ala Ser Gln Asp Ile Arg Ser Tyr Leu Asn 1 5 10 <210> 59 <211> 7 <212> PRT <213> Artificial sequence <220> <223> C4-LCDR2 <400> 59 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 60 <211> 9 <212> PRT <213> Artificial sequence <220> <223> C4 - LCDR3 <400> 60 Gln Gln Gly Glu Thr Leu Pro Trp Thr 1 5 <210> 61 <211> 10 <212> PRT <213> Artificial sequence <220> <223> C5-HCDR1 <400> 61 Gly Tyr Thr Phe Thr Thr Tyr Trp Met His 1 5 10 <210> 62 <211> 17 <212> PRT <213> Artificial sequence <220> <223> C5 - HCDR2 <400> 62 Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 63 <211> 8 <212> PRT <213> Artificial sequence <220> <223> C5 - HCDR3 <400> 63 Leu Leu Asp Tyr Ala Met Asp Tyr 1 5 <210> 64 <211> 11 <212> PRT <213> Artificial sequence <220> <223> C5 - LCDR1 <400> 64 Arg Ala Ser Gln Asp Ile Arg Ser Tyr Leu Asn 1 5 10 <210> 65 <211> 7 <212> PRT <213> Artificial sequence <220> <223> C5 - LCDR2 <400> 65 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 66 <211> 9 <212> PRT <213> Artificial sequence <220> <223> C5-LCDR3 <400> 66 Gln Gln Gly Glu Thr Leu Pro Trp Thr 1 5 <210> 67 <211> 10 <212> PRT <213> Artificial sequence <220> <223> C6-HCDR1 <400> 67 Gly Tyr Thr Phe Thr Thr Tyr Trp Met His 1 5 10 <210> 68 <211> 17 <212> PRT <213> Artificial sequence <220> <223> C6-HCDR2 <400> 68 Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe Lys 1 5 10 15 Gly <210> 69 <211> 8 <212> PRT <213> Artificial sequence <220> <223> C6 - HCDR3 <400> 69 Leu Leu Asp Tyr Ala Met Asp Tyr 1 5 <210> 70 <211> 11 <212> PRT <213> Artificial sequence <220> <223> C6 - LCDR1 <400> 70 Arg Ala Ser Gln Asp Ile Arg Asn Tyr Leu Asn 1 5 10 <210> 71 <211> 7 <212> PRT <213> Artificial sequence <220> <223> C6 - LCDR2 <400> 71 Tyr Thr Ser Arg Leu His Ser 1 5 <210> 72 <211> 9 <212> PRT <213> Artificial sequence <220> <223> C6 - LCDR3 <400> 72 Gln Gln Gly Asn Thr Leu Pro Trp Thr 1 5 <210> 73 <211> 121 <212> PRT <213> Artificial sequence <220> <223> A1 - VH <400> 73 Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Leu Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser His Tyr 20 25 30 Tyr Met Ser Trp Ile Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Gly Gly Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Asn Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Pro Tyr Ser Asn Tyr Val Trp Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ala 115 120 <210> 74 <211> 111 <212> PRT <213> Artificial Sequence <220> <223> A1 - VL <400> 74 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Thr Ser 20 25 30 Ser Tyr Thr Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Gln His Ser Trp 85 90 95 Glu Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 110 <210> 75 <211> 118 <212> PRT <213> Artificial Sequence <220> <223> A2 - VH <400> 75 Gln Gly Gln Met Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Thr 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Phe Thr Phe Ser Ser Ser 20 25 30 Tyr Ile Ser Trp Leu Lys Gln Arg Pro Arg Gln Ser Leu Glu Trp Ile 35 40 45 Ala Trp Ile Tyr Ala Gly Thr Gly Asn Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Thr Asp Lys Ala Gln Val Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg His Val Asn Trp Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser 115 <210> 76 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> A2 - VL <400> 76 Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala 20 25 30 Val Val Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Trp Ala Ser Ser Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Leu Thr Asn Val Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Arg Ser Tyr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys 100 105 <210> 77 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> A3 - VH <400> 77 Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Asp 1 5 10 15 Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser 115 <210> 78 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> A3 - VL <400> 78 Glu Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 79 <211> 120 <212> PRT <213> artificial sequence <220> <223> A4 - VH <400> 79 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr 20 25 30 Val Met Ser Trp Val Arg Gln Thr Pro Ala Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Val Ser Thr Tyr Tyr Pro Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Met Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Arg Glu Thr Ala Arg Ala Thr Gly Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ala 115 120 <210> 80 <211> 107 <212> PRT <213> Synthetic sequence <220> <223> A4 - VL <400> 80 Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp 20 25 30 Val Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Asn Thr Val Gln Ala 65 70 75 80 Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 81 <211> 120 <212> PRT <213> Synthetic sequence <220> <223> B1 - VH <40块> 81 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr 20 25 30 Val Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Ser Gly Gly Val Ser Thr Tyr Tyr Pro Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Arg Glu Thr Ala Arg Ala Thr Gly Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ala 115 120 <210> 82 <211> 107 <212> PRT <213> artificial sequence <220> <223> B1 - VL <400> 82 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp 20 25 30 Val Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Asp Tyr Ser Ser Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 83 <211> 120 <212> PRT <213> Artificial Sequence <220> <223> B2 - VH <400> 83 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr 20 25 30 Val Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Ser Gly Gly Val Ser Thr Tyr Tyr Pro Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Arg Glu Thr Ala Arg Ala Thr Gly Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ala 115 120 <210> 84 <211> 107 <212> PRT <213> Synthetic sequence <220> <223> B2 - VL <400> 84 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asp Asp 20 25 30 Val Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Asp Tyr Ser Ser Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 85 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> C1 - VH <400> 85 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Phe Ser Asp Thr Thr Tyr Ser Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 86 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> C1 - VL <400> 86 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 87 <211> 117 <212> PRT <213> artificial sequence <220> <223> C2 - VH <400> 87 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Ser Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 88 <211> 107 <212> PRT <213> artificial sequence <220> <223> C2 - VL <400> 88 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 5� 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 [[ID=?6]] Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 89 <211> 117 <212> PRTS <213> Artificial Sequence <220> <223> C3 - VH <400> 89 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 It should be noted that there seems to be an error in the original text where "5�" is likely a typo and should be "50". The above translation is based on the corrected understanding.Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Ser Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 90 <211> 107 <212> PRT <213> Artificial Sequence <220> <223> C3 - VL <400> 90 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 91 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> C4 - VH <400> 91 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 92 <211> 107 <212> PRT <213> artificial sequence <220> <223> C4 - VL <400> 92 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 93 <211> 117 <212> PRT <213> Artificial Sequence <220> <223> C5 - VH <400> 93 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 94 <211> 107 <212> PRT <213> Synthetic Sequence <220> <223> C5 - VL <400> 94 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 95 <211> 117 <212> PRT <213> Synthetic Sequence <220> <223> C6 - VH <400> 95 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser 115 <210> 96 <211> 107 <212> PRT <213> Artificial sequence <220> <223> C6 - VL <400> 96 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys 100 105 <210> 97 <211> 451 <212> PRT <213> Synthetic Sequence <220> <223> A1 - HC <400> 97 Asp Val Lys Leu Val Glu Ser Gly Gly Gly Leu Val Lys Leu Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Val Ala Ser Gly Phe Thr Phe Ser His Tyr 20 25 30 Tyr Met Ser Trp Ile Arg Gln Thr Pro Glu Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Asn Gly Gly Gly Gly Asn Thr Tyr Tyr Pro Asp Ser Val 50 55 60 Lys Asp Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Asn Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Gly Gly Pro Tyr Ser Asn Tyr Val Trp Phe Ala Tyr Trp Gly 100 105 110 Gln Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser 115 120 125 Val Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala 130 135 140 Ala Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val 145 150 155 160 Ser Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala 165 170 175 Val Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val 180 185 190 Pro Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His 195 200 205 Lys Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys 210 215 220 Asp Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly 225 230 235 240 Gly Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met 245 250 255 Ile Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His 260 265 270 Glu Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val 275 280 285 His Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr 290 295 300 Arg Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly 305 310 315 320 Lys Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile 325 330 335 Glu Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val 340 345 350 Tyr Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser 355 360 365 Leu Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu 370 375 380 Trp Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro 385 390 395 400 Val Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val 405 410 415 Asp Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met 420 425 430 His Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser 435 440 445 Pro Gly Lys 450 <210> 98 <211> 218 <212> PRT <213> Artificial sequence <220> <223> A1 - LC <400> 98 Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala Val Ser Leu Gly 1 5 10 15 Gln Arg Ala Thr Ile Ser Cys Arg Ala Ser Gln Ser Val Thr Thr Ser 20 25 30 Ser Tyr Thr Tyr Met His Trp Tyr Gln Gln Lys Pro Gly Gln Pro Pro 35 40 45 Lys Leu Leu Ile Lys Tyr Ala Ser Asn Leu Glu Ser Gly Val Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Asn Ile His 65 70 75 80 Pro Val Glu Glu Glu Asp Thr Ala Ile Tyr Tyr Cys Gln His Ser Trp 85 90 95 Glu Asn Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 99 <211> 448 <212> PRT <213> Artificial sequence <220> <223> A2 - HC <400> 99 Gln Gly Gln Met Gln Gln Ser Gly Ala Glu Leu Val Lys Pro Gly Thr 1 5 10 15 Ser Val Lys Leu Ser Cys Lys Thr Ser Gly Phe Thr Phe Ser Ser Ser 20 25 30 Tyr Ile Ser Trp Leu Lys Gln Arg Pro Arg Gln Ser Leu Glu Trp Ile 35 40 45 Ala Trp Ile Tyr Ala Gly Thr Gly Asn Thr Asn Tyr Asn Gln Lys Phe 50 55 60 Thr Asp Lys Ala Gln Val Thr Val Asp Thr Ser Ser Ser Thr Ala Tyr 65 70 75 80 Met Gln Leu Ser Ser Leu Thr Ser Glu Asp Ser Ala Ile Tyr Tyr Cys 85 90 95 Ala Arg His Val Asn Trp Asp Tyr Phe Asp Tyr Trp Gly Gln Gly Thr 100 105 110 Thr Leu Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro 115 120 125 Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly 130 135 140 Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn 145 150 155 160 Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln 165 170 175 Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser 180 185 190 Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser 195 200 205 Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr 210 215 220 His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser 225 230 235 240 Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg 245 250 255 Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro 260 265 270 Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala 275 280 285 Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val 290 295 300 Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr 305 310 315 320 Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr 325 330 335 Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu 340 345 350 Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys 355 360 365 Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser 370 375 380 Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp 385 390 395 400 Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser 405 410 415 Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala 420 425 430 Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 100 <211> 214 <212> PRT <213> Synthetic sequence <220> <223> A2 - LC <400> 100 Asp Ile Val Met Thr Gln Ser His Lys Phe Met Ser Thr Ser Val Gly 1 5 10 15 Asp Arg Val Ser Ile Thr Cys Lys Ala Ser Gln Asp Val Gly Thr Ala 20 25 30 Val Val Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Trp Ala Ser Ser Arg His Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Leu Thr Asn Val Gln Ser 65 70 75 80 Glu Asp Leu Ala Asp Tyr Phe Cys Gln Gln Tyr Arg Ser Tyr Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Asn Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 101 <211> 447 <212> PRT <213> Artificial Sequence <220> <223> A3 - HC <400> 101 Glu Val Gln Leu Gln Gln Ser Gly Thr Val Leu Ala Arg Pro Gly Asp 1 5 10 15 Ser Val Lys Met Ser Cys Lys Thr Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Lys Gln Arg Pro Gly Gln Gly Leu Glu Trp Ile 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Ala Lys Leu Thr Ala Val Thr Ser Ala Ser Thr Ala Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Thr Asn Glu Asp Ser Ala Val Tyr Tyr Cys 85 90 95 Thr Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Ser 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn<0龄02766>370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly Lys 435 440 445 <210> 102 [龄<211> 214 <212> PRT <213> Artificial Sequence <220> <223> A3 - LC <400> 102 Glu Ile Gln Met Thr Gln Thr Thr Ser Ser Leu Ser Ala Ser Leu Gly 1 5 10 15 Asp Arg Val Thr Ile Ser Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Asp Gly Thr Val Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Ser Leu Thr Ile Ser Asn Leu Glu Gln 65 70 75 80 Glu Asp Ile Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 103 <211> 450 <212> PRT <213> Synthetic Sequence <220> <223> A4 - HC <400> 103 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Lys Pro Gly Gly 1 5 10 15 Ser Leu Lys Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr 20 25 30 Val Met Ser Trp Val Arg Gln Thr Pro Ala Lys Arg Leu Glu Trp Val 35 40 45 Ala Thr Ile Ser Ser Gly Gly Val Ser Thr Tyr Tyr Pro Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Ser Ser Leu Met Ser Glu Asp Thr Ala Met Tyr Tyr Cys 85 90 95 Ala Arg Arg Glu Thr Ala Arg Ala Thr Gly Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 104 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> A4 - LC <400> 104 Ser Ile Val Met Thr Gln Thr Pro Lys Phe Leu Leu Val Ser Ala Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp 20 25 30 Val Thr Trp Tyr Gln Gln Lys Pro Gly Gln Ser Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Asp Arg Phe Thr Gly 50 55 60 Ser Gly Tyr Gly Thr Asp Phe Thr Phe Thr Ile Asn Thr Val Gln Ala 65 70 75 80 Glu Asp Leu Ala Val Tyr Phe Cys Gln Gln Asp Tyr Ser Ser Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 105 <211> 450 <212> PRT <213> Artificial Sequence <220> <223> B1 - HC <400> 105 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr 20 25 30 Val Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ser Thr Ile Ser Ser Gly Gly Val Ser Thr Tyr Tyr Pro Asp Thr Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ser Lys Asn Thr Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Lys Arg Glu Thr Ala Arg Ala Thr Gly Phe Ala Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430<了 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 106 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> B1 - LC <400> 106 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asn Asp 20 25 30 It should be noted that there seems to be a misspelling in the tag "<了 " which is likely meant to be " ". This has been left as is in the translation to maintain the integrity of the original text. Val Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Asp Tyr Ser Ser Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 107 <211> 450 <212> PRT <213> Artificial Sequence <220> <223> B2 - HC <400> 107 Glu Val Gln Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Ala Ala Ser Gly Leu Thr Phe Ser Ser Tyr[[ID=​​​​​​​​​​​​​​​​​​​​​ Gly Thr Leu Val Thr Val Ser Ala Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp 210 215 220 Lys Thr His Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly 225 230 235 240 Pro Ser Val Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile 245 250 255 Ser Arg Thr Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu 260 265 270 Asp Pro Glu Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His 275 280 285 Asn Ala Lys Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg 290 295 300 Val Val Ser Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys 305 310 315 320 Glu Tyr Lys Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu 325 330 335 Lys Thr Ile Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr 340 345 350 Thr Leu Pro Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu 355 360 365 Thr Cys Leu Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp 370 375 380 Glu Ser Asn Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val 385 390 395 400 Leu Asp Ser Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp 405 410 415 Lys Ser Arg Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His 420 425 430 Glu Ala Leu His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro 435 440 445 Gly Lys 450 <210> 108 <211> 214 <212> PRT <213> Artificial sequence <220> <223> B2 - LC <400> 108 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Lys Ala Ser Gln Ser Val Ser Asp Asp 20 25 30 Val Thr Trp Tyr Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Tyr Tyr Ala Ser Asn Arg Tyr Thr Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Phe Thr Phe Thr Ile Ser Ser Val Gln Pro 65 70 75 80 Glu Asp Ile Ala Thr Tyr Tyr Cys Gln Gln Asp Tyr Ser Ser Pro Trp 85 90 95 Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 109 <211> 446 <212> PRT <213> artificial sequence <220> <223> C1 - HC <400> 109 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Phe Ser Asp Thr Thr Tyr Ser Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 110 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> C1 - LC <400> 110 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 111 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> C2 - HC <400> 111 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Ser Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 112 <211> 214 <212> PRT <213> Artificial sequence <220> <223> C2 - LC <400> 112 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 113 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> C3 - HC <400> 113 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Ser Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 114 <211> 214 <212> PRT <213> Artificial Sequence <220> <223> C3 - LC <400> 114 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 115 <211> 446 <212> PRT <213> Synthetic sequence <220> <223> C4 - HC <400> 115 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Leu Ser Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 116 <211> 214 <212> PRT <213> Artificial sequence <220> <223> C4 - LC <400> 116 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45[[ID=3l]] Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala[[ID=l45]] 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 117 <211> 446 <212> PRT <213> artificial sequence <220> <223> C5 - HC <400> 117 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 118 <211> 214 <212> PRT <213> Artificial sequence <220> <223> C5 - LC <400> 118 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Ser Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Glu Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Glu Thr Leu Pro Trp 85 90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 119 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> C6 - HC <400> 119 Gln Val Gln Leu Val Gln Ser Gly Ala Glu Val Lys Lys Pro Gly Asp 1 5 10 15 Ser Val Lys Val Ser Cys Lys Ala Ser Gly Tyr Thr Phe Thr Thr Tyr 20 25 30 Trp Met His Trp Val Arg Gln Ala Pro Gly Gln Gly Leu Glu Trp Met 35 40 45 Gly Ala Ile Tyr Pro Gly Asn Ser Asp Thr Thr Tyr Asn Gln Lys Phe 50 55 60 Lys Gly Lys Val Thr Met Thr Arg Asp Thr Ser Thr Ser Thr Val Tyr 65 70 75 80 Met Lys Leu Ser Ser Leu Arg Ser Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg Leu Leu Asp Tyr Ala Met Asp Tyr Trp Gly Gln Gly Thr Leu 100 105 110 Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val Phe Pro Leu 115 120 125 Ala Pro Ser Ser Lys Ser Thr Ser Gly Gly Thr Ala Ala Leu Gly Cys 130 135 140 Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser Trp Asn Ser 145 150 155 160 Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val Leu Gln Ser 165 170 175 Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro Ser Ser Ser 180 185 190 Leu Gly Thr Gln Thr Tyr Ile Cys Asn Val Asn His Lys Pro Ser Asn 195 200 205 Thr Lys Val Asp Lys Arg Val Glu Pro Lys Ser Cys Asp Lys Thr His 210 215 220 Thr Cys Pro Pro Cys Pro Ala Pro Glu Ala Ala Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser His Glu Asp Pro Glu 260 265 270 Val Lys Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Tyr Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Ala Leu Pro Ala Pro Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Arg Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Lys Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Gln Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Pro Gly 435 440 445 <210> 120 <211> 214 <212> PRT <213> Artificial sequence <220> <223> C6 - LC <400> 120 Asp Ile Gln Met Thr Gln Ser Pro Ser Ser Leu Ser Ala Ser Val Gly 1 5 10 15 U Asp Arg Val Thr Ile Thr Cys Arg Ala Ser Gln Asp Ile Arg Asn Tyr 20 25 30 Leu Asn Trp His Gln Gln Lys Pro Gly Lys Ala Pro Lys Leu Leu Ile 35 40 45 Trp Tyr Thr Ser Arg Leu His Ser Gly Val Pro Ser Arg Phe Ser Gly 50 55 60 Ser Gly Ser Gly Thr Asp Tyr Thr Leu Thr Ile Ser Ser Leu Gln Pro 65 70 75 80 Glu Asp Phe Ala Thr Tyr Phe Cys Gln Gln Gly Asn Thr Leu Pro Trp 85 :90 95 Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg Thr Val Ala Ala 100 105 110 Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln Leu Lys Ser Gly 115 120 125 Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr Pro Arg Glu Ala 130 135 140 Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser Gly Asn Ser Gln 145 150 155 160 Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr Tyr Ser Leu Ser 165 170 175 Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys His Lys Val Tyr 180 185 190 Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro Val Thr Lys Ser 195 200 205 Phe Asn Arg Gly Glu Cys 210 <210> 121 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> PD1-1 - HC <400> 121 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ala Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Val Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 122 <211> 218 <212> PRT <213> Artificial Sequence <220> <223> PD1-1 - LC <400> 122 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Thr Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 123 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> PD1-2 - HC <400> 123 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Ala Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Pro Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 124 <211> 218 <212> PRT <213> Artificial Sequence <220> <223> PD1-2 - LC <400> 124 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Thr Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 125 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> PD1-3 - HC <400> 125 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Lys Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Val Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 126 <211> 218 <212> PRT <213> Artificial Sequence <220> <223> PD1-3 - LC <400> 126 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Val Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 127 <211> 446 <212> PRT <213> Artificial Sequence <220> <223> PD1-4 - HC <400> 127 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Lys Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Val Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 128 <211> 218 <212> PRT <213> Artificial sequence <220> <223> PD1-4 - LC <400> 128 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Val Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 129 <211> 446 <212> PRT <213> Synthetic sequence <220> <223> PD1-5 - HC <400> 129 Glu Val Met Leu Val Glu Ser Gly Gly Gly Leu Val Gln Pro Gly Gly 1 5 10 15 Ser Leu Arg Leu Ser Cys Thr Ala Ser Gly Phe Thr Phe Ser Lys Ser 20 25 30 Ala Met Ser Trp Val Arg Gln Ala Pro Gly Lys Gly Leu Glu Trp Val 35 40 45 Ala Tyr Ile Ser Gly Gly Gly Gly Asp Thr Tyr Tyr Ser Ser Ser Val 50 55 60 Lys Gly Arg Phe Thr Ile Ser Arg Asp Asn Ala Lys Asn Ser Leu Tyr 65 70 75 80 Leu Gln Met Asn Ser Leu Arg Ala Glu Asp Thr Ala Val Tyr Tyr Cys 85 90 95 Ala Arg His Ser Asn Val Asn Tyr Tyr Ala Met Asp Tyr Trp Gly Gln 100 105 110 Gly Thr Leu Val Thr Val Ser Ser Ala Ser Thr Lys Gly Pro Ser Val 115 120 125 Phe Pro Leu Ala Pro Cys Ser Arg Ser Thr Ser Glu Ser Thr Ala Ala 130 135 140 Leu Gly Cys Leu Val Lys Asp Tyr Phe Pro Glu Pro Val Thr Val Ser 145 150 155 160 Trp Asn Ser Gly Ala Leu Thr Ser Gly Val His Thr Phe Pro Ala Val 165 170 175 Leu Gln Ser Ser Gly Leu Tyr Ser Leu Ser Ser Val Val Thr Val Pro 180 185 190 Ser Ser Ser Leu Gly Thr Lys Thr Tyr Thr Cys Asn Val Asp His Lys 195 200 205 Pro Ser Asn Thr Lys Val Asp Lys Arg Val Glu Ser Lys Tyr Gly Pro 210 215 220 Pro Cys Pro Pro Cys Pro Ala Pro Glu Phe Leu Gly Gly Pro Ser Val 225 230 235 240 Phe Leu Phe Pro Pro Lys Pro Lys Asp Thr Leu Met Ile Ser Arg Thr 245 250 255 Pro Glu Val Thr Cys Val Val Val Asp Val Ser Gln Glu Asp Pro Glu 260 265 270 Val Gln Phe Asn Trp Tyr Val Asp Gly Val Glu Val His Asn Ala Lys 275 280 285 Thr Lys Pro Arg Glu Glu Gln Phe Asn Ser Thr Tyr Arg Val Val Ser 290 295 300 Val Leu Thr Val Leu His Gln Asp Trp Leu Asn Gly Lys Glu Tyr Lys 305 310 315 320 Cys Lys Val Ser Asn Lys Gly Leu Pro Ser Ser Ile Glu Lys Thr Ile 325 330 335 Ser Lys Ala Lys Gly Gln Pro Arg Glu Pro Gln Val Tyr Thr Leu Pro 340 345 350 Pro Ser Gln Glu Glu Met Thr Lys Asn Gln Val Ser Leu Thr Cys Leu 355 360 365 Val Lys Gly Phe Tyr Pro Ser Asp Ile Ala Val Glu Trp Glu Ser Asn 370 375 380 Gly Gln Pro Glu Asn Asn Tyr Lys Thr Thr Pro Pro Val Leu Asp Ser 385 390 395 400 Asp Gly Ser Phe Phe Leu Tyr Ser Arg Leu Thr Val Asp Lys Ser Arg 405 410 415 Trp Gln Glu Gly Asn Val Phe Ser Cys Ser Val Met His Glu Ala Leu 420 425 430 His Asn His Tyr Thr Gln Lys Ser Leu Ser Leu Ser Leu Gly 435 440 445 <210> 130 <211> 218 <212> PRT <213> Artificial Sequence <220> <223> PD1-5 - LC <400> 130 Glu Ile Val Leu Thr Gln Ser Pro Ala Thr Leu Ser Leu Ser Pro Gly 1 5 10 15 Glu Arg Ala Thr Met Ser Cys Arg Ala Ser Glu Asn Ile Asp Val Ser 20 25 30 Gly Ile Ser Phe Met Asn Trp Tyr Gln Gln Lys Pro Gly Gln Ala Pro 35 40 45 Lys Leu Leu Ile Tyr Val Ala Ser Asn Gln Gly Ser Gly Ile Pro Ala 50 55 60 Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 65 70 75 80 Arg Leu Glu Pro Glu Asp Phe Ala Val Tyr Tyr Cys Gln Gln Ser Lys 85 90 95 Glu Val Pro Trp Thr Phe Gly Gln Gly Thr Lys Leu Glu Ile Lys Arg 100 105 110 Thr Val Ala Ala Pro Ser Val Phe Ile Phe Pro Pro Ser Asp Glu Gln 115 120 125 Leu Lys Ser Gly Thr Ala Ser Val Val Cys Leu Leu Asn Asn Phe Tyr 130 135 140 Pro Arg Glu Ala Lys Val Gln Trp Lys Val Asp Asn Ala Leu Gln Ser 145 150 155 160 Gly Asn Ser Gln Glu Ser Val Thr Glu Gln Asp Ser Lys Asp Ser Thr 165 170 175 Tyr Ser Leu Ser Ser Thr Leu Thr Leu Ser Lys Ala Asp Tyr Glu Lys 180 185 190 His Lys Val Tyr Ala Cys Glu Val Thr His Gln Gly Leu Ser Ser Pro 195 200 205 Val Thr Lys Ser Phe Asn Arg Gly Glu Cys 210 215 <210> 131 <211> 785 <212> PRT <213> Artificial Sequence <220> <223> Mature Murine CD73-HuFc-His6 <400> 131 Trp Glu Leu Thr Ile Leu His Thr Asn Asp Val His Ser Arg Leu Glu 1 5 10 15 Gln Thr Ser Asp Asp Ser Thr Lys Cys Leu Asn Ala Ser Leu Cys Val 20 25 30 Gly Gly Val Ala Arg Leu Phe Thr Lys Val Gln Gln Ile Arg Lys Glu 35 40 45 Glu Pro Asn Val Leu Phe Leu Asp Ala Gly Asp Gln Tyr Gln Gly Thr 50 55 60 Ile Trp Phe Thr Val Tyr Lys Gly Leu Glu Val Ala His Phe Met Asn 65 70 75 80 Ile Leu Gly Tyr Asp Ala Met Ala Leu Gly Asn His Glu Phe Asp Asn 85 90 95 Gly Val Glu Gly Leu Ile Asp Pro Leu Leu Arg Asn Val Lys Phe Pro 100 105 110 Ile Leu Ser Ala Asn Ile Lys Ala Arg Gly Pro Leu Ala His Gln Ile 115 120 125 Ser Gly Leu Phe Leu Pro Ser Lys Val Leu Ser Val Gly Gly Glu Val 130 135 140 Val Gly Ile Val Gly Tyr Thr Ser Lys Glu Thr Pro Phe Leu Ser Asn 145 150 155 160 Pro Gly Thr Asn Leu Val Phe Glu Asp Glu Ile Ser Ala Leu Gln Pro 165 170 175 Glu Val Asp Lys Leu Lys Thr Leu Asn Val Asn Lys Ile Ile Ala Leu 180 185 190 Gly His Ser Gly Phe Glu Met Asp Lys Leu Ile Ala Gln Lys Val Arg 195 200 205 Gly Val Asp Ile Val Val Gly Gly His Ser Asn Thr Phe Leu Tyr Thr 210 215 220 Gly Asn Pro Pro Ser Lys Glu Val Pro Ala Gly Lys Tyr Pro Phe Ile 225 230 235 240 Val Thr Ala Asp Asp Gly Arg Gln Val Pro Val Val Gln Ala Tyr Ala 245 250 255 Phe Gly Lys Tyr Leu Gly Tyr Leu Lys Val Glu Phe Asp Asp Lys Gly 260 265 270 Asn Val Ile Thr Ser Tyr Gly Asn Pro Ile Leu Leu Asn Ser Ser Ile 275 280 285 Pro Glu Asp Ala Thr Ile Lys Ala Asp Ile Asn Gln Trp Arg Ile Lys 290 295 300 Leu Asp Asn Tyr Ser Thr Gln Glu Leu Gly Arg Thr Ile Val Tyr...

Claims

1. An antibody that specifically binds to CD73, comprising: A heavy chain variable region comprising an hcCDR1 having an amino acid sequence as shown in SEQ ID NO:55, an hcCDR2 having an amino acid sequence as shown in SEQ ID NO:56, and an hcCDR3 having an amino acid sequence as shown in SEQ ID NO:57; and a light chain variable region comprising an lcCDR1 having an amino acid sequence as shown in SEQ ID NO:58, an lcCDR2 having an amino acid sequence as shown in SEQ ID NO:59, and an lcCDR3 having an amino acid sequence as shown in SEQ ID NO:

60.

2. The antibody according to claim 1, wherein the antibody is a humanized antibody molecule.

3. The antibody according to claim 1 or 2, wherein the antibody is a monoclonal antibody molecule, Fab, F(ab')2, Fv or scFv.

4. The antibody according to claim 1 or 2, comprising a heavy chain constant region selected from the group consisting of IgG1, IgG2, IgG3, IgG4, IgM, IgA and IgE constant regions. The antibody of claim 4 , wherein the heavy chain constant region is IgG1. The antibody according to claim 4 , wherein the heavy chain constant region is IgG1 with L234A and / or L235A mutations.

7. The antibody of claim 1 or 2, wherein the light chain constant region is κ or λ.

8. The antibody of claim 1 or 2, wherein the antibody has a heavy chain variable region comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:

91.

9. The antibody of claim 1 or 2, wherein the antibody has a heavy chain variable region comprising the amino acid sequence of SEQ ID NO:

91.

10. The antibody of claim 1 or 2, wherein the antibody has a light chain variable region comprising an amino acid sequence that is at least 85% identical to SEQ ID NO:

92.

11. The antibody of claim 1 or 2, wherein the antibody comprises a light chain variable region comprising the amino acid sequence of SEQ ID NO:

92.

12. The antibody of claim 1 or 2, wherein the antibody comprises a heavy chain comprising the amino acid sequence of SEQ ID NO:

115.

13. The antibody of claim 1 or 2, wherein the antibody comprises a light chain comprising the amino acid sequence of SEQ ID NO:

116.

14. The antibody according to claim 1 or 2, wherein the antibody comprises: A heavy chain variable region comprising the amino acid sequence of SEQ ID NO: 91 and a light chain variable region comprising the amino acid sequence of SEQ ID NO:

92.

15. The antibody according to claim 1 or 2, wherein the antibody comprises: A heavy chain comprising the amino acid sequence of SEQ ID NO: 115 and a light chain comprising the amino acid sequence of SEQ ID NO:

116.

16. An isolated nucleic acid molecule comprising a nucleic acid sequence encoding the heavy chain variable region and the light chain variable region of the antibody according to any one of claims 1 to 15.

17. An expression vector comprising the nucleic acid molecule comprising the nucleotide sequence according to claim 16.

18. A host cell comprising the expression vector according to claim 17, wherein the host cell is not derived from a plant cell.

19. The host cell of claim 18, wherein the cell is a mammalian cell.

20. A method for preparing an antibody according to any one of claims 1 to 15, comprising the following steps: - culturing a host cell according to claim 18 or 19 under conditions that allow the formation of an antibody according to any one of claims 1 to 15; and - Recovering the antibody.

21. The method of claim 20, further comprising the step of further purifying and / or formulating the antibody.

22. The method according to claim 20 or 21, further comprising the step of formulating the antibody into a pharmaceutical composition.

23. A pharmaceutical composition comprising an anti-CD73 antibody according to any one of claims 1 to 15 and a pharmaceutically acceptable carrier. The pharmaceutical composition according to claim 23 , further comprising a PD-1 antagonist.

25. A kit comprising the antibody according to any one of claims 1 to 15 and a PD-1 antagonist.

26. The composition according to claim 24 or the kit according to claim 25, wherein the PD-1 antagonist is an anti-PD-1 antibody or an anti-PDL-1 antibody.

27. The composition or kit of claim 26, wherein the PD-1 antagonist is an anti-PD-1 antibody selected from the group consisting of PDR-001, pembrolizumab, nivolumab, and pidilizumab.

28. The composition or kit of claim 26, wherein the PD-1 antagonist is an anti-PDL-1 antibody selected from the group consisting of atezolizumab, avelumab, or durvalumab.

29. The composition or kit of claim 26, wherein the PD-1 antagonist is an anti-PD-1 antibody comprising: (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 122; or (ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 123 and a light chain comprising the amino acid sequence of SEQ ID NO: 124; or (iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 125 and a light chain comprising the amino acid sequence of SEQ ID NO: 126; or (iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 127 and a light chain comprising the amino acid sequence of SEQ ID NO: 128; or (v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 129 and a light chain comprising the amino acid sequence of SEQ ID NO:

130.

30. The composition or kit of any one of claims 23 to 29, further comprising one or more additional therapeutic agents.

31. Use of an antibody according to any one of claims 1 to 15 in the preparation of a medicament for treating cancer, wherein the cancer is selected from renal cancer, gastrointestinal cancer and lung cancer.

32. The use according to claim 31, wherein the medicament further comprises a PD-1 antagonist.

33. The use according to claim 32, wherein the PD-1 antagonist is an anti-PD-1 antibody or an anti-PDL-1 antibody.

34. The use according to claim 33, wherein the PD-1 antagonist is an anti-PD-1 antibody selected from the group consisting of: PDR-001, pembrolizumab, nivolumab and pilizumab.

35. The use according to claim 33, wherein the PD-1 antagonist is an anti-PDL-1 antibody selected from the group consisting of atezolizumab, avelumab or durvalumab.

36. The use according to claim 33, wherein the PD-1 antagonist is an anti-PD-1 antibody molecule comprising: (i) a heavy chain comprising the amino acid sequence of SEQ ID NO: 121 and a light chain comprising the amino acid sequence of SEQ ID NO: 122; or (ii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 123 and a light chain comprising the amino acid sequence of SEQ ID NO: 124; or (iii) a heavy chain comprising the amino acid sequence of SEQ ID NO: 125 and a light chain comprising the amino acid sequence of SEQ ID NO: 126; or (iv) a heavy chain comprising the amino acid sequence of SEQ ID NO: 127 and a light chain comprising the amino acid sequence of SEQ ID NO: 128; or (v) a heavy chain comprising the amino acid sequence of SEQ ID NO: 129 and a light chain comprising the amino acid sequence of SEQ ID NO:

130.

37. The use according to any one of claims 31 to 36, wherein the cancer is non-small cell lung cancer.

38. The use according to any one of claims 31 to 36, wherein the medicament further comprises one or more other therapeutic agents.

39. The use according to claim 38, wherein the one or more other therapeutic agents are selected from chemotherapy, targeted anti-cancer therapy, oncolytic drugs, cytotoxic agents, immune-based therapies, cytokines or cellular immunotherapy.

40. The use according to claim 38, wherein the other therapeutic agent is an A2AR antagonist, a CD39 antagonist, a LAG-3 antagonist, a CTLA-4 antagonist, an EGFR antagonist or a HER2 antagonist.